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Abstract 
 
Introduction 
High resolution melting analysis (HRMA) accurately, rapidly and cost effectively detects single 
nucleotide polymorphisms by monitoring DNA dissociation kinetics. This technology was 
applied to HIV samples to assess whether it could be used to detect clinically relevant drug 
resistance mutations.  
 
Methods 
HRMA-PCR assays incorporating unlabeled probes were designed to genotype 12 mutation 
codons in the HIV-1 p66/p51 of engineered plasmids and 116 HIV-1 samples. 
 
Results 
HRMA correctly genotyped 63%-88% of the K103N, Y181C, M184V, Q151M and G190A 
mutations. Each assay had a 1.7%-3.4% discordance, most of which was due to the increased 
analytical sensitivity of HRMA (~5-20%). Only mutant K65R and V106M were correctly 
identified while the 41, 67, 70, 215 and 225 codons could not be genotyped. Assay modifications 
had some success in masking the affects of polymorphisms.  
 
Conclusion 
These assays can be used for genotyping selected major HIV-1 resistance mutations and should 
be further developed as a resistance surveillance tool. 
 
 v 
 
Acknowledgments  
I would like to sincerely thank the following people: 
 
 Dr. Gillian Hunt for her invaluable supervision, help and insight throughout the course of 
my Masters.  
 Professor Lynn Morris for her guidance and the opportunity to complete my Masters in 
her laboratory. 
 Johanna Ledwaba for all of the help in and out of the laboratory over the years. 
 The entire NICD AIDS Virus Research Unit for all the assistance and advice. 
 The University of the Witwatersrand, the Poliomyelitis Research Foundation and the 
National Research Foundation for student grants. 
 The National Health Laboratory Service Research Trust for project funding. 
 My parents, Brian and Cheryl, for allowing me to study and for all the love and support 
over the years. 
 My brothers, extended family and friends for their support and friendship.             
 vi 
 
Table of Contents  
 
Declaration................................................................................................................................. ii 
Presentations ............................................................................................................................. iii 
Abstract .................................................................................................................................... iv 
Acknowledgments .......................................................................................................................v 
Table of Contents ...................................................................................................................... vi 
List of Figures .......................................................................................................................... xii 
List of Tables ...........................................................................................................................xiv 
Abbreviations ......................................................................................................................... xvii 
Chapter 1:  Literature Review ..................................................................................................1 
1.1 Human Immunodeficiency Virus .................................................................................1 
1.1.1 Classification .........................................................................................................1 
1.1.2 Structure of HIV ....................................................................................................2 
1.1.3 HIV Life Cycle ......................................................................................................4 
1.1.4 Disease Progression ...............................................................................................5 
1.2 Antiretroviral Drug Therapy ........................................................................................6 
1.2.1 Mode of Action ......................................................................................................8 
1.3 Drug Resistance ...........................................................................................................9 
1.3.1 Mutation Classification ........................................................................................ 10 
Table of Contents 
 
vii 
 
1.3.2 Major NRTI Mutations ........................................................................................ 11 
1.3.2.1 M184V ......................................................................................................... 12 
1.3.2.2 Q151M ......................................................................................................... 12 
1.3.2.3 K65R ............................................................................................................ 12 
1.3.2.4 Thymidine Analogue Mutations (TAMs) ...................................................... 13 
1.3.3 Minor NRTI Mutations ........................................................................................ 13 
1.3.4 Major NNRTI Mutations ...................................................................................... 14 
1.3.4.1 K103N .......................................................................................................... 14 
1.3.4.2 Y181C .......................................................................................................... 14 
1.3.4.3 V106M ......................................................................................................... 15 
1.3.4.4 G190A .......................................................................................................... 15 
1.3.5 Minor NNRTI Mutations ..................................................................................... 15 
1.3.6 Mutations in Other Drug Classes .......................................................................... 16 
1.3.7 Prevalence of Mutations ....................................................................................... 17 
1.4 Resistance Detection .................................................................................................. 17 
1.4.1 Phenotypic Assays ............................................................................................... 17 
1.4.2 Genotypic Assays ................................................................................................ 18 
1.4.2.1 Hybridization Assays .................................................................................... 18 
1.4.2.2 Dideoxynucleotide Sequencing ..................................................................... 19 
1.4.2.3 Competitive PCR Assays (Real-time PCR) ................................................... 19 
Table of Contents 
 
viii 
 
1.4.2.4 Fluorescently Labeled Probes and Real-time PCR ......................................... 20 
1.4.2.5 DNA Melting Analysis (DMA) ..................................................................... 20 
1.4.2.6 High Resolution Melting Analysis (HRMA) ................................................. 22 
1.4.2.6.1 HRMA Incorporating Unlabeled Oligonucleotide Probes .......................... 23 
1.4.2.6.2 HRMA Applications ................................................................................. 26 
1.5 Study Objectives ........................................................................................................ 26 
1.5.1 Research Question ............................................................................................... 27 
1.5.2 Main Objectives ................................................................................................... 27 
1.5.3 Specific Objectives .............................................................................................. 27 
Chapter 2:  Materials and Methods ......................................................................................... 29 
2.1 RNA Isolation............................................................................................................ 29 
2.2 cDNA Construction by Reverse Transcription ........................................................... 29 
2.3 RT-PCR of the p66/p51 Fragment of the pol Gene ..................................................... 30 
2.4 Purification of PCR Products ..................................................................................... 31 
2.5 High Resolution Melting Analysis (HRMA) .............................................................. 31 
2.5.1 Primer Design for HRMA .................................................................................... 31 
2.5.2 Unlabelled Probe Design for HRMA .................................................................... 32 
2.5.3 HRMA-PCR ........................................................................................................ 33 
2.6 HRM Data Analysis ................................................................................................... 34 
2.7 TOPO TA Cloning ..................................................................................................... 35 
Table of Contents 
 
ix 
 
2.8 Site-Directed Mutagenesis ......................................................................................... 36 
2.9 Isolation of Plasmids .................................................................................................. 37 
2.10 Population Sequencing............................................................................................... 39 
Chapter 3:  Results ................................................................................................................. 40 
3.1 Selection of Mutations for HRMA ............................................................................. 40 
3.2 Selection of HIV-1 Patient Samples ........................................................................... 40 
3.3 Design and Optimization of HRMA-PCR .................................................................. 43 
3.3.1 HRMA-PCR Primers ........................................................................................... 44 
3.3.2 HRMA Template ................................................................................................. 46 
3.3.3 HRMA-PCR Conditions ...................................................................................... 46 
3.3.4 HRM Melting Program ........................................................................................ 47 
3.4 HRMA Probe Design and Optimization ..................................................................... 47 
3.4.1 HRMA Probes ..................................................................................................... 47 
3.4.2 HRMA Probe Polymorphism Masking ................................................................. 48 
3.5 Interpretation and Validation of HRMA Results ........................................................ 49 
3.5.1 K103N Assay ....................................................................................................... 49 
3.5.2 Y181C Assay ....................................................................................................... 57 
3.5.3 M184V Assay ...................................................................................................... 63 
3.5.4 Q151M Assay ...................................................................................................... 67 
3.5.5 G190A Assay ....................................................................................................... 72 
Table of Contents 
 
x 
 
3.5.6 K65R Assay ......................................................................................................... 76 
3.5.7 V106M Assay ...................................................................................................... 80 
3.5.8 M41L Assay ........................................................................................................ 82 
3.5.9 D67N Assay......................................................................................................... 85 
3.5.10 K70R Assay ......................................................................................................... 86 
3.5.11 T215F and T215Y Assay ..................................................................................... 88 
3.5.12 P225H Assay ....................................................................................................... 90 
3.6 HRMA Validation ..................................................................................................... 91 
3.6.1 Specificity and Sensitivity .................................................................................... 92 
3.6.1.1 K103N .......................................................................................................... 92 
3.6.1.2 Y181C .......................................................................................................... 92 
3.6.1.3 M184V ......................................................................................................... 93 
3.6.1.4 Q151M ......................................................................................................... 93 
3.6.1.5 G190A .......................................................................................................... 93 
3.6.2 Repeatability and Reproducibility ........................................................................ 93 
3.7 Summary of HRMA Results ...................................................................................... 94 
Chapter 4:  Discussion and Conclusion .................................................................................. 96 Appendix A: Primer Sequences ............................................................................................. 108 Appendix B: Vector Map ........................................................................................................ 109 Appendix C: Media and Reagents .......................................................................................... 110 
Table of Contents 
 
xi 
 
Bacterial Culture Reagents .................................................................................................. 110 
 Ampicillin (100 mg/mL) .......................................................................................... 110 
 Lysogeny broth (LB) ............................................................................................... 110 
 LB agar .................................................................................................................... 110 
 X-Galactosidase (40 mg/mL) ................................................................................... 110 
Agarose Gel Electrophoresis Solutions ................................................................................ 110 
 TAE Buffer (1x) ...................................................................................................... 110 
 Agarose Gels ........................................................................................................... 111 
 Tracking Dye ........................................................................................................... 111 
DNA Buffer ........................................................................................................................ 111 
 Tris-HCl (pH 8) ....................................................................................................... 111 
Appendix D: HRMA Results ................................................................................................... 112 
Appendix E: Ethics Clearance ................................................................................................. 119 
References .............................................................................................................................. 120 
 
 
 
 
 
    
 xii 
 
List of Figures  
Figure  Page 1.1 Diagrammatic representation of the HIV-1 structure……………………………... 2 
1.2 Schematic representation of the HIV-1 genome……………………………………. 3 
1.3 Structure of the HIV-1 RNA dependent DNA polymerase………………………… 4 
1.4 Melting curve analysis……………………………………………………………… 21 
1.5 Dye redistribution. …………………………………………………………………. 23 
1.6 HRMA with unlabelled probes. ……………………………………………………. 24 
2.1 Diagram of data formats. …………………………………………………………... 34 
2.2 Diagrammatic representation of the HRMA assays………………………………. 35 
3.1 Agarose gels of the PCR products following RT-PCR and HRMA………………... 45 
3.2 Optimization of the reverse primer for HRMA-PCR………………………………. 46 
3.3 Optimization of the melt for HRMA. ……………………………………………… 47 
3.4 Optimization of probe concentration for HRMA. …………………………………. 48 
3.5 Application of 103 HRMA assay to plasmids and patient samples………………… 51 
3.6 Application of 103 HRMA assay with polymorphism masking to patient samples... 53 
3.7 Application of 103 HRMA assay with polymorphism masking to plasmids and 
patient samples. …………………………………………………………………….. 53 
3.8 103 HRMA assay and analytical sensitivity. ………………………………………. 56 
3.9 Application of 181 HRMA assay to plasmids and patient samples………………… 58 
3.10 Determination of 181 HRMA assay limit of detection……………………………... 59 
3.11 Application of 181 HRMA assay with polymorphism masking to patient samples... 62 
3.12 Application of 184 HRMA assay to plasmids and patient samples………………… 64 
List of Figures 
 
xiii 
 
3.13 Application of 184 HRMA assay with polymorphism masking to patient samples... 65 
3.14 Determination of 184 HRMA assay limit of detection……………………………... 66 
3.15 Application of 151 HRMA assay to plasmids……………………………………… 69 
3.16 Application of 151 HRMA assay to patient samples. ……………………………… 69 
3.17 Application of 151 HRMA assay with polymorphism masking to patient samples... 71 
3.18 Application of 190 HRMA assay to plasmids and patient samples………………… 73 
3.19 Application of 190 HRMA assay with polymorphism masking to patient samples... 74 
3.20 Application of 65 HRMA assay to plasmids and patient samples………………….. 78 
3.21 Application of 65 HRMA assay with polymorphism masking to plasmids and 
patient samples. …………………………………………………………………….. 79 
3.22 Application of 106 HRMA assay to plasmids. …………………………………….. 81 
3.23 Application of 106 HRMA assay to patient samples……………………………….. 82 
3.24 Application of 41 HRMA assay to plasmids and patient samples………………….. 84 
3.25 Application of 67 HRMA assay to plasmids and patient samples………………….. 86 
3.26 Application of 70 HRMA assay to plasmids. ……………………………………… 87 
3.27 Application of 70 HRMA assay to patient samples………………………………… 88 
3.28 Application of 215 HRMA assay to plasmids and patient samples………………… 89 
3.29 Application of 225 HRMA assay to plasmids……………………………………… 91 
3.30 Application of 225 HRMA assay to patient samples……………………………….. 91 
3.31 Formulae for the calculation of specificity and sensitivity…………………………. 92 
B1 Diagram of pCR 2.1 TOPO vector…………………………………………………. 109  
 
 
 
 xiv 
 
List of Tables  
Table  Page 
1.1 ARV drugs available in the USA………………………………………………… 7 
1.2 Selected HIV-1NRTI drug resistance mutations. ………………………………... 11 
1.3 Selected HIV-1NNRTI drug resistance mutations. ……………………………… 14 
3.1 p66/p51 sequences of 116 samples from 103 patients at selected mutation 
codons. …………………………………………………………………………… 41 
3.2 Primer sequences for the HRMA-PCR assays. ………………………………….. 45 
3.3 Sequences for the altered primers for the HRMA-PCR assays…………………... 45 
3.4 Probe sequences for the K103N assay. …………………………………………... 50 
3.5 Summary of K103N assay results. ………………………………………………. 52 
3.6 No result and discordant patient sequences with polymorphisms within the 
binding region of the K103N assay probes. Correctly genotyped samples without 
polymorphisms were excluded. ………………………………………………….. 55 
3.7 Probe sequences for the Y181C assay. ………………………………………….. 57 
3.8 Summary of Y181C assay results. ……………………………………….………. 59 
3.9 No result and discordant patient sequences with polymorphisms within the 
binding region of the Y181C assay probes. Correctly genotyped samples without 
polymorphisms were excluded. ………………………………………………….. 61 
3.10 Probe sequences for the M184V assay. ………………………………………….. 63 
3.11 Summary of M184V assay results. ………………………………………………. 63 
3.12 No result and discordant patient sequences with polymorphisms within the 
binding region of the M184V assay probes. Correctly genotyped samples 
 
 
List of Tables 
 
xv 
 
without polymorphisms were excluded. …………………………………………. 65 
3.13 Probe sequences for the Q151M assay. ………………………………………….. 67 
3.14 Summary of Q151M assay results. ………………………….…………………… 68 
3.15 No result and discordant patient sequences with polymorphisms within the 
binding region of the Q151M assay probes. Correctly genotyped samples 
without polymorphisms were excluded. …………………………………………. 70 
3.16 Probe sequences for the G190A assay. ……………………...…………………… 72 
3.17 Summary of G190A assay results. ……………………………….……………… 73 
3.18 No result and discordant patient sequences with polymorphisms within the 
binding region of the G190A assay probes. Correctly genotyped samples without 
polymorphisms were excluded. ……………………………………..…………… 75 
3.19 Probe sequences for K65R assay. ………………………………...……………… 77 
3.20 Probe sequences for V106M assay. ……………………………………………… 80 
3.21 Probe sequences for M41L assay. …………………………………..…………… 83 
3.22 Probe sequences for D67N assay. …………………………………...…………… 85 
3.23 Probe sequences for K70R assay. ……………………………………..………… 87 
3.24 Probe sequences for T215F/Y assay. ……………………………….…………… 88 
3.25 Probe sequences for P225H assay. ………………………………………….…… 90 
3.26 Summary of the results for the 103, 181, 184, 151, 190, 65 and 106 assays…….. 95 
A1 Primer sequences for nested RT-PCR, cDNA synthesis and population 
sequencing. …………………………………………………………….………… 108 
A2 Primer sequences for site-directed mutagenesis. ………………………………… 108 
D1 DNA bases and incompletely specified bases. ……………………………...…… 112 
List of Tables 
 
xvi 
 
D2 Population sequences and HRMA predictions for the 103 assay…………..…….. 113 
D3 Population sequences and HRMA predictions for the 181 assay. ……………….. 114 
D4 Population sequences and HRMA predictions for the 184 assay. ……………….. 115 
D5 Population sequences and HRMA predictions for the 151 assay. ……………….. 116 
D6 Population sequences and HRMA predictions for the 190 assay. ……………….. 117 
D7 Population sequences and HRMA predictions for the 65 assay. ………………… 118 
D8 Population sequences and HRMA predictions for the 106 assay. ……………….. 118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvii 
 
Abbreviations 
 
°C  Degrees Celsius 
µL Microlitre 
µM Micromolar 
3TC Lamivudine 
ABC Abacavir 
AIDS Acquired immune deficiency syndrome 
Amp Ampicillin 
AMV  Avian myeloblastosis virus 
ARV Antiretroviral 
AS-PCR Allele specific-PCR 
ATP Adenosine triphosphate 
ATZ/r Ritonavir boosted Atazanavir  
AZT Zidovudine 
bp Base pair 
CCR5 Chemokine (C-C motif) receptor 5 
CD4+ Cluster of differentiation 4 positive  
cDNA Complementary DNA 
cpz Chimpanzee 
CXCR4 Chemokine (C-X-C motif) receptor 4 
d4t Stavudine 
Da Dalton 
Abbreviations 
 
xviii 
 
ddI Didanosine 
ddNTPs Dideoxynucleotide triphosphates 
-dF/dT Negative first derivative plot 
dH2O Distilled water 
DMA DNA melting analysis 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide/side triphosphate 
DRV/r Ritonavir boosted Darunavir 
ds Double-stranded 
DTT Dithiothreitol  
EDTA Ethylenediaminetetraacetic acid 
EFV Efavirenz 
ENF Enfuvirtide 
Env Envelope 
ETR Etravirine 
FN False negative 
FP False positive 
FPV/r Ritonavir boosted Fosamprenavir 
FTC Emtricitabine 
g Gram 
g Gravitational acceleration 
gag Group antigen 
gor Gorilla 
Abbreviations 
 
xix 
 
gp Glycoprotein 
HAART Highly active antiretroviral therapy 
HCl Hydrochloric acid 
HIV Human immunodeficiency virus 
HIV group M Major 
HIV group N Non-M/non O 
HIV group O Outlier 
HRMA High resolution melting analysis 
HSV Herpes simplex virus  
HU Hydroxyurea 
I Inosine 
IC50 Half maximal inhibitory concentration 
IDV/r Ritonavir boosted Indinavir 
kb Kilobase 
kD Kilodalton 
L Litre 
LB Lysogeny broth 
LNA Locked nucleic acid 
LPV/r Ritonavir boosted Lopinavir 
LTR Long terminal repeats 
M Molar 
mg Milligram 
MgCl2 Magnesium chloride 
Abbreviations 
 
xx 
 
mL Millilitre 
mM Millimolar 
mm3 Millimetre cubed 
Mol Mole 
MVC Maraviroc 
NaCl  Sodium chloride 
Nef Negative replication factor 
NFV/r Ritonavir boosted Nelfinavir 
ng Nanogram 
nm Nanometre 
NNRTI Non-nucleoside RT inhibitor 
NRTI Nucleoside RT inhibitor 
NVP Nevirapine 
PCR Polymerase chain reaction 
pH Potentiometric hydrogen ion concentration 
PI Protease inhibitor 
pmol Picomol 
PR Protease 
RAL Raltegravir 
Rev Regulator of virus protein expression 
RNA Ribonucleic acid 
rpm Revolutions per minute 
RRE Rev responsive element 
Abbreviations 
 
xxi 
 
RT Reverse transcriptase 
RT-PCR Reverse transcription-PCR 
s Second 
sd-NVP Single-dose NVP 
SIV Simian immunodeficiency virus 
sm  Sooty mangabey 
SNP Single nucleotide polymorphism 
SOC Super optimal broth 
SQV/r Ritonavir boosted Saquinavir 
ss Single-stranded 
TAE Tris-acetate-EDTA 
TAM Thymidine analogue mutation 
Tat Transcriptional transactivator of LTR 
TDF Tenofovir 
T-lymphocyte Thymus-lymphocyte 
Tm Melting temperature 
TN True negative 
TP True positive 
TPV/r Ritonavir boosted Tipranavir 
Tris Tris(hydroxymethyl)aminomethane 
U Enzyme unit 
Vif Virion infectivity factor 
Vpr Viral protein R 
Abbreviations 
 
xxii 
 
Vpu Viral protein U 
X-gal  Bromo-chloro-indolyl-galactopyranoside 
ZDV Zidovudine 
α Alpha 
β Beta 
 
DNA bases and incompletely specified bases  
A Adenine  
C Cytosine 
T Thymine  
G Guanine  
R G or A 
Y T or C 
M A or C 
S G or C 
W A or T 
H A or C or T 
Amino acids 
  
A Alanine 
C Cysteine 
D Aspartic acid 
E Glutamic acid 
Abbreviations 
 
xxiii 
 
F Phenylalanine 
G Glycine 
H Histidine 
I Isoleucine 
K Lysine 
L Leucine 
M Methionine 
N Asparagine 
P Proline 
Q Glutamine 
R Arginine 
S Serine 
T Threonine 
V Valine 
W Tryptophan 
Y Tyrosine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
Chapter 1:  Literature Review 
 
1.1 Human Immunodeficiency Virus 
The human immunodeficiency virus (HIV) is the aetiologic agent of acquired immune deficiency 
syndrome (AIDS) (Barré-Sinoussi et al., 1983; Gallo et al., 1984). Unknown 27 years ago, today 
it is estimated that 33 million people are infected with HIV, and 25 million people have died 
from the disease. Annually there are ~2 million AIDS related deaths and a total of 2.8 million 
new infections worldwide. Sub-Saharan Africa is most severely affected with 67% of all HIV 
infections and 75% of AIDS deaths (Joint United Nations Programme on HIV/AIDS, 2008). 
Countrywide more than 16% of South Africans aged 25 and older are infected with HIV, while 
the prevalence in some regions exceeds 20% (Shisana et al., 2009). 
 
1.1.1 Classification 
HIV is part of the Retroviridae family, Othoretrovirinae subfamily and Lentivirus genus. To date, 
two species of HIV have been identified, namely HIV type 1 (HIV-1) and HIV type 2 (HIV-2). 
The viruses share ~50% sequence similarity and have a zoonotic origin from simian 
immunodeficiency virus (SIV) (Knipe et al., 2007). HIV-1 is most closely related to SIV which 
is found in wild common chimpanzees (Pan troglodytes), SIVcpz (Gao et al., 1999; Keele et al., 
2006). HIV-2 is most closely related to the SIV that infects sooty mangabeys (Cercocebus atys), 
SIVsm (Chen et al., 1996). HIV-1 is further classified into four groups, which include M, N, O 
and P. However the majority of viruses fall into the Main (M) group, which is divided into nine 
genomic clades (A-D, F-H, J, and K), five sub-subtypes (A1-3 and F1-2) and more than 40 
circulating recombinant forms (http://www.hiv.lanl.gov). Subtype C viruses account for 50% of 
all HIV-1 infections worldwide and is ubiquitous in Southern Africa (Hemelaar et al., 2006; Van 
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Harmelen et al., 1999). The Outlier (O) and Non-M/non-O (N) HIV-1 group viruses are usually 
found within central Africa and infect a minority of patients (Hemelaar et al., 2006). The newly 
discovered group P virus is most closely related to SIV in Gorillas (SIVgor) and has been 
identified in one Cameroonian patient (Plantier et al., 2009).  
 
1.1.2 Structure of HIV  
The mature HI virion is icosahedral in shape and ~120 nm in diameter (Gentile et al., 1994; 
Nermut et al., 1993). The virus is enveloped by a lipid bilayer which is punctuated with 
glycoprotein (gp) spikes. Protruding from the membrane are gp120 trimers which are non-
covalently linked to transmembrane gp41 trimers (Allan et al., 1985; Chan et al., 1997; Kwong et 
al., 1998; Veronese et al., 1985). The lipid bilayer encloses an elongated conical protein core 
which holds two strands of positive sense ssRNA and the reverse transcriptase (RT), integrase 
and protease enzymes (Gelderblom et al., 1987; Knipe et al., 2007) (Figure 1.1). The genome is 
~9700 nucleotides in length and codes for nine genes which generate 15 proteins (Figure 1.2). 
The three largest structural genes include gag, pol and env. The six smaller accessory genes 
include vif, vpr, tat, rev, vpu and nef. The long terminal repeats (LTR) contain the regulatory 
elements and flank the rest of the genome (Kuiken et al., 2009).  
 
 
 
 
 
Figure 1.1. Diagrammatic representation of the HIV-1 
structure. HIV-1 is 120 nm in diameter and 
approximately spherical in shape. Glycoprotein spikes 
protrude from the host-cell derived lipid membrane. 
The conical protein capsid contains RNA, reverse 
transcriptase, integrase and protease enzymes. Figure 
adapted from Knipe et al., 2007. 
gp120
gp41
Reverse 
transcriptase
RNACapsid
Lipid 
membrane
Matrix
Integrase
Protease
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Figure 1.2. Schematic representation of the HIV-1 genome. Gag (red) provides structural proteins for the virus. 
Pol (green) provides enzymes involved in reproduction and infection; including the protease, reverse transcriptase 
and integrase enzymes. Env (orange) provides the membrane proteins that allow for viral attachment and fusion to 
target cells. The regulatory and accessory proteins (grey) play a role in viral transcription and have important 
virulence factors. The Long Terminal Repeats (LTR, blue) flank the viral genome and are involved in transcription 
(Knipe et al., 2007). Figure adapted from Kuiken et al., 2009. 
 
 
The Gag gene encodes the matrix (p17 subunit), capsid (p24 subunit), nucleocapsid (p7 subunit) 
and p6 structural proteins. Pol encodes the enzymatic proteins protease (p10 subunit), reverse 
transcriptase (p51 and p66 subunits) and integrase (p31 subunit). A -1 frame shift allows the 
Gag-Pol polyprotein to be translated (Kuiken et al., 2009). The Gag and Gag-Pol proteins 
undergo 12 proteolytic reactions by protease to generate the different structural and enzymatic 
proteins (Knipe et al., 2007; Oliveira et al., 2003). Env encodes the external non-covalently 
linked trimeric glycoproteins, gp120 and gp41.  The accessory proteins are Tat (p16 and p14 
subunits), Rev (p19 subunit), Vif (p23 subunit), Vpr (p10-p15 subunits), Vpu (p16 subunit) and 
Nef (p25-p27 subunits) (Knipe et al., 2007; Kuiken et al., 2009). Each virion consists of ~2000 
Gag proteins, ~200 Gag-Pol proteins, two strands of RNA and ~300 Vpr molecules (Muller et 
al., 2000; Wilk et al., 2001) 
 
Reverse transcriptase is an asymmetric heterodimeric enzyme, consisting of the 66 kD (p66) and 
51 kD (p51) subunits (Figure 1.3) (Huang et al., 2008). The p51 subunit consists of the first 440 
amino acids of pol, while p66 consists of all 560 amino acids of pol. The subunits share similar 
p66
vif vpr5’ LTR LTR 3’gag
tat
vpu
env
nef
rev rev
tat
p17 p10p24 p31p51 gp41gp120p6p7
pol
PR RT INStructural Proteins Coat Proteins
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subdomains but the catalytic sites are located in p66 while p51 plays a structural role (Sarafianos 
et al., 2009). 
 
  
 
 
 
 
 
 
 
 
 
Figure 1.3. Structure of the HIV-1 RNA dependent DNA polymerase. The HIV-1 reverse transcriptase is composed 
of the p51 and p66 subunits. The p66 subunit consists of the fingers (red), palm (yellow), thumb (orange), 
connection domains (light blue) and RNase H (dark blue). The p51 subunit is indicated in gray, the DNA template as 
dark green, and the primer in light green. Diagram adapted from Huang et al., 1998.  
 
 
1.1.3 HIV Life Cycle 
HIV-1 infects cells that express the CD4 receptor including CD4+ T- lymphocytes, macrophages 
and dendritic cells. The gp120 undergoes structural changes when bound to CD4, which allows 
the virus to attach to the CCR5 or CXCR4 co-receptors. Once the virus is attached to the target 
cell the fusion peptide region of gp41 penetrates the cell (Wyatt and Sodroski, 1998). Following 
lipid membrane fusion, the virus undergoes uncoating, allowing viral particles to enter the 
cytoplasm of the target cell (Lehmann-Che and Saïb, 2004). Reverse transcriptase (RT) is the 
virus encoded RNA dependent DNA polymerase and transcribes RNA into DNA. The enzyme 
also has RNase H function which is required for degradation of the viral RNA allowing for 
cDNA formation (Sarafianos et al., 2009). A pre-integration complex forms consisting of viral 
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cDNA, integrase, protease, Vpr and reverse transcriptase. The pre-integration complex moves 
into the nucleus and integrase mediates the integration of the viral DNA into a transcriptionally 
active region of the host genome (Lehmann-Che and Saïb, 2004). 
 
Parallel host cell and proviral activation occurs due to gene activation by host transcriptional 
regulators which bind to the LTR (Kuiken et al., 2009). Short viral transcripts are produced 
during basal transcription, which form hairpin stem-loops to which Tat binds. Together this 
structure recruits other factors that allow for the production of full length HIV-1 transcripts 
(Kuiken et al., 2009; Zheng et al., 2005). The full length transcripts are spliced into 2 kb or 4.4 
kb fragments. The former can exit the nucleus easily while the latter require Rev and the Rev 
response element (RRE) to exit (Zheng et al., 2005). The shorter fragments are translated in the 
cytoplasm and Tat, Rev and Nef are produced. Rev binds the RRE and shuttles the larger 
transcripts into the cytoplasm (Pollard and Malim, 1998). During virion assembly the RNA 
strands and Gag polyproteins assemble at the host cell membrane. p6 causes membrane budding 
during which, and/or after, protease cleaves gag leading to virion maturation (Bieniasz, 2009; 
Klein et al., 2007). 
 
1.1.4 Disease Progression 
HIV transmission occurs via sexual exposure to an infected partner, exposure to infected blood 
or blood products or exposure in utero, intrapartum or via breast feeding (Centers for Disease 
Control and Prevention, 2005). HIV infection commonly occurs across mucosal surfaces and at 
these points of entry, dendritic cells interact with the virus and facilitate the infection of CD4+ T-
lymphocytes (Geijtenbeek and van Kooyk, 2003). The viral load is high following infection but 
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decreases as cytotoxic T-lymphocytes control the virus, which establishes a viral set-point 
(Musey et al., 1997). As the disease progresses the virus continues to targets CD4+ T-
lymphocytes and so as the viral load increases the CD4+ T-lymphocytes count decreases. 
Consequently the CD4+ T-lymphocyte count and viral load are strongly correlated with the 
development of AIDS (Goedert et al., 1987; Mellors et al., 1995b; Phillips et al., 1991). 
 
The World Health Organization proposes four stages of HIV/AIDS immunodeficiency and the 
median time from the initial stage, HIV infection, to AIDS is 9.8 years in adults (Osmond, 1989). 
Patients in the final stage, AIDS, are characterized by a CD4+ T-lymphocyte count of < 200 
cells/mm3 and severe HIV-associated infections (World Health Organization (WHO), 2007).   
 
1.2 Antiretroviral Drug Therapy 
Antiretroviral (ARV) therapy suppresses viral replication allowing for the partial reconstitution 
of the immune system and slowing the progression to AIDS (Connick et al., 2000; Tochikura et 
al., 1989). However as HIV is integrated into the cellular material of the host immune cells, 
patients must remain on ARV therapy indefinitely (Weller and Williams, 2001).  
 
By 2007 over two million HIV infected patients in Sub-Saharan Africa were receiving ARV 
therapy (WHO/UNAIDS, 2008). The ARV drugs in the following Table have been approved by 
the US Food and Drug Administration (Johnson et al., 2009).  
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Table 1.1. ARV drugs available in the USA. 
Nucleoside reverse transcriptase inhibitors (NRTIs) 
Abacavir (ABC) 
Didanosine (ddI) 
Emtricitabine (FTC) 
Lamivudine (3TC) 
Stavudine (d4T) 
Tenofovir (TDF) 
Zidovudine (ZDV/AZT) 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
Efavirenz (EFV) 
Etravirine (ETR) 
Nevirapine (NVP) 
Protease inhibitors (PIs) 
Atazanavir/Ritonavir (ATZ/r) 
Darunavir/r (DRV/r) 
Fosamprenavir/r (FPV/r) 
Indinavir/r (IDV/r) 
Lopinavir/r (LPV/r) 
Nelfinavir/r (NFV/r) 
Saquinavir/r (SQV/r) 
Tipranavir/r (TPV/r) 
Entry inhibitor 
Enfuvirtide (ENF) 
CCR5 inhibitor 
Maraviroc (MVC) 
Integrase inhibitor 
Raltegravir (RAL) 
Table adapted from Johnson et al., 2009. 
 
 
Each ARV drug class interferes with a different stage in the viral life-cycle. Highly active ARV 
therapy (HAART) takes advantage of this, as it consists of at least three drugs in at least two of 
the drug classes (Clavel and Hance, 2004). The South African Department of Health treatment 
guidelines for HIV infected adults and adolescents has recommended a first-line combination of 
the NRTI drugs d4T and 3TC in combination with the NNRTI drugs EFV or NVP. Second-line 
therapy includes the same NRTI drugs in combination with the Ritonavir boosted protease 
inhibitor Lopinavir (LPV/r or Kaletra (KAL) or Alluvia) (National Department of Health South 
Africa, 2004). Recently, the first-line regimen has been changed to include TDF and 3TC or FTC 
(National Department of Health South Africa 2010, 2010). 
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1.2.1 Mode of Action 
The NRTI drugs are base analogues that are structurally similar to natural nucleosides but lack 
the 3’ hydroxide group. These bases are phosphorylated by host cell kinases and compete with 
the normal dNTPs for incorporation into the transcribed cDNA. As the base analogue lacks the 
3’ hydroxide group the next base cannot form the 5’-3’ phosphodiester bond and DNA synthesis 
is terminated (Menendez-Arias, 2008). 
 
The NNRTIs are a structurally diverse set of small (< 600 Da) hydrophobic compounds. Unlike 
the NRTIs, the NNRTIs do not require host mediated metabolism to function. The NNRTIs 
prevent RT activity by repositioning the catalytic aspartate residues which are located in RT on a 
β-sheet in p66. The repositioning prevents the enzyme from undergoing conformational changes, 
thereby locking the enzyme in an inactive state (De Clercq, 1998). 
 
PIs bind to and prevent protease from cleaving the viral Gag and Gag-Pol polyproteins, thereby 
preventing viral maturation. The inhibitors have been synthesized to resemble the phenylalanine-
proline residues in Gag and Gag-Pol that are cleaved by protease. A hydroxyethylene bond 
instead of the normal peptidic linkage is located at the site at which the protease attempts to 
cleave the drug which prevents cleavage (De Clercq, 2001). 
 
The entry inhibitor, Enfuvirtide, binds to gp41 and prevents the protein from undergoing 
conformational changes required for fusion (Lalezari et al., 2009). The integrase inhibitor, 
Raltegravir, binds to the catalytic domain of integrase, preventing the insertion of the viral cDNA 
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into the host genome (Sichtig et al., 2009). The CCR5 inhibitor, Maraviroc, binds to and blocks 
the CCR5 co-receptors on immune cells from viral attachment (Shafer and Schapiro, 2008).  
 
1.3 Drug Resistance 
ARV drug therapy dramatically reduces viral replication and as a consequence of the wide-
spread use of HAART (≥ 3 drugs from ≥ 2 classes) the AIDS related mortality and morbidity has 
decreased (Joint United Nations Programme on HIV/AIDS, 2008). However the development of 
drug resistance mutations or infection with a resistant virus can lead to treatment failure (Erice et 
al., 1993; Kozal et al., 1993; Larder et al., 1989). Drug resistance mutations can develop in 
response to treatment with each available ARV drug (Johnson et al., 2009). In the settings of 
wild-type, drug susceptible virus, prevention of drug resistance evolution, and by extension, 
success of ARV drug therapy are dependent upon long-term adherence. Depending on the drug 
regimen, adherence of > 60–95% is required to achieve virologic suppression and prevent drug 
resistance development (Gardner et al., 2009).  
 
Inadequate drug exposure can lead to the expansion of drug resistant quasi-species. These sub-
populations can quickly out-compete the wild-type virus leading to treatment failure (Gardner et 
al., 2009). The HIV-1 population within an individual is genetically heterogeneous as a result of 
three factors. (i) HIV-1 exhibits a high turnover rate as 1010 virions/day can be produced 
(Perelson et al., 1996; Piatak Jr et al., 1993). (ii) RT has a high copy error rate, due to the lack of 
proofreading (Roberts et al., 1988); substitutions, additions and deletions are introduced with a 
rate of up to 5 errors/round of replication (Preston et al., 1988). (iii) Recombination can occur if 
an individual is infected with two different HIV strains (Burke, 1997; Zhuang et al., 2002). 
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These factors lead to the evolution of highly diverse subpopulations of quasi-species in an 
infected patient. If any of the random mutations that develop provide a selective advantage in the 
presence of ARV drugs, then that mutant quasi-species will out-compete the less fit viruses 
(Simon et al., 2006).  
 
However drug resistance does not always develop in vivo in response to sup-optimal ARV drug 
therapy. While relatively uncommon, transmission of drug resistant HIV does occur and is a 
growing concern world-wide (Bennett et al., 2008; Erice et al., 1993). In addition natural 
polymorphisms carried by HIV-2 result in resistance to most NNRTIs (Witvrouw et al., 1999). 
Similarly, the various HIV-1 subtypes do not respond equally to each ARV drug due to natural 
polymorphisms (Palmer et al., 1998). In contrast to treatment failure due to drug resistance, drug 
toxicity often limits the success of therapy and is dependent upon host genetics (Tozzi, 2010). 
 
1.3.1 Mutation Classification 
HIV mutations are classified as either primary/major, secondary/minor or compensatory 
mutations. When present alone the primary mutations are capable of inducing high levels of drug 
resistance. Secondary mutations are less potent as their presence alone only marginally reduces 
drug susceptibility. Consequently these mutations are almost exclusively found with other 
primary/major mutations. Mutations can result in decreased viral fitness, which is compensated 
for by the development of compensatory mutations, which restore viral fitness (Shafer, 2002). 
 
The genetic barrier of a drug or class of drugs is a measure of the ease with which resistance 
develops during treatment. One or two single nucleotide polymorphisms (SNPs) lead to high 
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level resistance to drugs with a low genetic barrier, while a number of SNPs are required for 
resistance to develop to drugs with a high genetic barrier. Generally the RT inhibitors have a low 
genetic barrier, while PIs have a high genetic barrier (Luber, 2005). 
 
1.3.2 Major NRTI Mutations 
NRTIs resemble natural nucleosides and are incorporated into growing DNA strands. The 
incorporation of the NRTI prevents continued elongation as the modified bases lacks 3’ 
hydroxide groups (Menendez-Arias, 2008). Two types of NRTI mutations exist; those that result 
in (i) enhanced discrimination against the base analogue and the (ii) removal of the chain 
terminating element. Enhanced discrimination retards the incorporation of 3TC, ABC, ddI, FTC 
and TDF and so viral replication continues (Shafer and Schapiro, 2008). The thymidine analogue 
drugs (ZDV and d4T) select for the second type of mutation, and are termed thymidine analogue 
mutations (TAMs) (Clavel and Hance, 2004). The mutant RT has an altered conformation near to 
the growing DNA chain which allows for ATP binding. ATP bound in this position cleaves the 
phosphodiester bond between the terminated DNA chain and the base analogue, leading to 
continued elongation (Boyer et al., 2001). Mutations identified in p66/p51 of pol that induce 
resistance to the NRTI class of drugs are listed in the following Table. 
 
Table 1.2. Selected HIV-1 NRTI drug resistance mutations. 
Codon Wild-type sequence Mutant sequence Amino acid change 
M41L ATG C/TTG Methionine (M) → Leucine (L) 
K65R AAA/G AGG Lysine (K) → Arginine (R) 
D67N GAC/T AAC/T Aspartate (D) → Arginine(R) 
K70R AAA/G AGG Lysine (K) → Arginine (R) 
Q151M CAA/G ATG Glutamine (E) → Methionine (M) 
M184V ATG GTG Methionine (M) → Valine (V) 
T215F ACC TTC Threonine (T) → Phenylalanine (F) 
T215Y ACC TAC Threonine (T) → Tyrosine (Y) 
Table adapted from Clark et al., 2007. 
Chapter 1: Literature Review 
12 
 
1.3.2.1 M184V 
A common NRTI mutation is the change from methionine (M) to valine (V) at codon 184 
(M184V) of HIV-1 RT. The mutation occurs as a result of a SNP at this position (ATG → GTG), 
replacing methionine at the center of the RT catalytic site. The valine blocks the binding of the 
NRTIs due to steric hindrance. When 3TC is used in mono-therapy, M184V develops within 
weeks, resulting in high level resistance (Clavel and Hance, 2004). M184V also results in low 
level resistance to ddI and ABC, but increased susceptibility to ZDV, d4T and TDF (Shafer and 
Schapiro, 2008). Viruses harbouring M184V have decreased RT processivity and so are 
significantly less fit than the wild-type virus (Martinez-Picado and Martinez, 2008). 
 
1.3.2.2 Q151M 
Codon 151 is situated within a highly conserved region of the finger sub-domain of the 
polymerase (Iversen et al., 1996). There is a high genetic barrier for the glutamine (G) to 
methionine (M) mutation to develop as two bases changes are required (CAG → ATG). 
Additionally, the intermediate viruses are substantially less fit than the wild-type virus 
(Kosalaraksa et al., 1999). Consequently, the emergence of Q151M is rare, occurring in ~5% of 
NRTI resistant patients (Clavel and Hance, 2004). The Q151M mutation results in high level 
resistance to ZDV, d4T, ddI and ABC (Shafer and Schapiro, 2008). 
 
1.3.2.3 K65R 
A lysine (K) to arginine (R) change at codon 65 confers resistance to many NRTIs and is 
selected for by TDF, ABC, ddI, 3TC, FTC and d4T (Xu et al., 2009). The M184V and K65R 
double mutation is strongly deleterious as K65R also decreases polymerase processivity. A62V 
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and S68G are compensatory mutations that rescue the unfit viruses harbouring K65R (Martinez-
Picado and Martinez, 2008). 
 
1.3.2.4 Thymidine Analogue Mutations (TAMs) 
The level of resistance to ZDV, d4T and the other NRTIs is proportional to the number of TAMs 
present. The resistance mutations fall into two categories, type I and type II TAMS. The type I 
pattern includes M41L, L210W and T215Y and type II, D67N, K70R, T215F and K219Q/E 
(Shafer and Schapiro, 2008). K70R and T215Y/F confer moderate resistance to ZDV and d4T 
(Garcia-Lerma, 2005). The presence of D67N, K70R and T215Y or M41L/T215Y double 
mutations, are required for high level resistance (Menendez-Arias, 2008). M41L, D67N, L210W 
and K219Q/E are secondary mutations and only confer resistance when associated with K70R 
and T215Y/F (Garcia-Lerma, 2005). There is partial re-sensitization of TAM mutants to the 
NRTIs when K65R, L74V or M184V are present as these mutations prevent the binding of ATP 
stopping the removal of the blocked base (Goldschmidt and Marquet, 2004). 
 
1.3.3 Minor NRTI Mutations 
The majority (95%) of the minor mutations occur in the presence of major mutations. These 
include, K20R, T39A, K43E/Q/N, E44D/A, T69N/S/I/G/insertion, V75M/A, V118I, G196E, 
K122E, E203K/D and  H208Y (Delaugerre et al., 2001; Gonzales et al., 2003; Mellors et al., 
1995a; Saracino et al., 2006; Shafer and Schapiro, 2008; Svicher et al., 2006). 
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1.3.4 Major NNRTI Mutations 
NNRTIs are small compounds that specifically inhibit HIV-1 RT. Currently 30 structurally 
different classes of NNRTIs have been established. Resistance to these compounds occurs when 
a NNRTI no longer binds to its target site on RT and so are no longer active against the virus 
(Martins et al., 2008). Mutations identified in p66/p51 that confer resistance to the NNRTI class 
of drugs are listed in the following Table. 
 
Table 1.3. Selected HIV-1 NNRTI drug resistance mutations. 
Codon Wild-type sequence Mutant sequence Amino acid change 
K103N AAA/G AAC/T Lysine (K)→ Asparagine (N) 
V106M GTA/G ATG Valine (V)→ Methionine (M) 
Y181C TAT TGT Tyrosine (Y) → Cysteine (C) 
G190A GGG/A/C/T GCA Glycine (G) → Alanine (A) 
P225H CCC/T CAC Proline (P) → Histidine (H) 
Table adapted from Clark et al., 2007. 
 
 
1.3.4.1 K103N 
The lysine (K) to asparagine (N) or serine (S) change at amino acid 103 of HIV-1 RT results in 
high level resistance to NVP and EFV. A hydrogen bond forms between 103N and 188Y which 
stabilizes the NNRTI binding pocket drastically reducing NNRTI binding and conferring broad 
drug resistance (Harrigan et al., 2005; Ren and Stammers, 2008). This mutation carries only a 
small fitness cost as RNase H activity is marginally slowed, thus K103N can persist at low levels 
for years in the absence of drugs (Martinez-Picado and Martinez, 2008).  
 
1.3.4.2 Y181C 
The tyrosine (Y) to cysteine (C) change at position 181 results in the loss of an aromatic ring 
interaction between the amino acid residue and ARV drug. As there are more extensive aromatic 
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interactions between the enzyme and NVP than with EFV, Y181C is associated with strong NVP 
and moderate EFV resistance (Ren and Stammers, 2008).  
 
1.3.4.3 V106M 
Methionine (M) instead of valine (V) at codon 106 decreases the side-chain length thereby 
weakening the drug contact with RT (Martins et al., 2008). The GTA sequence is usually present 
at codon 106 in subtype B viruses, with GTG in subtype C viruses. The ATG mutation (V106M) 
is then more likely to arise in the subtype C GTG background, due to a lower genetic barrier. 
V106M is selected for by EFV, but results in broad NNRTI resistance (Brenner et al., 2003; 
Loemba et al., 2002). The virus is only moderately unfit, probably due to slightly slower RNAse 
H activity (Martinez-Picado and Martinez, 2008).  
 
1.3.4.4 G190A 
The glycine (G) to alanine (A) change at codon 190 is selected for by NVP and increases the size 
of the side-chain at this site. The increased bulk prevents optimal binding of NNRTIs with the 
hydrophobic binding pocket (Ren and Stammers, 2008). G190A, unlike G190E does not confer 
severe fitness costs (Boyer et al., 1998). G190C/T/V are rare and confer high level resistance the 
NNRTIs (Shafer and Schapiro, 2008). 
 
1.3.5 Minor NNRTI Mutations 
The minor NNRTI mutations include, A98G, K101P/Q, V108I, I135T/M, V179D/I/E P225H, 
L283I (De Clercq, 2004; Parkin et al., 2006; Shafer and Schapiro, 2008). 
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1.3.6 Mutations in Other Drug Classes 
In total, more than 80 mutations at more than 40 sites confer resistance to one or more of the PIs. 
Similar to NNRTI mutations, the PI mutations lead to a decreased affinity of the protease 
inhibitor to the target site (Ohtaka and Freire, 2005). I47V/A and V82A/F/T/S confer high level 
PI resistance (Johnson et al., 2009). 
 
The integrase inhibitor, Raltegravir, looses activity when one of the major integrase inhibitor 
mutations (Q148H/K/R, N155H and Y143R/H/C) is present with one or more minor mutations 
(L74M, E138A/K and G140S). The most common combination seen in patients failing 
Raltegravir therapy is Q148H and G140S (Johnson et al., 2009). The mutations alter the 
integrase inhibitor binding site, decreasing the affinity of the drug for the enzyme (Shafer and 
Schapiro, 2008).  
 
The CCR5 inhibitor, Maraviroc, binds to CCR5 complexes on host cells, preventing HIV from 
attaching to these co-receptors. However, resistant viruses are capable of binding to these altered 
sites on target cells. There is also increased binding to drug-free CCR5 and expansion of pre-
existing CXCR4 dependent viruses; which do not require CCR5 co-receptors for binding 
(Latinovic et al., 2009).  
 
The fusion inhibitor, Enfuvirtide, binds to amino acids 36–45 of gp41. Multiple mutations in this 
region result in strong Enfuvirtide resistance, but also decrease viral fitness (Greenberg and 
Cammack, 2004). The N126K, N137K and S138A are compensatory mutations often present in 
Enfuvirtide resistant viruses (Shafer and Schapiro, 2008). 
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1.3.7 Prevalence of Mutations 
While there are many mutations that confer drug resistance only a minority are found in > 10% 
patients failing ARV drug therapy. These prevalent mutations in p66/p51 include M41L, D67N, 
K70R, L90M, K103N, Y181C, M184V, T215Y and L210W (Cheung et al., 2004; Rhee et al., 
2004). 
 
1.4 Resistance Detection 
Resistance testing is performed to ascertain to which drugs a particular HI virus is susceptible or 
resistant. Standardized regimens are highly successful in suppressing viral replication but some 
patients who have experienced virologic failure respond better to individualized HAART 
regimens. The personalized regimens are formulated in part from the information generated from 
resistance testing (Baxter et al., 2000; Durant et al., 1999; Torre and Tambini, 2002; Tural et al., 
2002). 
 
1.4.1 Phenotypic Assays 
Phenotypic assays test the sensitivity of patient derived virus under ARV drug pressure ex vivo. 
HIV is isolated from patient plasma or peripheral blood mononuclear cells and used to infect 
HIV free cells. The infected cells are then cultured in increasing concentrations of ARV drugs 
and the growth is monitored by measuring p24 levels (Alcorn and Faruki, 2000; Baldanti et al., 
2004). The IC50 from patient derived virus is compared to that of a wild-type control (Alcorn and 
Faruki, 2000). A 3-10 fold increase in the IC50 is associated with intermediate resistance, while > 
10 fold increase is considered high level resistance. Alternatively, single-cycle assays can be 
used, wherein the patient derived RT/PR is cloned into a HIV vector and cultured in cells. Such 
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assays are more reproducible and have a higher through-put than traditional phenotypic assays 
(Hanna and D’Aquila, 2001). While phenotypic assays are a direct measure of viral fitness, high 
cost and long assay time limit the utility of phenotypic testing (Baldanti et al., 2004). 
 
1.4.2 Genotypic Assays 
In contrast to phenotypic assays, genotypic assays are used to infer HIV-1 drug resistance from 
sequence data, rather than directly detecting resistance. While there are numerous genotyping 
assays available, only a subset are used for HIV-1 drug resistance detection. Genotyping assays 
involve virus isolation and reverse transcription-PCR (RT-PCR) of the viral RNA. Normally RT 
and PR are then amplified during a PCR step. Additional regions of the genome, corresponding 
to other mutational hotspots can be amplified for investigation (Hanna and D’Aquila, 2001). 
 
1.4.2.1 Hybridization Assays 
The fragmentation of the HIV genome and its subsequent association with probes is used to 
determine the viral genotype in hybridization assays. Biotinylated or fluorescently labeled viral 
nucleic acid is exposed to tens or thousands of labeled/unlabelled probes bound to a surface. The 
surface is scanned and the levels of reporter signal are used to determine the genotype at 
mutation codons of interest. Hybrization assays are reusable and show high concordance with 
sequencing results. However, these assays are subtype specific and cannot reliably genotype 
insertions and deletions (Stuyver et al., 1997; Vahey et al., 1999; Wallis et al., 2005; Wilson et 
al., 2000). 
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1.4.2.2 Dideoxynucleotide Sequencing 
The Sanger method is the most widely used sequencing technique and is based on chain-
termination. Labeled dideoxyribonucleotide triphosphates (ddNTPs) are added in combination 
with regular nucleotides to a PCR. During cycling, the ddNTPs cause chain termination as they 
lack a 3’ hydroxyl group. Eventually fragments of all possible lengths are produced, which are 
separated according to size by polyacrylamide gel electrophoresis. The base pair sequence is then 
elucidated, as the labeled ddNTPs fluoresce at different wavelengths (Pettersson et al., 2009). 
While population sequencing is the gold standard for HIV genotyping it is expensive, labour 
intensive and insensitive (> 20% of mixed species) (Eshleman et al., 2004; Grant et al., 2003; 
Hanna and D’Aquila, 2001; Vossen et al., 2009a). 
 
Pyrosequencing technology is based on sequencing-by-synthesis. Upon nucleotide incorporation, 
a pyrophosphate is released which is converted to ATP. The reaction is setup such that this leads 
to photon emission, which is proportional to the number of dNTPs added to a growing DNA 
chain (Ahmadian et al., 2006). Pyrosequencing has a high analytical sensitivity as it detects ~1% 
of mixed species. While this methodology is useful for indentifying important minority 
populations it is expensive and labour intensive (Ahmadian et al., 2006; Bushmana et al., 2008). 
 
1.4.2.3 Competitive PCR Assays (Real-time PCR) 
Real-time PCR allows for hybridization-based allele-discrimination during PCR (Landegren et 
al., 1998). Real-time PCR differs from traditional PCR due to the inclusion of a fluorescent 
reporter. The signal produced by the fluorescent reporter, a dye or probe, reflects the amount of 
PCR product produced in real-time (Kubista et al., 2006). 
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Allele-specific real-time PCR (AS-PCR), usually an application of real-time PCR, is used for 
genotyping specific loci (Larder et al., 1991). Primers are designed to match both the wild-type 
and mutant viral sequences. The PCR is monitored in real-time and the crossing point is used to 
determine the relative quantities of each measured genotype (Palmer et al., 2006; Toni et al., 
2009). While these assays are fast, cheap and sensitive (~ 1%), they are subtype specific and only 
one mutation at a time can be interrogated (Paredes et al., 2007). 
 
1.4.2.4 Fluorescently Labeled Probes and Real-time PCR 
Taqman assays are usually used for HIV quantitation, but can be adapted for mutation 
identification (Mohey et al., 2005). In Taqman assays, a real-time PCR is setup with a probe that 
consists of a donor and acceptor dye pair. When the acceptor and donor are in close proximity to 
one another, the fluorescence produced by the donor is quenched by the acceptor. Cleavage of 
the probe by Taq polymerase allows the donor dye to fluoresce which is correlated with a 
particular genotype (Holland et al., 1991; Kubista et al., 2006). 
 
1.4.2.5 DNA Melting Analysis (DMA) 
PCR product differentiation by DNA melting analysis (DMA) is dependent upon differences in 
the melting temperature (Tm) of double stranded (ds) nucleic acids. The Tm of DNA is the 
temperature at which 50% of dsDNA denatures to single stranded DNA (ssDNA). The Tm is 
affected by the length of the dsDNA, base composition and the extent of base complementarity. 
Amplicons with the same base composition and length will have the same Tm; a deviation from 
this, including a SNP, will alter the Tm. This alteration in Tm is used for genotyping by DMA 
(Lay and Wittwer, 1997; Reed et al., 2003; Ririe et al., 1997). 
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An intercalating dye is added to a DMA assay to track product formation during PCR and for 
melting curve analysis following the PCR. At the end of the temperature cycling, the PCR 
products are slowly heated. At low temperatures, below the Tm of the nucleic acid, the dye is 
bound to the dsDNA and fluorescence is at a maximum. As the temperature increases, the 
fluorescence slowly decreases due to greater internal rotation of the bound dye. When the Tm of 
the nucleic acid is reached, the DNA melts and the dye dissociates from the ssDNA leading to a 
dramatic drop in the fluorescence (Figure 1.4). The fluorescence differences, which are Tm 
dependent, are used to construct melting curves, from which sequence variation can be detected 
(Kubista et al., 2006). 
 
 
 
Figure 1.4. Melting curve analysis. Two amplicons that differ by an A (purple) to G (green) transition will have a 
slightly different Tm, and so the melting curves will be parallel but shifted along the temperature axis. However a 
heterozygous mixture of these two genotypes produces an altered melting curve shape. Thus homozygous 
difference are distinguished by Tm differences, while heterozygous genotypes by shape differences (Herrmann et 
al., 2006a). 
 
 
DMA is limited to the differentiation of amplicons with major sequence and length differences 
(Ririe et al., 1997). SNP differentiation is possible if high levels of SYBR Green I or other 
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fluorescent dyes are added post-PCR. This two-step process is required as high concentrations of 
certain intercalating dyes, which are required for SNP analysis, inhibit PCR (Lipsky et al., 2001).  
 
DMA allows for mutation scanning along the entire length of the amplicon. The addition of a 
fluorescein-labeled primer and/or probes allows for the interrogation of a limited region of the 
amplicon (Gundry et al., 2003; Millward et al., 2002; Wittwer et al., 2001). 
 
1.4.2.6 High Resolution Melting Analysis (HRMA) 
HRMA is a variation of DMA that allows for closed-tube, one-step differentiation of PCR 
products, by SNPs, with specialized dyes and melting instruments with increases melting 
resolution (Wittwer et al., 2003). Melting resolution depends on a number of factors which vary 
across melting instruments: (i) tight temperature control, decreasing inter-sample variation both 
spatially and temporally; (ii) smooth melt gradients (0.1°C/s) and (iii) sensitive temperature and 
fluorescence detection (Herrmann et al., 2006a; Herrmann et al., 2006b). A new generation of 
specialized melting instruments can collect up to 100 data points/°C, which allows for small 
fluorescence changes to be monitored, permitting more accurate genotyping than with DMA 
(Zhou et al., 2005). HRMA dyes allow for a one-step SNP differentiation procedure as the dyes 
do not inhibit PCR and do not undergo dye redistribution during melting analysis (Figure 1.5) 
(Liew et al., 2004; Wittwer et al., 2003). The limit of detection of HRMA assays is ~ 3% of 
mixed species (Krypuy et al., 2006; Simi et al., 2008; Wojdacz and Dobrovic, 2007). 
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Figure 1.5. Dye redistribution. (A) SYBR Green I redistributes to dsDNA during melting. (B) The new HRMA dyes 
can be added in saturating concentrations and therefore not prone to redistribution. This allows for more precise 
fluorescence monitoring (Gundry et al., 2003; Wittwer et al., 2003). Diagram adapted from Corbett Research, 
2006. 
 
 
 
1.4.2.6.1 HRMA Incorporating Unlabeled Oligonucleotide Probes 
DMA and HRMA indicate base changes within the entire amplicon which is useful for mutation 
discovery (mutation scanning). However the addition of unlabelled, 3’ blocked oligonucleotide 
probes can signal the presence or absence of a particular genotype (Zhou et al., 2004). In this 
procedure, two melting peaks are generated, one due to the melting transition of the probe-
amplicon duplexes and the other the amplicon-amplicon duplexes. The presence of a SNP 
prevents the binding of non-corresponding short probes and no melting peak is generated (Figure 
1.6) (Zhou et al., 2004). Negative first derivative plots (-dF/dT) are constructed to visualize the 
genotype differences and are derived from melting curves (example in Figure 1.4). 
 
The amplicon-amplicon duplexes melt with a larger fluorescence transition than the shorter 
probe duplexes. This signal can overwhelm the smaller probe signal thereby preventing allele 
detection. To bypass this, asymmetric PCRs are setup to overproduce the strand to which the 
probe binds; thereby increasing the probe and decreasing the amplicon signal (Montgomery et 
al., 2007a; Montgomery et al., 2007b; Zhou et al., 2004; Zhou et al., 2005). The probes are 
blocked at the 3’ end to prevent polymerase mediated extension during PCR by 3’ 
phosphorylation, 2’,3’ di- and deoxynucleotide, 3’-3’linkage or 3’-spacer C3 (Zhou et al., 2004). 
A B
Chapter 1: Literature Review 
24 
 
 
Figure 1.6. HRMA with unlabelled probes. (A) Key to diagram. (B) For HRMA with probe analysis, an asymmetric 
PCR is setup, with the excess primer (green) over producing the strand to which the probe (purple) binds. Not each 
amplicon (black) contains a SNP (box). (C) At the end of the PCR, the products are cooled, allowing the formation of 
duplexes. Short probes do not bind if a mismatch is present between the probe and amplicon. (D) Fluorescence is 
monitored during a temperature increase. Amplicon-amplicon duplexes melt at a higher temperature than the 
probe-amplicon duplexes. If a probe binds to an amplicon, a probe peak is generated (black curve). If a probe is 
mismatched to an amplicon no curve is generated (red line) (Erali et al., 2008). 
 
 
Optimal probe length varies from 10 to 30 bp, with a G+C content of ~30%. The peak 
corresponding to the melting of the probe increases in height (i.e. intensity) with increasing 
probe length. Typically, larger probes (> 25 bp) provide the strongest signal with large amplicons 
(> 100 bp). Peak height also depends on the concentration of the probe and amount of competing 
DNA (Zhou et al., 2004; Zhou et al., 2005). The probe is subject to more destabilization when 
the mismatch is in the center, rather than at the extremities (Erali et al., 2008).  
 
Melting analysis is altered when the region to which the probe anneals contains polymorphisms. 
To overcome this problem, a number of modifications can be introduced into the probe.  
Temperature (°C)
-d
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dT
No SNP, no 
probe binding
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D
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 Incorporation of a mismatch at a site that interacts with a polymorphic base can bypass the 
affects of the polymorphism. As a consequence of the mismatch, the wild-type and 
polymorphic probe-amplicon duplexes contain one mismatch, while the mutant sequences 
harbour two mismatches (Margraf et al., 2007; Margraf et al., 2006). 
 
 A deletion of one to three problematic polymorphic bases in a probe can be incorporated. 
Upon formation of the probe-target duplex, the unmatched base or bases of the target ssDNA 
bulge out. Thus regardless of the base/s at the polymorphic site, both wild-type and 
polymorphic amplicons will have the same Tm. 
 
 The incorporation of a universal base into a probe can bypass polymorphisms as these bases 
pair indiscriminately with any DNA nucleotide (Margraf et al., 2007; Margraf et al., 2006; 
Zheng et al., 2008). Hypoxanthine and its universal base analogue, inosine, are produced by 
RNA editing and are found in transfer RNA. However inosine is strictly not a universal base, 
as it does not pair indiscriminately; despite this inosine is widely used and has proved useful 
in primer, probe and micro-array design (Watkins Jr and SantaLucia Jr, 2005). Alternatively, 
3-nitropyrrole can be used, which pairs indiscriminately and the duplexes formed are less 
stable than the natural base pairs (Loakes, 2001; Loakes and Brown, 1994). 
 
 Locked nucleic acids (LNAs) are stable in the presence of polymorphisms. LNAs are 
nucleotide analogues which contain a methylene linkage connecting the 2’ and 4’ carbons of 
the ribose ring. By restricting the conformation of the nucleotide the LNAs are optimized for 
base pairing (Kaur et al., 2006). Consequently, LNAs have a high affinity for their 
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complementary base and the Tm is higher than that of unmodified bases (> 3-8 °C) (Koshkin 
et al., 1998). The inclusion of locked nucleic acids (LNA) improves variant discrimination 
with short probes (< 15 bp) because of the higher thermal stability (Chou et al., 2005; 
Simeonov and Nikiforov, 2002; Ugozzoli et al., 2004).  
 
1.4.2.6.2 HRMA Applications 
Due to its simplicity, cost effectiveness, accuracy and flexibility HRMA is widely used. Besides 
for homozygotic and heterozygotic variant screening and typing, HRMA has been applied to 
methylation and quantification studies (Rouleau et al., 2009; Vossen et al., 2009b; Wojdacz and 
Dobrovic, 2007). Mutation scanning HRMA assays have been setup to type clinically relevant 
bacterial and viral species (Cheng et al., 2006; Giglio et al., 2005; Hewson et al., 2009; Jeffery et 
al., 2007; Lin et al., 2008; Nakagawa et al., 2009; Odell et al., 2005; Price et al., 2007; Sabol et 
al., 2009; Steer et al., 2009; Tajiri-Utagawa et al., 2009; Toi and Dwyer, 2008). In addition, 
HRMA assays have been setup to detect mutations associated with somatic diseases in human 
genetic material (Grievink and Stowell, 2008; Hill et al., 2006; Krenková et al., 2009; Krypuy et 
al., 2006; Liew et al., 2004; Nguyen-Dumont et al., 2009; Nienke van der Stoep et al., 2009; 
Poláková et al., 2008; Poulson and Wittwer, 2007; Reed and Wittwer, 2004; Simi et al., 2008; 
Vandersteen et al., 2007; Willmore-Payne et al., 2005; Zhou et al., 2004; Zhou et al., 2005). 
HRMA has not been applied to the detection of drug resistance mutations in HIV. 
 
1.5 Study Objectives 
HRMA is a useful platform for SNP detection and typing. Assays can be designed to rapidly and 
accurately detect genotypes at selected loci (Zhou et al., 2005). HIV-1 drug resistance mutations 
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typically consist of SNPs and many of these mutations have clinically relevant implications 
(Shafer and Schapiro, 2008). While Sanger population sequencing is expensive, time-consuming 
and insensitive it is the gold standard for HIV drug resistance mutation detection (Hanna and 
D’Aquila, 2001). Consequently the development of new and refinement of current HIV SNP 
detection methodologies is desirable. 
 
1.5.1 Research Question  
Can high resolution melting analysis (HRMA) assays be designed to detect HIV-1 resistance-
related mutation codons? 
 
1.5.2 Main Objectives   
The main objective of this study is to determine whether HRMA incorporating probes is a 
feasible approach for accurately and rapidly identifying HIV-resistance-related mutation codons 
in HIV-1 patient samples. The optimal size and design of probes for use in an HRMA assay 
applied to highly polymorphic genetic material will be established. Additionally, the possibility 
that this method can be used as a mutation screening tool for large numbers of samples will be 
investigated.  
 
1.5.3 Specific Objectives   
 Specific HIV-1 RT drug resistance mutations will be introduced into plasmids by site-
directed mutagenesis. 
 Primers will be designed and asymmetric PCRs setup to amplify these codons in the 
plasmids. 
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 Short, unlabelled, 3’ blocked oligonucleotide probes will be designed to genotype the 
mutation sites during HRMA following PCR. 
 Thermocycling and HRMA will be carried out on the LightCycler 480 Real-Time PCR 
machine (Roche Applied Science, GmbH, Germany).  
 The LightCycler HRM Master (Roche Applied Science, GmbH, Germany), which contains a 
saturating dsDNA binding fluorescent dye will be utilized.  
 After optimization on the plasmids the assays will be applied to the same mutation codons in 
the HIV-1 p66/p51 gene in previously genotyped patient samples.  
 Patient HIV-1 RNA will be isolated and amplified by a nested RT-PCR for use in HRMA 
 A number of masking techniques will be utilized in order to minimize the effect that 
polymorphisms have on HRMA.  
 Clonal analysis and serial dilutions will be setup to establish the limit of detection of the 
assays.  
 Validation of successful assays, which includes sensitivity, specificity, repeatability, 
reproducibility and limit of detection will be completed. 
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2.1 RNA Isolation 
HIV-1 RNA was isolated from 200 µL of stored patient plasma using the MagNA Pure LC 
Instrument and the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche Applied Science, 
GmbH, Germany) according to the manufacturers’ instructions. In total 116 patient samples were 
utilized and details are in section 3.2 (page 40). The kit contains three Wash Buffers, a 
Lysis/Binding buffer, Proteinase K, Magnetic Glass Particles and an Elution Buffer. The 
Lysis/Binding buffer contains a chaotropic salt which disrupts the cell membrane leading to 
lysis. The Proteinase K digests the released proteins and nucleases and the Binding buffer allows 
for the binding of the nucleic acid to positively charged Magnetic Glass Particles.  
 
2.2 cDNA Construction by Reverse Transcription 
Complementary DNA (cDNA) was synthesized with Thermoscript RT (Invitrogen, USA) as per 
the manufacturers’ instructions. The reagents for the reactions were added in the following final 
concentrations: 10 pmol/µL IN3 primer, 1 mM dNTPs, 1x cDNA synthesis buffer, 5 mM DTT, 
20 U RNaseOUT (Invitrogen, USA) and 7.5 U Thermoscript RT. The IN3 (Appendix A, Table 
A1) primer amplified HIV-1 from nucleotide 3757 (HXB2 Genbank accession number 
AF033819).  
 
Four microlitres of purified RNA was added to the primer/dNTP mix, and then denatured at 65 
°C for 5 minutes. Thereafter the tubes were placed on ice for one minute and the master mix was 
added. The mixture was incubated for one hour at 55 °C to allow for cDNA synthesis; thereafter 
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the enzyme was deactivated by heating to 85 °C for five minutes. The tubes were cooled on ice 
for one minute before 1 U of RNase H was added. The reaction was incubated at 37 °C for 20 
minutes to degrade the RNA. The cDNA was stored at -20 °C. 
 
2.3 RT-PCR of the p66/p51 Fragment of the pol Gene 
A 986 bp region spanning amino acids 1 to 321 of HIV-1 RT was amplified with an in-house, 
two stage nested reverse transcription PCR (RT-PCR) (Loubser et al., 2006). For the outer 
reaction, the forward and reverse primers, pFor-out and pRev-out (Appendix A, Table A1) were 
utilized at final concentrations of 20 pmol/µL per primer. The amplified region spanned 
nucleotides 1,951 to 3,037 of HIV-1 p66/p51 (HXB2 Genbank accession number AF033819). 
The final concentrations of the reagents were: 1.4 mM MgCl2, 160 µM dNTP, 4 U/µL AMV RT 
(Roche Applied Science, GmbH, Germany), 1.25 U/µL Super-Therm enzyme (Southern Cross 
Biotechnology (Pty.) Ltd., South Africa), 10 U/µL RNase Inhibitor (Roche Applied Science, 
GmbH, Germany), and 1 x for the ammonium sulphate based buffer. With the addition of 5 µL 
of RNA, the total volume was 50 µL. The RT-PCR conditions for the first reaction were 42 °C 
for 60 minutes, 95 °C for seven minutes and 35 cycles of 92 °C for 20 seconds, 50 °C for 30 
seconds and 72 °C for 90 seconds and a final ten minutes at 72 °C. 
 
The second round of the PCR procedure amplified nucleotides 2,056 to 3,004 (HXB2 Genbank 
accession number AF033819) and was performed using the pFor-in and pRev-in forward and 
reverse primers (Appendix, Table A1). The Taq polymerase, primers, MgCl2, dNTP and buffer 
were added to the same final concentrations as before. The total volume was 100 µL with 10 µL 
of first round PCR product added. The cycling conditions were the same as above, excluding the 
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initial 42 °C for 60 minutes. The PCR products were visualized on 1% agarose gels and the 
products were stored at -20 °C.  
 
2.4 Purification of PCR Products 
PCR samples were purified using the High Pure PCR Product Purification Kit (Roche Applied 
Science, GmbH, Germany) according to the manufacturers’ protocol. Purification was required 
to remove excess primers, salts, dNTPs and enzymes to prevent inhibition of downstream 
reactions. Five hundred microlitres of Binding Buffer was mixed with each PCR reaction and 
placed into a filter tube and centrifuged for one minute at 13 000 g. The chaotropic salt guanidine 
thiocyanate in the Binding Buffer causes the DNA to bind to glass fibers within the filter tube. 
This allows contaminant removal during the ensuing wash steps. The flow through was discarded 
from the collection tubes and 500 µL of Wash Buffer was added prior to re-centrifugation. This 
step was repeated with 200 µL of Wash Buffer. The PCR DNA was eluted in 50 µL of the 
Elution Buffer by one minute of centrifugation at 13 000 g. The samples were quantified using 
the NanoDrop1000 spectrophotometer (Thermo Fisher Scientific Inc, USA) at 260 nm. The 
DNA was diluted (1:100) in Tris-HCl pH 8, and stored at -20 °C. 
 
2.5 High Resolution Melting Analysis (HRMA) 
2.5.1 Primer Design for HRMA 
An HIV-1 South African based consensus sequence, using 648 subtype C sequences was 
assembled using Sequencher version 4.5 (Gene Codes Corporation, USA). The sequences were 
downloaded from the Los Alamos HIV Database (http://www.hiv.lanl.gov), and primers and 
probes were designed using this consensus sequence (Tables 3.2 and 3.3, page 45). Six PCRs 
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(Table 3.2), spanning the mutations of interest, were designed encompassing amino acids 37–44 
(nucleotides 2,203–2,227), 60–74 (nucleotides 2,272–2,317), 100–108 (nucleotides 2,391–
2,421), 146–154 (nucleotides 2,529–2,557), 181–191 (nucleotides 2,636–2,668) and 212–229 
(nucleotides 2,729–2,783) of the HIV-1 p66/p51 gene (HXB2 Genbank accession number 
AF033819). Including the primer, the amplicon length ranged from 72 bp to 100 bp.  
 
In addition, “altered” primers were designed to anneal to the sites directly adjacent the 103, 151, 
184 and 190 mutation codons (Table 3.3, page 45). These primers produced a PCR product of 3 
bp (excluding the primer) which would mask the polymorphisms flanking the codons of interest, 
preventing erroneous HRMA. The Tm of each primer, after salt adjustment, was between 58 °C 
and 62 °C (Kibbe, 2007). The primers were diluted in dH2O pH 7.4 and stored at -20 °C.  
 
2.5.2 Unlabelled Probe Design for HRMA 
Short probes of 11, 15 and 16 bp in length were designed for codon genotyping during HRMA. 
Probes were designed to be complementary to the wild-type and mutant codons at each position 
of interest. The probe length was minimized to prevent hybridization to polymorphic flanking 
regions and to allow for simple melt curve interpretation. The mutation of interest was in the 
center of the probe to maximize probe instability when melting (Naiser et al., 2008). Each probe 
was designed to hybridize to the sense strand. In order to prevent probe extension during 
thermocycling, the probes were blocked at the 3’ end by phosphorylation. The probes were 
manufactured by Inqaba Biotec, South Africa. 
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To facilitate polymorphism masking in the event that polymorphisms disrupted HRMA, a 
number of modifications were introduced into the probes (Margraf et al., 2006). Probes 
containing LNAs, ambiguous, universal, deleted and mismatched bases at selected polymorphic 
regions were tested. Ambiguous bases incorporated a mixture of each base at the selected region. 
Universal bases included inosine at the polymorphic region. Deleted bases consisted of a 
complementary probe with a missing nucleotide/s at the polymorphic site. An extra base/s was 
added onto the probe to maintain the 15 bp length. Deliberate mismatches were incorporated to 
the ensure instability of the probe-amplicon interaction in cases of non-specific binding. 
 
2.5.3 HRMA-PCR 
The real-time PCRs were performed using the ready-to-use master mix, LightCycler HRM 
Master (Roche Applied Science, GmbH, Germany). The mix contains LightCycler 480 High 
Resolution Melting Dye (Roche Applied Science, GmbH, Germany) which intercalates with 
dsDNA, allowing for HRMA.  
 
Asymmetric PCRs were designed to ensure the visibility of the weaker probe signal. The optimal 
concentration of the reagents for each assay was determined using the wild-type HIV-1 plasmid 
as the template molecule. The final concentrations of the reagents for the HRM-PCR were 1x 
LightCycler HRM Master, 2.5 mM MgCl2, 10 pmol/µL of the forward primer and 2.5 ng of 
template DNA. The optimal concentrations for the reverse primers and probes were 0.3–1 
pmol/µL and 2 µM, respectively. The final volume of the reactions was 10 µL. The real-time 
PCRs were carried out in 96 multi-well plates, sealed with LightCycler Sealing Foil (Roche 
Applied Science, GmbH, Germany) and centrifuged for one minute at 150 rpm. 
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The LightCycler 480 Real-Time PCR conditions were: 94 °C for five minutes with a ramp rate 
of 4.4 °C/s; 45 cycles at 95 °C for 10 seconds at 4.4 °C/s, 55 °C for 15 seconds at 2.2 °C/s and 72 
°C for 15 seconds at 4.4 °C/s; high resolution melting at 95 °C for one minute at 4.4 °C/s, 40 °C 
for one minute at 2.2 °C/s, then a temperature increase from 40 °C to 95 °C at 1-3 °C/s, followed 
by 40 °C for ten seconds at 2.2 °C/s. During PCR optimization, the products were run on 2% 
agarose gels, to test for specific and successful amplification.  
 
2.6 HRM Data Analysis 
The melting data was analyzed (Figure 2.1) using the LightCycler 480 Gene Scanning Software 
version 1.2.0.0625 (Roche Applied Science, GmbH, Germany). For data normalization, 
fluorescence base lines were selected before and after the melting transition. The pre-melt 
fluorescence was adjusted to a relative value of 100%, while the post-melt fluorescence, to 0%. 
This normalization of the data was required to distinguish homozygous mutants by Tm 
differences. Negative first derivative (-dF/dT) plots of the normalized data were used to visualize 
probe and amplicon melting in a single curve. The Tm of the probe and amplicon appear as peaks 
(Erali et al., 2008; Montgomery et al., 2007b). The assay procedure is diagramed in Figure 2.2. 
 
 
 
 
 
 
Figure 2.1. Diagram of data formats. (A) Raw Data (B) Normalization: genotype 1 and genotype 2 are homozygous, 
differentiated by a SNP. Normalized homozygous mutants are parallel to one another. (C) Negative first derivative 
plots: homozygotes have a sharp melting peak while heterozygotes have a broader peak. The latter is due to the 
mixture of two genotypes, with two different Tm’s (Erali et al., 2008; Montgomery et al., 2007b; Wittwer et al., 
2003). 
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Figure 2.2. Diagrammatic representation of the HRMA assays. Samples were prepared and stored, while master 
mixes were prepared and used as needed. 
 
 
 
2.7 TOPO TA Cloning 
Cloning of five HIV-1 patient samples (10b, 26, 47, 73 and 92) was conducted to detect 
mutations at the 103, 151, 181, 184 and 190 codons present at minority levels. HRMA identified 
minority resistance populations in these samples which were not detected by population 
sequencing. The TOPO TA Cloning Kit with the pCR 2.1-TOPO vector (Appendix B, Figure 
B1) and TOP10 chemically competent cells (Invitrogen, USA) were utilized for cloning 
according to the manufacturer’s guidelines. Four microlitres of PCR product from the second 
round nested PCR were mixed with 1 µL of the vector and 1 µL of the supplied salt solution 
(200 mM NaCl and 10 mM MgCl2). The solution was gently mixed and incubated at room 
temperature for 30 minutes. The salt solution increases the number of transformants as it 
prevents topoisomerase I from rebinding and nicking the DNA after ligation. After incubation, 5 
µL of the cloning reaction was added to a vial of TOP10 cells thawed on ice. This mixture was 
incubated on ice for 20 minutes; thereafter the cells were heat-shocked at 42 °C for 30 seconds. 
The cells were placed on ice and 250 µL of room temperature SOC medium was added. The 
vials were incubated at 37 °C with horizontal shaking (200 rpm) for one hour. Before the cells 
were spread onto selective agar plates (100 mg/ml ampicillin), 40 µl of X-gal (40 mg/ml) was 
spread onto the plates for blue-white screening. A third of the cell mixture was spread onto the 
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selective plates and incubated at 37 °C for 16 hours. Positive colonies (white) were selected by 
blue-white screening. 
 
Colony PCR was performed using inner primers for the RT-PCR as per section 2.3 page 30. 
Following PCR the products were diluted (1:100) in Tris-HCl pH 8 and used as template for 
HRMA. HRMA was performed on 100 colonies per patient sample to detect mutations present at 
minority levels. 
 
2.8 Site-Directed Mutagenesis 
Plasmids containing each mutation under analysis were required for HRM-PCR optimization and 
for serial dilutions. Site-directed mutagenesis was performed on a previously engineered plasmid 
which contained 1,129 bp of the p66/p51 gene of the HIV-1 subtype C CM9 virus (CM9 
Genbank accession number AF411967), cloned into the pCR 2.1 vector (Invitrogen, USA) 
(Cilliers et al., 2005; Loubser et al., 2006). Mutagenesis was performed using the QuikChange® 
II Site-Directed Mutagenesis Kit (Stratagene, USA). The oligonucleotide primers for site-
directed mutagenesis were designed according to the manufacturer’s instructions (Appendix A, 
Table A2). In addition a full length (9,913 bp) recombinant subtype C HIV-1 clone, MJ4 (MJ4 
Genbank accession number AF321523), was utilized for the 181 and 184 assay optimization and 
serial dilutions (Ndung’u et al., 2001). CM9 plasmid containing K65R and K103N and PMJ4 
containing Y181C and M184V were previously engineered in our laboratory by Shayne Loubser 
and Visva Pillay. The author introduced the HIV-1 resistance related mutations M41L, D67N, 
K70R, Q151M, G190A, T215F, T215Y and P225H into the CM9 plasmid. 
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For side-directed mutagenesis the reagents were prepared to the following final concentrations, 
according the manufacturer’s guidelines: 1 x reaction buffer, 125 ng for both primers, 1 mM 
dNTP and 50 ng of template DNA in 50 µL reactions. PCR conditions were 95 °C for 30 
seconds, 20 cycles of 95 °C for 30 seconds, 55 °C for one minute and 68 °C for six minutes. As 
the wild-type parental strand is methylated, it is digested by the methylation specific 
endonuclease Dpn I. One microlitre of Dpn I was added following the PCR and the mixture was 
incubated for one hour at 37 °C. 
  
To transform the mutated plasmids, 1 µL of the restricted DNA was added to 50 µL of thawed 
XL1-Blue supercompetent cells (Stratagene, USA). After incubation on ice for 30 minutes, the 
cells were heat-shocked at 42 °C for 45 seconds and placed on ice for two minutes. The cells 
were then incubated in 0.5 mL of non-selective SOC medium for one hour at 37 °C with 
horizontal shaking at 230 rpm. Thereafter, 150 µL of the mixture was spread onto ampicillin 
(amp)-containing agar plates (100 mg/mL) and incubated for 16 hours at 37 °C. As the pCR 2.1 
vector contains a gene for ampicillin resistance, only transformed cells grew on the amp+ plates. 
 
2.9 Isolation of Plasmids 
The GenElute HP Plasmid Midiprep Kit (Sigma-Aldrich, GmbH, Germany) was used to isolate 
the plasmid DNA from the transformed Escherichia coli cells. Following the manufacturer’s 
protocol, a single colony from each plate was used to inoculate 5 mL of lysogeny broth (LB)-
amp+ (100 mg/mL). After an eight hour incubation at 37 °C with horizontal shaking at 230 rpm, 
the cells were diluted to 1:1000 in 15 mL of LB-amp+. The cells were again incubated, under the 
same conditions for 16 hours.  
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Following incubation the cells were collected by centrifugation at 5000 g for ten minutes. The 
supernatant was discarded and 4 mL of the Resuspension/RNase A Solution was added and the 
bacterial pellet was resuspended by vortexing. Four millilitres of Lysis Solution was added and 
the cells were gently mixed, allowing cell lysis and a pH increase. The increase in pH leads to 
denaturation of the chromosomal DNA, while the covalently closed circular plasmid DNA 
remains renatured. After five minutes the cell lysate was neutralized by the addition of 4 mL of 
Neutralization Solution. Neutralization leads to the formation of an insoluble network of 
chromosomal DNA while the plasmid DNA remains in solution (Birnboim and Doly, 1979). The 
solution was gently mixed and 3 mL of Binding Solution was added. Following further gentle 
mixing the cell lysate was poured into the barrel of a filter syringe. Binding columns were placed 
into collection tubes, 4 mL of Column Preparation Solution was added, and the tubes 
centrifuged. The centrifugation during the preceding and proceeding wash steps occurred at 3000 
g for two minutes. The eluate, containing cell debris, lipids and chromosomal DNA, was 
discarded each time. The cleared lysate in the filter syringe was emptied into the binding column, 
to which it absorbed, and was then centrifuged. Four millilitres of Wash Solution 1 was added 
and the column centrifuged. Four millilitres of Wash Solution 2 was added and the column 
centrifuged for five minutes. Following the final wash step the binding column was placed into a 
new collection tube and 1 mL of the Elution Solution was added. The tube was centrifuged for 
five minutes and the eluate saved. The purified plasmids were quantified on a NanoDrop1000 
spectrophotometer (Thermo Fisher Scientific Inc, USA) at 260 nm, diluted in Tris-HCl pH 8, and 
stored at -20 °C. 
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2.10 Population Sequencing 
Sanger population sequencing reactions were setup according to the BigDye Terminator v3.1 
Cycle Sequencing Kit guidelines (Applied Biosystems, USA). This reagent contains 
fluorescently labeled ddNTPs required sequencing. The reaction mix consisted of 0.5 x 
Sequencing Buffer, 3.2 pmol/µL primer, 60-300 ng of template DNA and 2 µL of the Ready 
Reaction Mix, to a total of 10 µL. The forward primers pFor-in and LC-outF (Appendix A, Table 
A1) amplified nucleotides 2,056 and 2,344, respectively (Loubser et al., 2006). The reverse 
primers pRev-in and M8 (Appendix A, Table A1) amplified from nucleotides 3,004 and 2,847, 
respectively (HXB2 Genbank accession number AF033819) (Loubser et al., 2006). 
Thermocycling was performed under the following conditions: 96 °C for one minute followed by 
25 cycles of 96 °C for ten seconds, 50 °C for five seconds and 60 °C for four minutes. 
 
The products were purified by alcohol precipitation. Fifty microlitres of 3 M pH 4.6 sodium 
acetate and ethanol (1:25) mixture was added to each tube. After vortexing, the strips were 
centrifuged at room temperature for 30 minute at 2000 g. The supernatant was decanted and the 
pellet was spun upside-down for one minute at 150 g. Seventy micolitres of ice-cold ethanol was 
then added and the tubes spun for five minutes at 2000 g, and the supernatant discarded. The 
pellet was spun upside-down again for one minute at 150 g. The wash steps remove excess 
ddNTPs and other contaminants. Following drying at 65 °C for three minutes, the pellets were 
resuspended in 10 µL of Formamide and loaded onto 96 well plates (Applied Biosystems, USA) 
for sequencing. The sequencing was carried out on an ABI 3100 Genetic Analyzer (Applied 
Biosystems, USA). The sequences were analyzed on Sequencher version 4.5 (Gene Codes 
Corporation, USA). 
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Chapter 3:  Results 
 
3.1 Selection of Mutations for HRMA 
The current South African Department of Health treatment guidelines for HIV infected adults 
recommends a first-line ARV combination of two NRTIs and one NNRTI and a second-line 
combination of two NRTIs and one boosted PI (National Department of Health South Africa 
2010, 2010). To date, three studies have shown the predominance of the M184V/I (64%-78%), 
K103N (39%-55%), TAMs (23%-32%), V106M (19%-31%), G190A/S (16%-20%), P225H 
(7%-14%), Y181C (10%), K65R (3%-9%) and Q151M (1%-3%) mutations in South African 
patients failing first- or second-line treatment (Marconi et al., 2008; Orrell et al., 2009; Wallis et 
al., 2009). Consequently, these mutations were selected for investigation in this project. 
 
3.2 Selection of HIV-1 Patient Samples 
Previously sequenced, stored plasma (n=116) from HIV-1 patients (n=103) were selected for 
analysis. The patient samples were obtained from four previously established cohorts. Samples 
were selected to ensure the presence of a variety of HIV-1 p66/p51 genotypes, both wild-type 
and mutant. Ethics clearance (M090360) was received from the Human Research Ethics 
Committee in order to utilize the samples (Appendix E). 
 
Samples 1 to 9 were selected from a longitudinal study of HIV-1 mutations in mothers and 
infants following exposure to single-dose NVP (sd-NVP) for the prevention of mother-to-child 
transmission of HIV. Maternal plasma from two different time-points were analyzed. The first 
time-point was drawn during patient enrolment (designated ‘a’) and the second time-point was 
six weeks post-exposure to sd-NVP, (‘b’) (Martinson et al., 2007). Samples 10 to 20 were 
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selected from a longitudinal study of two groups of pregnant woman: one exposed to sd-NVP 
during a previous pregnancy and one drug naïve cohort (Martinson et al., 2009). Maternal 
plasma was utilized and four of the ten samples had two time-points; enrolment (‘a’) and six 
weeks post sd-NVP exposure (‘b’). In both studies the principal maternal drug resistance 
mutation was K103N. Samples 21 to 62 were selected from a cross-sectional study of HIV 
infected patients on ART. The most common drug resistance mutations in these patients were 
M184V and K103N (El-Khatib et al., 2009). The remaining samples, 63 to 103, were selected 
from a random group of patients failing first- and second-line ARV drug regimens (Pillay et al., 
2008). In total, 13 of the patients had two time-points and the remaining 90 were single time-
point. In each of these cohorts, patients were enrolled at South African hospitals and 97% of the 
patients were subtype C and the remaining were subtype B. 
 
The following Table shows the genotypes of the relevant codons of the patient samples utilized 
in this study. The genotypes were previously determined by Sanger population sequencing. The 
most common mutations were K103N (n=43) and M184V (n=40). 
 
 
Table 3.1. p66/p51 sequences of 116 samples from 103 patients at selected mutation codons. 
 
  
Codon 
 
Patient sample Drugs 41 65 67 70 103 106 151 181 184 190 215 225 Subtype 
Sample 1a naïve ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 1b sd-NVP ATG AAG GAC AAG AAM GTG CAG TRT ATG GGA ACC CCC C 
Sample 2a naïve ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 2b sd-NVP ATG AAG GAC AAG AAM RTG CAG TAT ATG GGA ACC CCC C 
Sample 3a naïve ATG AAG GAC AAG AAA GTT CAG TAT ATG GGA ACC CCC C 
Sample 3b sd-NVP ATG AAG GAC AAG AAA GTT CAG TRT ATG GGA ACC CCC C 
Sample 4a naïve ATG AAG GAC AAR AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 4b sd-NVP ATG AAG GAC AAG AAM GTG CAG TAT ATG GSA ACC CCC C 
Sample 5a naïve ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 5b sd-NVP ATG AAG GAC AAG AAA RTG CAG TAT ATG GGA ACC CCC C 
Sample 6a naïve ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 6b sd-NVP ATG AAG GAC AAG AAC GTG CAG TAT ATG GGA ACC CCC C 
Sample 7a naïve ATG AAG GAC AAG AAA GTG CAA TAT ATG GGA ACT CCC C 
Sample 7b sd-NVP ATG AAG GAC AAG AAM GTG CAA TAT ATG GGA ACT CCC C 
Sample 8a naïve ATG AAG GAC AAG AAA GTG CAA TAT ATG GGA ACY CCC C 
Sample 8b sd-NVP fail† AAA AAH AGT AAH TCC CAA TAT GGA ACA fail fail C 
Sample 9a naïve ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
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Codon 
 
Patient sample Drugs 41 65 67 70 103 106 151 181 184 190 215 225 Subtype 
Sample 9b sd-NVP ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 10a naïve ATG AAG GAC AAG AAA GTG CAA TAT ATG GGA ACC CCC C 
Sample 10b sd-NVP ATG AAG GAC AAG AAM GTG CAA TRT ATG GGA ACC CCC C 
Sample 11a naïve ATG AAG GAY AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 11b sd-NVP ATG AAG GAC AAG AAA GTA CAG TAT ATG GGA ACC CCC C 
Sample 12a naïve ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 12b sd-NVP ATG AAG GAC AAG AAM RTG CAG TRT ATG GSA ACC CCC C 
Sample 13a naïve ATG AAG GAC AAG AAA GTG CAA TAT ATG GGA ACC CCC C 
Sample 13b naïve ATG AAG GAC AAG AAM GYG CAA TAT ATG GGA ACC CCC C 
Sample 14 naïve ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 15 naïve ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA fail fail C 
Sample 16 naïve ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 17 naïve ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 18 sd-NVP ATG AAG GAC AAA AAA GTA CAG TAT ATG GGA ACC CCC C 
Sample 19 sd-NVP ATG AAG GAC AAR AAM GTG CAG TRT ATG GGA ACC CCC C 
Sample 20 naïve ATG AAG GAC AAG AGA GTG CAG TAT ATG GGR ACC CCC C 
Sample 21 d4T/3TC/EFV ATG AAG AAC AAG AAA ATG CAG TAT GTG GGA ACC CCC C 
Sample 22 d4T/3TC/EFV ATG AAG GAC AAG AAC GTG CAG TAT GTG GGA ACC CCC C 
Sample 23 d4T/3TC/NVP ATG AAG GAC AAG AAA ATG CAG TAT GTG GGA ACC CCC C 
Sample 24 d4T/3TC/EFV ATG AAG GAT AAG AAC GTG CAG TAT GTG GGA ACC CCC C 
Sample 25 d4T/3TC/KAL ATG AAG GAC AAG AAA GTT CAG TAT RTG GGA ACC CCC C 
Sample 26 d4T/3TC/EFV ATG AAG GAC AAA AAA GTA CAG TAT GTG GGA ACC CCC C 
Sample 27 AZT/3TC/KAL ATG AAG GAC AAG AAA GTG CAG TAY ATG GGR ACC CCC C 
Sample 28 d4T/3TC/EFV ATG AAG GAC AAG AAA ATG CAG TAT GTR GGA TTC CAC C 
Sample 29 d4T/3TC/EFV ATG AAG GAC AAG AAC GTG CAA TAT GTG GGA ACC CCC C 
Sample 30 AZT/3TC/EFV TTG AAG GAT AAG AAT GTG CAA TAT GTG GGA TAC CCC C 
Sample 31 AZT/3TC/EFV ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 32 AZT/ddI/KAL ATG AAG GAC AAG AGA ATG CAA TAT ATG GGA ACC CCC C 
Sample 33 d4T/3TC/EFV ATG AAG AAT AAG AGA ATG CAG TAT GTG GCA ACC CCC C 
Sample 34 AZT/ddI/KAL ATG AAG GAC AAR AAC GTG CAG TAT ATG GGA ACC CCC C 
Sample 35 AZT/3TC/EFV ATG AAG GAC AAG AAA ATG CAG TAT RTR GSA ACC CCC C 
Sample 36 d4T/3TC/EFV ATG AAG GAC AAG AAC GTG CAG TAT GTG GGC TAC CCC C 
Sample 37 d4T/3TC/EFV ATG AAG GAC AAG AAA GTG CAG TAT ATG GSA ACC CCC C 
Sample 38 AZT/3TC/KAL ATG AAG GAC AAA AAC GTG CAG TAT ATG GGA ACC CCC C 
Sample 39 d4T/3TC/EFV ATG AAG GAC AAG AAG GTG CAG TAT ATG GGA ACC CCC C 
Sample 40 d4T/3TC/EFV ATG AAG RAC AAG AAC ATG CAG TAT GTG GGA ACC CCC C 
Sample 41 AZT/3TC/NVP ATG AAG GAC AAG AAC GTG CAA TAT GTG GGA ACC CCC C 
Sample 42 AZT/ddI/KAL ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 43 d4T/3TC/EFV ATG AAG GAC AAG AAC GTG CAA TAT ATG GGA ACC CCC C 
Sample 44 AZT/3TC/EFV ATG AAG GAC AAG AAT GTG CAA TAT GTG GGA ACC CAC C 
Sample 45 AZT/3TC/EFV ATG AAG GAC AAA AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 46 d4T/3TC/EFV ATG AAG GAC AAG AAA GTG CAG TAT RTG GGA ACC CCC C 
Sample 47 d4T/3TC/EFV ATG AAG GAC AAG AAG GTG CAG TAT GTG GGA ACC CCC C 
Sample 48 d4T/3TC/EFV ATG AAG GAC AAG AAC GTG CAA TAT GTG GGA ACC CCC C 
Sample 49 d4T/3TC/EFV ATG AAG GAC AAA AAR GTG CAG TAT GTG GGA ACC CCC C 
Sample 50 d4T/3TC/EFV ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 51 d4T/3TC/EFV ATG AAG GAC AAG AAA ATG CAG TAT RTG GGA ACC CCC C 
Sample 52 d4T/3TC/NVP ATG AAA GAC AAA AAC GTA CAA TAT GTA GGA ACC CCT C 
Sample 53 d4T/3TC/EFV ATG AAG GAC AAG AAA ATG CAG TAT GTG GGA ACC CCY C 
Sample 54 AZT/ddI/KAL ATG AAG GAC AAG AGT GTG CAG TAT GTG GCA ACT CCC C 
Sample 55 d4T/3TC/EFV ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 56 d4T/3TC/EFV ATG AAG GAC AAG AAC GTG CAG TAT ATG GGA ACC CCC C 
Sample 57 d4T/3TC/EFV ATG AAG GAC AAG AAC GTA CAG TAT GTG GGA ACC CAC C 
Sample 58 AZT/ddI/KAL ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 59 d4T/3TC/KAL ATG AAG GAC AAG AAA GTG CAG TAT ATG GGC CCC CCC C 
Sample 60 AZT/ddI/KAL ATG AAG GAC AAG AAM GTG CAG TAT ATG GGA ACT CCC C 
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Codon 
 
Patient sample Drugs 41 65 67 70 103 106 151 181 184 190 215 225 Subtype 
Sample 61 AZT/3TC/EFV ATG AAG GAC AAG AAA GTG CAG TAT GTG GGA ACC CCC C 
Sample 62 d4T/3TC/EFV ATG AAG GAC AAG AAA ATG CAG TAT GTG GGA ACC CCT C 
Sample 63 AZT/EFV/SQV ATG AAG AAC AGG AAT GTA CAA TAT ATG GGA ACC CCC C 
Sample 64 naïve ATG AAG GAC AAG AAA GTA CAG TAT ATG GGA ACC CCC C 
Sample 65 AZT/3TC/ABC TTG AAG AAC AAG AAA GTG CAG TAT GTR GGA ACC CCC C 
Sample 66 AZT/ddI ATG AAG GAC AAG AAA GTA CAG TAT ATG GGA ACC CCC C 
Sample 67 d4T/ddI/EFV ATG AAA RAC ARG AGA ATG CAG TAT ATG GGA ACC CCC C 
Sample 68 AZT/ddI/EFV TTG AAG AAC AAG AAA ATG CAG TAT ATG GCA TAC CCC C 
Sample 69 d4T/3TC/NFV ATG AAG GAC AAG AAA GTA CAG TAT GTR GGR ACC CCT C 
Sample 70 AZT/3TC/NVP ATG AAA GAC ARA AAA GTA CAG TAT GTG GGA ACC CCC B 
Sample 71 AZT/3TC/ABC ATG AAG AAC AGG AGC GTG CAG TAT GTA GGA AYC CCC C 
Sample 72 AZT/3TC/EFV ATG AAG GAC AAG AAC GTG CAA TAT ATG GGA TAT CCC C 
Sample 73 AZT/3TC/NFV ATG AAG AAC AGG AAT GTG CAA TAT ATG GCA ACC CCC C 
Sample 74 d4T/ddI/HU ATG AAG GAC AAG AAG GTG CAG TAT ATG GGA TAC CCC C 
Sample 75 d4T/3TC/NVP ATG AAG GAT AAG AAA GTG CAG TAT GTG GCA ACC CCT C 
Sample 76 d4T/3TC/LPV ATG AAG AAC ARA AAT GTG CAG TAT ATG GCA TAC CCC C 
Sample 77 d4T/ddI/HU ATG AAG GAC AAG AAA GTG CAA TAC ATG GGA ACC CCC C 
Sample 78 AZT/3TC/NVP ATG AAG AAT AGG AAC GTG CAG TAT GTG GGA AYC CCC C 
Sample 79 AZT/3TC/NVP ATG AAG AAC AGG AAA GTG CAG TAT GTG GCA ACC CCC C 
Sample 80 ddI/ABC/NFV ATG AAG AAC AGG AAA GTG CAG TAT GTG GGA ACC CCC C 
Sample 81 d4t/ddI/EFV ATG AAG GRC AAG AAA ATG CAG TAT ATG GGA ACC CCC C 
Sample 82 d4T/ddI ATG AAG GAC AAG AAA GTG ATG TAT ATG GGA ACC CCC C 
Sample 83 d4T/ddI/RTV ATG ARG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 84 d4T/ddI/EFV ATG ARG TAC AAG AAC ATG ATG TAT ATG GGA ACT CCT C 
Sample 85 d4T/ddI/EFV/NFV CTG AAR AAC AGA AAA GTA ATG TRT ATG AGC TAC CCT B 
Sample 86 AZT/3TC/NVP ATG AAG GAC AAA AAG GTA CAG TGT GTG GGA ACC CCC C 
Sample 87 EFV/3TC/AZT ATG AAG GAC AAG AAC ATG CAG TAT GTG GGA ACC CCC C 
Sample 88 d4T/3TC/EFV ATG AAG GAC AAG AAA ATG CAA TAT GTG GGA ACT TCC C 
Sample 89 d4T/3TC/RTV ATG AAG GAC AAG AAG GTG CAG TAT ATG GGA ACC CCC C 
Sample 90 AZT/3TC/RTV ATG AAG GAC AAG AAA GTG CAG TAC GTG GGA ACC CCC C 
Sample 91 d4T/3TC/RTV ATG AAG GAC AAG AAG GTG CAG TAT GTG GGA ACC CCC C 
Sample 92 d4T/ddI/EFV ATG AAG GAC AAG AAC GTA CAG TAT ATG GGA ACC CCC C 
Sample 93 AZT/3TC/NVP ATG AAG GAC AAG AAA GTG CAG TRT GTG GSA ACY CCC C 
Sample 94 d4T/ddI/EFV ATG AAG GAC AAG AAC GTG CAG TAT GTG GGA TAC CCC C 
Sample 95 AZT/3TC/NVP* ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 96 d4T/ddI/RTV ATG AAG GAC AAG AAA GTG CAG TAT ATG GGA ACC CCC C 
Sample 97 d4T/ddI/EFV ATG ARG GAC ARG AAA ATG MTG TAT ATG GGA ACC CCC C 
Sample 98 d4T/ddI ATG AAG GAT AAG AAA GTG CAG TAT ATG GGA WMC CCC C 
Sample 99 d4T/ddI YTG AAG GAC AAG AAA GTA CAG TAT ATG GGA TAC CCC C 
Sample 100 d4T/ddI MTG AAA GAC AAA AAA GTA ATG TAT ATG GGA ACC CCT B 
Sample 101 d4T/EFV/LPV TTR AAG AAC AGG AAA ATG CAG TAT ATG GSA TGT CCC C 
Sample 102 AZT/3TC/EFV ATG AAG GAC AAG AAC GTG CAG TAT GTG GGA ACC CAC C 
Sample 103 d4T/ddI/EFV TTG AAG GAC AAG AAC ATG CAG TAT ATG GGA TAC CCC C 
Total mutations 8 3 17 12 43 23 5 8 40 14 9 4 
 
Genotypes in blue indicate drug resistance mutations. † Fail indicates failure of population sequencing. * Previous regimen (current 
not available). Hydroxyurea (HU) reduces dNTP production and is rarely used for ARV therapy (Lori and Lisziewicz, 1999). 
 
 
3.3 Design and Optimization of HRMA-PCR 
Plasmids were required for assay optimization and for use in serial dilutions. The p66/p51 
fragment from the CM9 HIV-1 subtype C clinical isolate (Genbank accession number 
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AF411967) was previously cloned into the pCR 2.1 vector (Appendix B, Figure B1). The K65R, 
K103N and V106M mutations had been previously introduced into the wild-type plasmid by 
site-directed mutagenesis. Due to mismatches the 181F and 181R primers could not be used to 
amplify the CM9 plasmid. The sequence of the subtype C pMJ4 plasmid (Genbank accession 
number AF321523) better matched the 181F/R primers and so was utilized for 181 and 184 
assay optimization. The Y181C and M184V mutations had been previously introduced in pMJ4. 
 
The author utilized the QuikChange® II Site-Directed Mutagenesis Kit (Stratagene, USA) to 
introduce the M41L, D67N, K70R, Q151M, G190A, T215F, T215Y and P225H mutations into 
the CM9 plasmid (primer sequences Appendix A, Table A2). The plasmids were isolated with 
the GenElute HP Plasmid Midiprep Kit (Sigma-Aldrich, GmbH, Germany) and genotyped by 
population sequencing to confirm the presence of the mutations. 
 
 
3.3.1 HRMA-PCR Primers 
The HRMA-PCR primers (Tables 3.2 and 3.3) were designed using a South African HIV 
consensus sequence (SAC) constructed with 648 HIV sequences from South African patients, 
downloaded from the Los Alamos HIV Database (http://www.hiv.lanl.gov). Six PCRs, spanning 
the mutations of interest were designed encompassing amino acids 37–44, 60–74, 100–108, 146–
154, 181–191 and 212–229 of the HIV-1 p66/p51 fragment. Asymmetric and short PCRs (72 bp-
100 bp) were setup to minimize the size of the larger amplicon-amplicon peak (Figure 3.1). A 
gradient (0.1-1 pmol/µL) with the limiting reverse primer for the HRMA-PCR was tested (Figure 
3.2) to determine the optimal primer concentrations. Altered primers, which directly flanked the 
codons of interest, were designed for polymorphism masking (Table 3.3). 
Chapter 3: Results 
 
45 
 
Table 3.2.  Primer sequences for the HRMA-PCR assays. 
Codon/s Template Name Primer sequence (5' - 3') 
Concentration 
(pmol/µL) 
Tm (°C) 
Product 
length (bp) 
41 CM9 
41F AAGAGAAAATAAAAGCATTAACAGC 10 
58 74 
41R AGGCCCAATTTTTGTAATTTTTCC 0.4 
65, 67, 70 CM9 
62F GCCTGAAAATCCATATAACACTCC 10 
62 97 
62R TCTTTTATTGAGTTCCCTGAAATCTAC 0.5 
103, 106 CM9 
100F  AGGAATACCACACCCAGCAG 10 
60 72 
100R AAATATGCATCCCCCACATCC 0.4 
151 CM9 
151F TGAAACACCAGGGATTAGATATC 10 59 
73 
151R CTGGAATATTGCTGGTGATCC 0.4 60 
181, 184, 
190 
MJ4 
181F AGCAAAAAATCCAGAAATAGTCATC 10 
59 81 
181R CTATGTTGCCCTATTTCTAAGTC 0.6 
215, 225 CM9 
215F GGAGTTAAGAGAACATCTATTAAAG 10 59 
100 
215R  AGGATGGAGTTCATACCCCA 0.4 58 
 
 
 
 
 
Table 3.3. Sequences for the altered primers for the HRMA-PCR assays. 
Codon Template Name Primer sequence (5' - 3') 
Concentration 
(pmol/µL) 
Tm (°C) 
Product 
length (bp) 
103 CM9 
ap103F CACCCAGCAGGGTTAAAAAAG 10 60 
47 
ap103R ACATCCAGTACTGTCACTGATTT 1 59 
151 CM9 
ap151F TAGATATCAATATAATGTGCTTCCA 10 58 
48 
ap151R GCTGGTGATCCTTTCCATCC 1 60 
184 MJ4 
ap184F AATCCAGAAATAGTCATCTATCAATAT 10 59 
53 
ap184R TCAGATCCTACATACAAGTCATC 1 59 
190 MJ4 
ap190F CAATATATGGATGACTTGTATGTA 10 57 
50 
ap190R  TGTTGCCCTATTTCTAAGTCAGA 1 59 
 
 
 
 
 
                              
 
 
  
Figure 3.1. Agarose gels of the PCR products following RT-PCR and HRMA. (A) PCR products from patient samples 
were run on 1% agarose gels for one hour at 80 volts (an example shown in A). The fragment length of the second 
round PCR, shown here, was 986 bp. The Roche molecular weight marker IV (Roche Applied Science, GmbH, 
Germany) was utilized for size comparison (B) The HRMA-PCR products were run on 2% agarose gels for one hour 
at 80 volts (an example shown in B). The products ranged from 72 bp to 100 bp in length. The Roche molecular 
weight marker IX (Roche Applied Science, GmbH, Germany) was utilized. The no template control (NTC) is on the 
right side of each gel. 
 
986 bp 
B 
72 bp 
41 (74 bp) 
62 (97 bp) 
100 (72 bp) 
151 (73 bp) 
181 (81 bp) 
215 (100 bp) 
NTC 
A 
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3.3.2 HRMA Template  
RNA was isolated with the MagNA Pure LC Instrument (Roche Applied Science, GmbH, 
Germany) from stored patient plasma. The nucleic acid was amplified by a nested RT-PCR and 
the products run on agarose gels (Figure 3.1 A) (Loubser et al., 2006). Amplified samples were 
purified with the High Pure PCR Product Purification Kit (Roche Applied Science, GmbH, 
Germany) and diluted 1:100 in Tris HCl pH 8. 
 
DNA from different stages of the amplification process was used as template for HRMA. cDNA, 
first-round and second-round RT-PCR products were tested. The cDNA was too dilute as the 
crossing point for the PCR was ~40 cycles. First- or second-round PCR products, purified and 
diluted to 2.5 ng/reaction provided a suitable template for HRMA-PCR. The crossing point of the 
assays was ~10-20 cycles (data not shown). 
 
3.3.3 HRMA-PCR Conditions 
The optimal cycling conditions for HRMA-PCR on the LightCycler 480 Real-Time PCR were: 
94 °C for 5 minutes with a ramp rate of 4.4 °C/s; 45 cycles at 95 °C for 10 seconds at 4.4 °C/s, 
55 °C for 15 seconds at 2.2 °C/s and 72 °C for 15 seconds at 4.4 °C/s followed by HRM melting 
program. 
Figure 3.2. Optimization of the reverse primer 
for HRMA-PCR. A range of concentrations for 
each reverse primer was tested. From top to 
bottom, 0.4 (pink), 0.3 (green), 0.2 (blue) and 0.1 
(red) pmol/µl of the 100R primer with the wild-
type (AAA) 103 plasmid. Optimal reverse primer 
concentrations are in Tables 3.2 and 3.3. 
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3.3.4 HRM Melting Program 
The melting program, which allows for HRMA, directly followed the real-time PCR. Melting 
from 40 °C to 95 °C, at 1°C/second, with 25 points of data/°C, produced the most distinct 
melting peaks (Figure 3.3). The high resolution melting began with 95 °C for one minute at 4.4 
°C/s, 40 °C for one minute at 2.2 °C/s, then a temperature increase from 40 °C  to 95 °C at 1 
°C/s, followed by 40 °C for ten seconds at 2.2 °C/s. 
 
 
Figure 3.3. Optimization of the melt for HRMA. (A) The probe melting peak was absent when the melting step 
began at 65 °C. (B) When the melting began at 40 °C, a probe peak was present (arrow).  
 
 
 
3.4 HRMA Probe Design and Optimization  
3.4.1 HRMA Probes 
Unlabeled probes are incorporated into HRMA assays to enhance detection of specific alleles 
(Zhou et al., 2004). A minimum of two probes per mutation site was designed; one 
complementary to the wild-type and the other complementary to the mutant sequence at the site 
of interest. Genotype detection occurs by means of an additional melting peak to the left of the 
amplicon melting peak. Ideally, if probes are short (< 21 bp), the non-corresponding probe does 
not bind and no probe peak is generated (Zhou et al., 2004). For optimal probe-target 
destabilization in the presence of a non-corresponding mutation, the variable base is placed in the 
A B 
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center of the probe (Erali et al., 2008; Montgomery et al., 2007b). Probe and amplicon melting 
peaks were required to fall within a defined temperature range, specific to each assay. Probes of 
15 bp were designed on a South African consensus sequence and each probe was blocked by 3’ 
phosphorylation. A concentration gradient (0.5-10 µM) was tested with each probe and the 
optimal concentration, which generated the most distinct peaks was 2 µM (Figure 3.4, green 
curve).  
 
 
 
 
3.4.2 HRMA Probe Polymorphism Masking 
The heterogeneous nature of HIV led to differences in the results generated upon application of 
the probes to plasmids and patient samples. As benign polymorphisms can disrupt accurate 
HRMA, a number of probe and primer modifications were introduced to mask the affects of the 
polymorphisms (Margraf et al., 2006). These alterations include incorporation of universal, 
ambiguous, mismatched or deleted bases, or locked nucleic acids (LNAs). Universal and 
ambiguous bases pair indiscriminately despite sequence variation. Mismatched bases are 
intentionally inserted in order to prevent base pairing with either the conserved or polymorphic 
base; thus masking the melting effects of the polymorphism. A deletion of a base in the probe 
causes the polymorphic or conserved base in the amplicon to bulge out, preventing participation 
Figure 3.4. Optimization of probe concentration 
for HRMA. A concentration gradient with the 
probes was tested on the respective plasmids; 
from top to bottom, 5 (red), 2 (green) and 0.5 µM 
(blue) of the 103A (Table 3.4) probe with wild-type 
(AAA) 103 plasmids. 
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during HRMA (Margraf et al., 2006). LNAs are modified nucleic acids that have a higher 
binding affinity to their target and this may increase the binding affinity in the presence of 
destabilizing polymorphisms (Kaur et al., 2006; Koshkin et al., 1998). In addition PCRs using 
altered primers were designed (Table 3.3). In these assays the primers directly flank the mutation 
codon, thereby preventing polymorphic bases from interacting with the complementary probes. 
 
3.5 Interpretation and Validation of HRMA Results 
Three possible outcomes were generated, a correct genotype prediction, a discordant genotype 
prediction or no genotype prediction. Concordance between the HRMA result and the population 
sequencing result was considered a correct prediction. In addition to this, the probe and amplicon 
melting peaks had to fall within defined temperature intervals. When the genotypes by 
population sequencing and HRMA did not match, the result was considered discordant. In these 
cases HRMA on discordant samples was repeated and the patient samples were re-sequenced. No 
result occurred if no probe melting peaks were produced, if the melting peaks were small, if the 
melting peaks fell outside the defined melting intervals or if atypical curve shapes were 
generated. HRMA was repeated three times on these samples. In the Tables that follow the 
centre of the probe (red base) binds to the wild-type or mutant nucleotide of interest.  
 
3.5.1 K103N Assay 
K103N results in high level resistance to NVP and EFV (Ren and Stammers, 2008). Probes were 
designed to genotype the common wild-type (AAA/G) and mutant (AAC/T) sequences at codon 
103. The probes designed for the K103N assay included complementary probes (15 bp), 
complementary  short probes (11 bp), complementary  short probes with LNAs and ambiguous 
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probes (Table 3.4). Altered primers were also designed to facilitate polymorphism masking 
(Table 3.3). 
 
Table 3.4. Probe sequences for the K103N assay. 
Codon (sequence) Name Sequence (5' -3') Modification Length (bp) G+C (%) 
K103 (AAA) 103A CTGATTTTTTCTTTT - 15 20 
K103 (AAG) 103G CTGATTTCTTCTTTT - 15 27 
K103N (AAC) 103C CTGATTTGTTCTTTT - 15 27 
K103N (AAT) 103T CTGATTTATTCTTTT - 15 20 
K103 (AAA) 103A.S GATTTTTTCTT Short 11 18 
K103 (AAG) 103G.S GATTTCTTCTT Short 11 27 
K103N (AAC) 103C.S GATTTGTTCTT Short 11 27 
K103N (AAT) 103T.S GATTTATTCTT Short 11 18 
K103 (AAA) 103A.LNA GATTTTTTCTT LNA 11 18 
K103 (AAG) 103G.LNA GATTTCTTCTT LNA 11 27 
K103N (AAC) 103C.LNA GATTTGTTCTT LNA 11 27 
K103N (AAT) 103T.LNA GATTTATTCTT LNA 11 18 
K103 (AAA) N103A CTGATNTTTTCTTNT Ambiguous base 15 20-33 
K103 (AAG) N103G CTGATNTCTTCTTNT Ambiguous base 15 27-40 
K103N (AAC) N103C CTGATNTGTTCTTNT Ambiguous base 15 27-40 
K103N (AAT) N103T CTGATNTATTCTTNT Ambiguous base 15 20-33 
Ambiguous base (N) is in green and locked nucleic acids (LNAs) are shown underlined. 
  
 
The complementary probes accurately genotyped all four plasmids and 93 (80%) of the 116 
samples. No probe melting peak was generated with 21 (18%) of the samples and two (1.7%) 
predictions were discordant with the population sequencing result (Table 3.5). The Tm of the 
amplicon-amplicon duplexes was 78 ± 2 °C and the Tm of the probe-amplicon duplexes was 72 ± 
2 °C. Representative melting plots are shown in Figure 3.5. The genotype and HRMA results for 
the K103N assay are summarized in Appendix D, Table D2. 
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Figure 3.5. Application of 103 HRMA assay to plasmids and patient samples. Negative first derivative (-dF/dT) 
plots of the common SNP genotypes at position 103, obtained by using either engineered plasmids (left panels) or 
patient samples (right panels) and complementary probes. The presence of a probe peak alongside the amplicon 
peak indicates successful probe binding, allowing for the allocation of a 103 genotype to the sample. (A) Wild-type 
(AAA) plasmid and (B) wild-type (AAA) patient sample. (C) Wild-type (AAG) plasmid and (D) wild-type (AAG) patient 
sample. (E) Mutant (AAC) plasmid and (F) mutant (AAC) patient sample. (G) Mutant (AAT) plasmid and (H) mutant 
(AAT) patient sample. 
 
 
 
 
K103N Plasmids K103N Patient Samples
AAA (K103) AAC (K103N) AAT(K103N)AAG (K103)
AAA
AAC
AAG
AAA
AAC
AAG
Sample 59 (AAA)
Sample 47 (AAG)
Sample 41 (AAC)
Wild-type AAA 103 plasmid
Mutant AAC 103 plasmid
Wild-type AAG 103 plasmid
A B
C D
E
F
AAT AAT
Sample 44 (AAT)Mutant 103 AAT plasmid
G H
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HRMA incorporating polymorphism masking probes and altered primers was performed on the 
21 samples that did not generate codon 103 genotype predictions when using the complementary 
probes. Ambiguous bases were incorporated at two polymorphic sites in the long probes (Table 
3.4) as determined by analysis of the patient samples sequences (Table 3.6). Of the 21 samples to 
which these probes were applied, five genotypes were correctly predicted, five had discordant 
results and 11 samples did not generate a result (examples are shown in Figure 3.6). The short 
probes (illustrated in Figure 3.7) and probes incorporating LNAs (data not shown) did not 
generate probe melting peaks.  
 
Using altered primers with the complementary probes, 10 genotypes of the 21 samples were 
correctly identified, while nine samples did not generate a result and two predictions were 
discordant (examples are shown in Figure 3.6). The K103N assay results for each primer and 
probe are summarized in the following Table. 
 
Table 3.5. Summary of K103N assay results. 
Assay Correct Discordant No result 
Complementary probes 93 (80%) 2 (1.7%) 21 (18%) 
Of the 21 samples with no result:       
        Complementary short probes 0 0 0 
        Complementary short probes with LNAs 0 0 0 
        Ambiguous bases 5 5 11 
        Altered primers 10 2 9 
Total* 103 (89%) 9 (7.8%) 4 (3.4%) 
* Calculated from Table D2 (Appendix D). 
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Figure 3.6. Application of 103 HRMA assay with polymorphism masking to patient samples. Negative first 
derivative (-dF/dT) plots of possible SNP genotypes at position 103, obtained by using patient samples and 
complementary probes, ambiguous probes and altered primers. A wild-type (AAA) patient sample with (A) 
complementary and (B) ambiguous probes. A mutant (AAC) patient sample with (C) regular and (D) altered primers 
with the same complementary probes. 
 
 
 
 
 
 
Figure 3.7. Application of 103 HRMA assay with polymorphism masking to plasmids and patient samples. 
Negative first derivative (-dF/dT) plots of common SNP genotypes at position 103, obtained by using either (A) 
engineered mutant (AAC) plasmid and (B)  mutant (AAT) patient sample with complementary long probes (purple) 
or complementary short probes (turquoise). 
 
 
 
To investigate reasons for discordant (n=2) or no results (n=21, Table 3.5), the patient sequences 
corresponding to the region of probe binding were examined (Table 3.6). In all cases where no 
AAA (K103) AAC (K103N) AAT(K103N)AAG (K103)
K103N Patient Samples (Polymorphism Masking)
A
No genotype
B
C D
AAC
No genotype AAA 
Altered primer
Ambiguous probe
Sample 22 (AAC)
Sample 22 (AAC)
Sample 68 (AAA) Sample 68 (AAA)
Long Probe Short Probe
K103N Plasmid and Patient Samples (Polymorphism Masking)
A B
Mutant 103 AAC plasmid Sample 76 (AAT)
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polymorphisms were present (n=93), the complementary probes were capable of accurately 
genotyping codon 103. However the presence of polymorphisms in the probe binding region 
appeared to interfere with HRMA. Polymorphisms in the patient samples clustered in three 
groups, two and seven bases upstream, and six bases downstream from the central base of the 
probe. The variation at the seventh base upstream from the probe center was due to the presence 
of the V106M NNRTI mutation; however this mutation did not seem to disrupt HRMA. 
Polymorphisms at the other two sites appeared to disrupt HRMA and the ambiguous nucleotides 
were incorporated at these sites (Tables 3.4 and 3.6).  
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Six patient samples carried the unusual AGA/T/C (K103N/S) drug resistance mutations, of 
which four could not be genotyped with the complementary probes. These four samples (samples 
32, 33, 67 and 71 in blue in Table 3.6) had additional polymorphisms within the probe binding 
Wild-type sequence A A A A G A A A A A A T C A G
Patient Sample
Sample 1b W M
Sample 2b M R
Sample 10a G R
Sample 21 A
Sample 23 A
Sample 26 A G
Sample 35 A
Sample 41 G C
Sample 43 C G
Sample 51 A
Sample 53 A
Sample 56 M G C
Sample 62 G A
Sample 78 C R
Sample 81 A
Sample 84 G C A
Sample 87 C A
Sample 88 A
Sample 92 M C
Sample 99 C
Sample 101 A
Sample 103 C A
Sample 5a G
Sample 22 C G
Sample 28 C A
Sample 40 G C A
Sample 50 G G
Sample 60 M G
Sample 68 G A
Sample 79 G
Sample 94 C C
Sample 20 G
Sample 54 G T
Sample 5b G R
Sample 10b G M R
Sample 11b W
Sample 12b M G R
Sample 32 G A
Sample 46 G
Sample 67 C G A
Sample 33 G A
Sample 71 G G C
Sample 77 G
Sample 97 A
The purple indicates the sites where ambiguous bases were incorporated. The samples in blue (AGA/C)  did 
not generate a peak, samples in red (AGA/T) generated a discordant prediction.
Table 3.6. No result and discordant patient sequences with polymorphisms within the binding region of the 
K103N assay probes. Correctly genotyped samples without polymorphisms were excluded.
Modification: None                                                                    
Result: Correct prediction
Modification: Altered primers and/or                        
ambiguous probe                                                                                        
Result: Discordant prediction
Modification: Altered primers and ambiguous 
probe                                                                                           
Result: No prediction
Modification: Altered primers and/ or 
ambiguous probe                                                                         
Result: Correct prediction
Modification: None                                                                               
Result: Discordant prediction
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region other than these rare codon 103 mutations. The combination of sequence variation 
adjacent the center of the probe and additional polymorphisms probably prevented probe binding 
due to thermal instability. The remaining samples (samples 20 and 54 in red in Table 3.6) did not 
carry any other polymorphism besides the rare AGA/T and generated discordant results. These 
two (1.7%) discordant predictions were wild-type (AAA and AAG) by HRMA but drug resistant 
by population sequencing (AGA and AGT). 
 
To determine the limit of detection of the K103N assay using complementary probes, sample 47 
was selected for clonal analysis. This sample generated a large probe peak which corresponded 
to the presence of the AAG genotype at 103. In addition a very small peak, representing AAA 
was also formed (Figure 3.8 A). This sample was selected for clonal analysis, which detected the 
presence of the AAA genotype in 3 of 100 clones (3%).  
 
The complementary probes were applied to a serial dilution of K103N diluted in K103 and the 
limit of detection was ~5% of mixed species (Figure 3.8 B). 
 
 
 
Figure 3.8. 103 HRMA assay and analytical sensitivity. Negative first derivative (-dF/dT) plots of SNP genotypes at 
position 103, obtained by using a (A) patient sample and (B) engineered plasmids and complementary  probes. (A) 
Wild-type (AAG) patient sample; a small peak corresponding to the AAA genotype is visible and was confirmed by 
clonal analysis (3%). (B) Dilution series of mutant AAC plasmid diluted in wild-type AAA plasmid. 
A B
Sample 47 (AAG) Mutant 103 AAC plasmid
AAA (K103) AAC (K103N)
AAT (K103N)AAG (K103)
K103N Assay Limit of Detection
100%
50%
20%
10%
5%
1%
0%
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In summary the complementary probes accurately genotyped the majority of the patient samples 
(n=93), with two discordant predictions (Table 3.5 and Appendix D, Table D2). The discordant 
samples carried unusual drug resistance mutations and were identified as wild-type by HRMA. 
The various polymorphism masking techniques had some success as ten of the 21 samples with 
no result were genotyped. Seven additional discordant results arose from the application of the 
altered primers and probes incorporating ambiguous bases. The short probes and those 
incorporation LNAs did not increase the success of the 103 assay. Despite this, with the 
unmodified probes and primers, 80% of the patient samples were accurately genotyped with two 
discordances and so this assay is useful for genotyping the clinically important 103 codon in 
HIV-1 samples. 
 
3.5.2 Y181C Assay 
Y181C (TAT → TGT) is a NNRTI mutation that is associated with strong NVP and moderate 
EFV resistance (Ren and Stammers, 2008). The probes designed for the Y181C assay included 
complementary  probes and probes incorporating universal bases and deletions (Table 3.7). 
 
Table 3.7. Probe sequences  for the Y181C assay. 
Codon (sequence) Name Sequence (5' -3') Modification Length (bp) G+C (%) 
Y181 (TAT) wt181 ATATTGATAGATGAC - 15 27 
Y181C (TGT) mut181 ATATTGACAGATGAC - 15 33 
Y181 (TAT) wt181.univ  ATAITGATAGATGAC Inosine 15 33 
Y181C (TGT) mut181.univ  ATAITGACAGATGAC Inosine 15 40 
Y181 (TAT) wt181.del   ATA_TGATAGATGACT Deletion 15 27 
Y181C (TGT) mut181.del   ATA_TGACAGATGACT Deletion 15 33 
The inosine (I) is in pink, the deletion is represented by the orange underscore and the additional base is in purple. 
 
 
The complementary probes were applied to the wild-type and Y181C plasmids and 116 HIV-1 
samples. The assay successfully genotyped the plasmids and 102 samples (88%), 11 samples 
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(9.5%) produced no probe melting peaks and three (2.6%) genotypes were discordant with the 
sequencing results (Table 3.8). While the other assays reported here required one melting 
program, the HRMA for codon 181 required two successive melts for optimal results. The Tm of 
the amplicon-amplicon duplexes was 75.8 ± 1 °C and the Tm of the probe-amplicon duplexes 
was 65 ± 2 °C. Representative melting plots are shown in Figure 3.9. The genotype and HRMA 
results for the Y181C assay are summarized in Appendix D, Table D3.  
 
  
 
Figure 3.9. Application of 181 HRMA assay to plasmids and patient samples. Negative first derivative (-dF/dT) 
plots of common SNP genotypes at position 181, obtained by using either engineered plasmids (top box) or patient 
samples (bottom box) and complementary probes. The smaller probe peak at a lower Tm indicates successful probe 
binding, allowing for the allocation of a 181 genotype to the sample. (A) Wild-type (TAT) plasmid and (B) wild-type 
(TAT) patient sample. (C) Mutant (TGT) plasmid and (D) mutant (TGT) patient sample. (E) Mixture of wild-type and 
mutant plasmid and (F) patient sample. 
 
 
 
 
Y181C Plasmids
Y181C Patient Samples
TAT (Y181)                                          TGT (Y181C)
A
C
TAT TGT
E
TAT/TGT
Mutant TGT 181 plasmid
Wild-type TAT and mutant TGT 181 plasmidWild-type TAT 181 plasmid
B
TAT/TGT
D
Sample 83 (TAT) Sample 6b (TAT/TGT)Clone of sample 73 (TGT)
F
TAT 
TGT 
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Table 3.8. Summary of Y181C assay results. 
Assay Correct Discordant No result 
Complementary  probes 102 (88%) 3 (2.6%) 11 (9.5%) 
Of the 11 samples with no result:       
       Probe with inosine 3 0 8 
       Probe with deletion 7 0 4 
Total* 109 (94%) 3† (2.6%) 4 (3.4%) 
* Calculated from Table D3 (Appendix D). 
† The discordance arose due to the increased analytical sensitivity of HRMA. 
 
 
Discordance arose as HRMA identified wild-type Y181 (TAT) as well as minority Y181C 
(TGT) populations in three samples (6b, 69 and 73) which were determined to be completely 
wild-type (TAT) by population sequencing. One of these samples (73) was selected for clonal 
analysis and Y181C was detected in 33% of the 100 clones. This indicates that the 181 HRMA 
assay is more sensitive than population sequencing and so identifies minority resistant 
populations. 
 
The limit of detection of the Y181C assay was determined by serial dilutions to be ~5% of mixed 
species (Figure 3.8). Therefore the extra limit of detection accounts for the 2.6% discordance as 
the HRMA assays can detect minority populations that sequencing cannot.  
 
 
 
Mutant 181 TGT plasmid
Y181C Assay Limit of Detection
100%
50%
20%
10%
5%
1%
0%
Figure 3.10. Determination of 181 HRMA assay limit of 
detection. Negative first derivative (-dF/dT) plot of a 
dilution series of mutant (TGT) at position 181 diluted 
in wild-type (TAT) obtained by using engineered 
plasmids and complementary  probes for the 
determination of analytical sensitivity. The amplicon 
melting peaks have been cropped for increased 
visibility of the probe melting peaks. 
 
Chapter 3: Results 
 
60 
 
To investigate reasons for discordant or no results, the patient sample sequences corresponding 
to the region of probe binding were examined (Table 3.9). Polymorphism that clustered at the 5’ 
end of the probe binding region and five bases upstream from the center of the probe did not 
appear to interfere with HRMA, in that melting peaks were formed. However sequence variation 
in the middle of the probe did appear to prevent probe melting peak formation, which cannot be 
masked (Margraf et al., 2006). A guanine located four bases downstream from the probe center 
was present in six samples and in five of these samples no probe melting peaks were formed 
(example is shown in Figure 3.11 A). This polymorphism was then selected for masking as it is 
further from the center of the probe. Two types of masking techniques were attempted; 
incorporation of a universal base and the deletion of the polymorphic base (Table 3.7). The 
modified probes were applied to the 11 samples which generated no result with the 
complementary  probes. 
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Wild-type sequence G T C A T C T A T C A A T A T
Patient Sample
Sample 5a T
Sample 5b T
Sample 6a T
Sample 8a C
Sample 8b C
Sample 9a T
Sample 9b T
Sample 10a Y
Sample 19 A R
Sample 20 Y
Sample 25 Y
Sample 27 Y
Sample 30 T
Sample 32 A T
Sample 35 T
Sample 36 T
Sample 38 T
Sample 45 T C
Sample 48 T
Sample 50 A T
Sample 52 G C
Sample 57 T
Sample 60 T T R
Sample 63 C
Sample 64 T C
Sample 65 T C
Sample 66 T C
Sample 67 A T
Sample 70 T C
Sample 71 R
Sample 74 T
Sample 84 G
Sample 85 T R C
Sample 87 T T
Sample 89 C
Sample 91 T C
Sample 92 Y
Sample 95 G Y
Sample 96 T
Sample 99 T C
Sample 100 Y R C
Sample 103 T
Sample 15 G
Sample 34 G
Sample 49 M G
Sample 58 Y G
Sample 6b* T
Sample 69*
Sample 73*
Sample 26 T
Sample 62 A A G
Sample 77 C
Sample 90 C
* The discordance arose due to the increased sensitivity of HRMA as compared to population sequencing.
Modification: None                                                                     
Result: Correct prediction
Modification: Deletion probe                            
Result: Correct prediction
Modification: None and/ or deletion probe                                                         
Result: No prediction
Table 3.9. No result and discordant patient sequences with polymorphisms within the binding region of the Y181C 
assay probes. Correctly genotyped samples without polymorphisms were excluded.
Modification: None                                                
Result: Discordant prediction
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A deletion of the polymorphic site (guanine) was introduced at this position (Table 3.7), which 
causes the polymorphic base to bulge out during base pairing thereby preventing destabilization. 
In order to maintain the 15 bp probe length an extra nucleotide was added. These probes were 
applied to the 11 polymorphic patient samples, previously with no result, and the correct 
genotype was predicted with seven samples (example is shown in Figure 3.11 B). 
 
Inosine is a base that pairs indiscriminately and was incorporated at the same polymorphic 
position within the probes (Table 3.7). These probes were applied to the same 11 polymorphic 
patient samples. While small peaks were generated, three genotypes were correctly predicted and 
eight could not be genotyped (illustrated in Figure 5.11 C).  
 
 
 
Figure 3.11. Application of 181 HRMA assay with polymorphism masking to patient samples. Negative first 
derivative (-dF/dT) plots of wild-type (TAT) at position 181, obtained by using a wild-type patient sample and (A) 
complementary  probes, (B) deletion probes and (C) universal probes.  
 
 
In summary the complementary probes and probes incorporating a deletion successfully 
genotyped most samples (n=109) at position 181, with only four samples without a result (Table 
3.8 and Appendix D, Table D3). The 181 HRMA assay was more sensitive (~5%) than 
Y181C Patient Sample (Polymorphism Masking)
TAT (Y181)                                          TGT (Y181C)
Inosine probe
No genotype 
Sample 15 (TAT)
Deletion probe
No genotype 
TAT 
Sample 15 (TAT) Sample 15 (TAT)
A B C
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population sequencing and so the assay error rate may be zero for the samples selected. Thus this 
assay can be used to accurately genotype the 181 codon in most HIV-1 samples.  
 
3.5.3 M184V Assay 
M184V (ATG → GTG) is a NRTI mutation that results in high level resistance to 3TC, low level 
resistance to ddI and ABC, but increased susceptibility to ZDV, d4T and TDF (Shafer and 
Schapiro, 2008). Complementary probes (Table 3.10) and altered primers (Table 3.3) were 
utilized for the M184V HRMA assay. 
 
Table 3.10. Probe sequences for the M184V assay. 
Codon (sequence) Name Sequence (5' -3') Modification Length (bp) G+C (%) 
M184 (ATG) wt184V TCATCCATATATTGA - 15 33 
M184V (GTG) mut184V TCATCCACATATTGA - 15 27 
 
 
The genotypes of the wild-type and mutant plasmids and 92 of 116 patient samples (79%) were 
correctly predicted, 20 samples (17%) could not be genotyped and four (3.4%) genotypes were 
discordant with the sequencing results (Table 3.11). The Tm of the amplicon-amplicon duplexes 
was 75.5 ± 1 °C and the Tm of the probe-amplicon duplexes was 67 ± 1 °C. Representative 
melting plots are shown in Figure 3.12. The genotype and HRMA results for the M184V assay 
are summarized in Appendix D, Table D4. 
 
Table 3.11. Summary of M184V assay results. 
Assay Correct Discordant No result 
Complementary  long probes 92 (79%) 4 (3.4%) 20 (17.2%) 
Of the 20 samples with no result:       
      Altered primers 10 0 10 
Total* 102 (88%) 4† (3.4%) 10 (8.6%) 
* Calculated from Table D4 (Appendix D). 
† Three discordance arose due to the increased analytical sensitivity of HRMA. 
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Figure 3.12. Application of 184 HRMA assay to plasmids and patient samples. Negative first derivative (-dF/dT) 
plots of the common SNP genotypes at position 184, obtained by using either engineered plasmids (top box) or 
patient samples (bottom box) and complementary  probes. The presence of a probe peak alongside the amplicon 
peak indicates successful probe binding, allowing for the allocation of a 184 genotype to the sample. (A) Wild-type 
(ATG) plasmid and (B) wild-type (ATG) patient sample. (C) Mutant (GTG) plasmid and (D) mutant (GTG) patient 
sample. (E) Mixture of wild-type and mutant plasmids and (F) patient sample. 
 
 
 
Altered primers were designed (Table 3.3) and applied with the complementary  probes to the 20 
patient samples that could not be genotyped. Ten of the 20 genotypes could be correctly 
determined while the remaining samples could not be genotyped as no melting peaks were 
produced (example in Figure 3.13). Analysis of the sequences corresponding to the probe 
binding region indicated that sequence variation directly adjacent to the mutation site of interest 
usually prevented melting peak formation (Table 3.12). In addition, guanine four bases 
downstream from the probe center did appear to prevent probe curve formation. 
 
 
M184V Plasmids
M184V Patient Samples
ATG (M184)                                          GTG (M184V)
A C E
ATG GTG
Mutant GTG 184 plasmid Wild-type ATG and mutant GTG 184 plasmidWild-type ATG 184 plasmid
ATG/GTG
B
ATG GTG
Sample 38 (ATG) Sample 22 (GTG) Sample 25 (ATG/GTG)
ATG/GTG
D F
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Wild-type sequence T C A A T A T A T G G A T G A
Patient Sample
Sample 27 Y
Sample 28 G R
Sample 60 R
Sample 65 G R
Sample 69 G R
Sample 70 C G
Sample 77 C
Sample 90 C G
Sample 95 Y
Sample 34 G
Sample 49 G G
Sample 58 G
Sample 62 G G
Sample 63 C
Sample 84 G
Sample 89 C
Sample 91 C G
Sample 99 C
Sample 100 R C
Sample 10b*
Sample 35 R R
Sample 55*
Sample 92*
Sample 8a C
Sample 8b G G A
Sample 15 G
Sample 45 C
Sample 52 C
Sample 64 C
Sample 66 C
Sample 71 A
Sample 85 C
Table 3.12. No result and discordant patient sequences with polymorphisms within the binding region of the 
M184V assay probes. Correctly genotyped samples without polymorphisms were excluded.
Modification: None                                                
Result: Discordant prediction
* The discordance arose due to the increased sensitivity of HRMA as compared to population sequencing.
Modification: Altered primers                                                                     
Result: Correct prediction
Modification: Altered primers                                                                     
Result: No prediction
Modification: None                                                                     
Result: Correct prediction
Figure 3.13. Application of 184 
HRMA assay with 
polymorphism masking to 
patient samples. Negative first 
derivative (-dF/dT) plots of 
position 184, obtained by using 
a wild-type (ATG) patient 
sample and (A) normal and (B) 
altered primers; and a mutant 
(GTG) patient sample with (C) 
normal and (D) altered primers. 
 
M184V Patient Samples (Polymorphism Masking)
ATG (M184)                                          GTG (M184V)
A B
C D Altered primers
Altered primers
Sample 34 (ATG)
Sample 49 (GTG)
ATG
GTG
Sample 34 (ATG)
Sample 49 (GTG)
No genotype
No genotype
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The limit of detection was ~20% of mixed species, as determined by serial dilutions with the 
wild-type and M184V plasmid (Figure 3.14). This assay is slightly more sensitive than 
population sequencing but is less sensitive than the HRMA assays for codons 103 and 181. 
 
 
 
 
 
Discordance arose as HRMA identified wild-type M184 (ATG) as well as minority M184V 
(GTG) populations in three samples (10b, 55 and 92) which were determined to be completely 
wild-type (ATG) by population sequencing. Two of these samples (10b and 92) were selected for 
clonal analysis and M184V (GTG) was detected in 25% and 20% of the 100 clones, respectively. 
Consequently, the increased sensitivity of HRMA in comparison with population sequencing 
accounts for these three discordances. 
 
One sample (35) was identified as mutant M184V (GTG) by HRMA but wild-type (ATG) by 
population sequencing. The sample was resequenced and the reason for this discordance is 
unknown but it may be due to the unique A/GTA/G sequence at codon 184 of this sample. 
M184V Assay Limit of Detection
100%
50%
20%
10%
5%
1%
0%
Mutant 184 GTG plasmid
Figure 3.14. Determination of 184 HRMA assay limit of 
detection. Negative first derivative (-dF/dT) plot of a 
dilution series of mutant (GTG) at position 184 diluted in 
wild-type (ATG) obtained by using engineered plasmids and 
complementary  probes for the determination of analytical 
sensitivity. The amplicon melting peaks have been cropped 
for increased visibility of the probe melting peaks. 
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Excluding the samples which were discordant due to the extra analytical sensitivity of the 
M184V assay, the error rate of the assay is probably ~0.9%. 
 
In summary the complementary probes and altered primers accurately genotyped (n=102) most 
patient samples (Table 3.11 and Appendix D, Table D4). Similar to the assay for codon 181, the 
error rate is probably lower than that calculated due to the extra sensitivity of the HRMA assays. 
As with the preceding assays, at the respective sites (103 and 181), this assay can be utilized to 
accurately genotype the codon 184 in most HIV-1 patient samples. 
 
3.5.4 Q151M Assay 
Q151M (CAA/G → ATG)  results in high level resistance to the NRTIs ZDV, d4T, ddI and ABC 
(Shafer and Schapiro, 2008). The probes designed for the Q151M assay included complementary  
probes and probes incorporating mismatches (Table 3.13). Altered primers were also designed to 
facilitate polymorphism masking (Table 3.3)  
 
Table 3.13. Probe sequences for the Q151M assay. 
Codon (sequence) Name Sequence (5' -3') Modification Length (bp) G+C (%) 
Q151 (CAA) wt151A  TCCATCCTTGTGGAA - 15 47 
Q151 (CAG) wt151G  TCCATCCCTGTGGAA - 15 53 
Q151M (ATG) mt151      CCATCCCATTGGAAG - 15 53 
Q151 (CAA) wt151A.mm  TCCATCCTTGAGGAA Mismatch 15 47 
Mismatched base is in blue. 
  
 
When applied to plasmids and patient samples, the complementary probes often produced 
inconclusive results. Specifically, the wt151A probe, designed to signal the presence of the wild-
type CAA genotype, produced a melting peak when bound to either the CAA or CAG sequence, 
indicating limited non-specific binding at this position (Figure 3.15A). The wt151G probe, 
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designed to signal the wild-type CAG genotype, correctly produced a melting peak in the 
presence of the CAG sequence only; however the curve was shifted on the –dF/dT rather than the 
temperature axis (Figure 3.15B). Lastly, the mt151 probe, designed to indicate the mutant ATG 
sequence, did not generate a melting peak when applied to the Q151M (ATG) plasmids (Figure 
3.15C). However the mt151 probe was still applied to patient samples, with which it generated 
accurate melting peaks. The reason for the inconsistent performance of this probe, which was 
dependent on the genetic material, is unknown. The Tm of the amplicon-amplicon duplexes was 
76.5 ± 2 °C and the Tm of the probe-amplicon duplexes was 71 ± 2 °C. Representative melting 
plots are shown in Figures 3.15 and 3.16. The genotype and HRMA results for the Q151M assay 
are summarized in Appendix D, Table D5. 
 
To compensate for the limited non-specific binding of the wt151A probe, a deliberate mismatch 
(T→A) was incorporated to destabilize the probe binding (Table 3.13). The wt151A.mm, 
wt151G and mt151 probes were then applied to 116 patient samples. Eighty-one samples 
(69.8%) were correctly genotyped and four predictions (3.4%) were discordant with the 
population sequencing result. The remaining 31 (26.7%) samples could not be genotyped as 
small or no probe melting peaks were generated (Table 3.14). 
 
Table 3.14. Summary of Q151M assay results. 
Assay Correct Discordant No result 
Complementary  probes with mismatch 81 (70%) 4 (3.4%) 31 (27%) 
Of the 32 samples with no result:       
      Altered primers 17 0 14 
Total* 98 (85%) 4 (3.4%) 14 (12%) 
* Calculated from Table D5 (Appendix D). 
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Figure 3.15. Application of 151 HRMA assay to plasmids. Negative first derivative (-dF/dT) plots of the common 
SNP genotypes at position 151, obtained by using engineered plasmids and probes. The presence of a probe peak 
alongside the amplicon peak indicates successful probe binding, allowing for the allocation of a 151 genotype to 
the sample. (A) Wild-type (CAG) plasmid with a complementary  probe and (B) wild-type (CAG) plasmid with the 
wt151A.mm mismatched probe. This mismatch was introduced to prevent the non-specific binding of the wt151A 
probe. (C) Mutant (ATG) plasmid with the complementary  and mismatched probes. 
 
 
 
 
 
 
Figure 3.16. Application of 151 HRMA assay to patient samples. Negative first derivative (-dF/dT) plots of the 
common SNP genotypes at position 151, obtained by using patient samples and probes. (A) Wild-type (CAA) 
patient sample with complementary  and (B) mismatched probes. (C) Wild-type (CAG) patient sample with 
complementary  and (D) mismatched probes. (E) Mutant (ATG) patient sample with complementary  and (F) 
mismatched probes. 
 
 
Q151M Plasmids
CAA (Q151) CAG (Q151) ATG (Q151M)
A B
CAG/CAA CAG
Wild-type  CAG 151 plasmid Mutant ATG 151 plasmid
Mismatched probeCMismatched probe
Wild-type CAG 151 plasmid
CAG
CAA (Q151) CAG (Q151) ATG (Q151M)
Q151M Patient Samples
Sample 88 (CAA)
Sample 78 (CAG)
A
CAG
Mismatched probe
C
ATG
Sample 100 (ATG)
CAA
Sample 88 (CAA)
Sample 100 (ATG)
ATG
CAG/CAA
Sample 78 (CAG)
CAA
E
B D FMismatched probe Mismatched probe
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To determine reasons for the discordant or no results, the patient sequences corresponding to the 
region of probe binding were examined (Table 3.15). The majority of the polymorphisms 
clustered four bases upstream from codon 151.  
 
 
 
Wild-type sequence C T T C C A C A G G G A T G G A
Patient Sample
Sample 6a Y
Sample 11a R
Sample 11b R
Sample 23 W G
Sample 27 Y
Sample 36 M
Sample 41 R
Sample 51 G
Sample 54 G
Sample 66 A
Sample 69 G
Sample 71 M
Sample 81 K
Sample 84 C A T
Sample 87 R
Sample 97 C M T
Sample 102 G
Sample 34 G G
Sample 40 G
Sample 42 T G
Sample 45 G
Sample 58 G
Sample 59 G
Sample 64 A
Sample 65 A
Sample 75 G
Sample 76 A
Sample 95 R
Sample 99 T G
Sample 10b A
Sample 14 A
Sample 67
Sample 7a K A
Sample 7b K A
Sample 13a G A G
Sample 13b G A G
Sample 18 G
Sample 20 G
Sample 21 G G
Sample 38 C T
Sample 44 C A
Sample 52 C A
Sample 90 A
Table 3.15. No result and discordant patient sequences with polymorphisms within the binding region of the 
Q151M assay probes. Correctly genotyped samples without polymorphisms were excluded.
Modification: Altered primers                                                                     
Result: Correct prediction
Modification: Altered primers                                                                     
Result: No prediction
Modification: None                                 
Result: Discordant prediction
Modification: None                                                                     
Result: Correct prediction
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PCRs using altered primers were designed to mask polymorphisms (Table 3.3) and were applied 
with the complementary  probes to the 31 patient samples with no result. Seventeen genotypes 
were correctly predicted and 14 samples could not be genotyped (Table 3.14). However the 
melting peaks that were generated were small (examples are shown in Figure 3.17). 
 
 
Figure 3.17. Application of 151 HRMA assay with polymorphism masking to patient samples. Negative first 
derivative (-dF/dT) plots of wild-type (CAA) at position 151, obtained by using a wild-type patient sample and (A) 
normal primers and (B) altered primers.  
 
 
HRMA did not detect Q151M minority population in any samples and so the limit of detection 
could not be studied by clonal analysis. However one patient sample (sample 26) which was 
wild-type by population sequencing and by HRMA was selected for clonal analysis. This 
confirmed the genotype as the sample was 100% wild-type by analysis of 100 clones. A dilution 
series could not be performed as the mt151 probe could not detect the Q151M plasmid. 
 
The Q151M assay generated four discordant results (samples 10b, 14, 67, 70). The discordant 
predictions occurred between the wild-type genotypes CAA and CAG, rather than mutant ATG 
genotype. This discordances did not have clinical relevance as wild-type samples of one 
genotype were incorrectly predicted to be wild-type with the other 151 wild-type genotype. 
Q151M Patient Samples (Polymorphism Masking)
CAA (Q151)     CAG (Q151) ATG (Q151M)
Sample 29 (CAA)
A B
Sample 29 (CAA)
CAA
No genotype 
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In summary the two complementary  probes and one probe incorporating a mismatch accurately 
genotyped most of the samples (n=81) with a small discordance (n=4). Despite the generation of 
small peaks when the altered primers were utilized, polymorphism masking was successful with 
half (n=17) of the polymorphic samples (Table 3.14 and Appendix D, Table D5) and so the total 
number of samples genotyped was 98. While not as reliable or accurate as the preceding assays 
this assay did genotype most wild-type and all mutant 151 codons in the patient samples.  
 
3.5.5 G190A Assay 
G190A is a NNRTI mutation conferring resistance to NVP (Boyer et al., 1998). Complementary 
probes were designed to hybridize to the common GGA wild-type sequence and GCA mutant 
sequence (Table 3.16). In addition altered primers were designed for the purposes of 
polymorphism masking (Table 3.3). 
 
Table 3.16. Probe sequences for the G190A assay. 
Name (sequence) Sequence (5' -3') Modification Length (bp) G+C (%) 
wt190 (GGA) ATCAGATCCTACATA - 15 33 
mut190A (GCA) ATCAGATGCTACATA - 15 33 
   
 
The 190 assay was applied to the wild-type and mutant G190A plasmids and patient samples. 
Large probe peaks were generated that were partially merged with the amplicon melting peaks, 
however these probe peaks were consistent and could be used to successfully genotype position 
190 in 73 (63%) of the 116 patient samples. No clear probe peak was present in 41 samples 
(35%) and two (1.7%) samples generated discordant genotype predictions (Table 3.17). The Tm 
of the amplicon-amplicon duplexes was 73.9 ± 1 °C and the Tm of the probe-amplicon duplexes 
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was 71.5 ± 1 °C. Representative melting plots are shown in Figures 3.18 and 3.19. The genotype 
and HRMA results for the G190A assay are summarized in Appendix D, Table D6. 
 
Table 3.17. Summary of G190A assay results. 
Assay Correct Discordant No result 
Complementary  long probes 73 (63%) 2 (1.7%) 41 (35%) 
 
 
 
Figure 3.18. Application of 190 HRMA assay to plasmids and patient samples. Negative first derivative (-dF/dT) 
plots of the common SNP genotypes at position 190, obtained by using either engineered plasmids (top box) or 
patient samples (bottom box) and complementary  probes. The probe peak at a lower Tm indicates successful 
probe binding, allowing for the allocation of a 190 genotype to the sample. (A) Wild-type (GGA) and (B) mutant 
(GCA) plasmid; (C) wild-type (GGA) and (D) mutant (GCA) patient sample. The mut190A probe usually produced a 
small peak in the presence of the GGA sequence (arrow). 
 
 
Altered primers (Table 3.3) were designed and applied with the complementary  probes to the 41 
samples that could not be genotyped. In most of these samples, probe peaks corresponding to 
both the wild-type and mutant genotypes were generated, regardless of the sample genotype 
G190A Plasmids
C D
GGA GCA
Sample 54 (GCA)Sample 42 (GGA)
A B
GGA GCA
Wild-type GGA 190 plasmid Mutant GCA 190 plasmid
G190A Patient Samples
GGA (G190)                                  GCA (G190A)
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(examples are shown in Figure 3.19). Consequently the altered primers could not be used to 
genotype any patient samples. 
 
 
Figure 3.19. Application of 190 HRMA assay with polymorphism masking to patient samples. Negative first 
derivative (-dF/dT) plots of possible SNP genotypes at position 190, obtained by using patient samples and 
complementary  probes with normal or altered primers. Wild-type (GGA) patient sample with (A) normal and (B) 
altered primers. Wild-type (GGA) patient sample with (C) normal and (D) altered primers.  
 
 
A 190 genotype could not be allocated to samples with no melting peaks, small melting peaks or 
peaks that lacked sharp boundaries (illustrated in Figure 3.19 A and C). Samples generating 
small peaks and those with indistinct boundaries introduced ambiguity to the genotype 
interpretation. The sequences of the patient samples corresponding to the probe binding region 
were investigated to determine the affects of polymorphisms on melt curve generation (Table 
3.18). Similar to the preceding assays the presence of sequence variation directly adjacent to the 
mutation codon appeared to prevent probe melting peak formation. Polymorphisms at the 5’ end 
of the probe did not appear to disrupt HRMA as did base changes in most other locations. 
G190A Patient Samples (Polymorphism Masking)
GGA (G190)                                  GCA (G190A)
A B
C
Sample 63 (GGA)
Sample 32 (GGA)
Sample 32 (GGA)
Altered primers
Altered primers
No genotype
GGA 
Sample 63 (GGA)
D
No genotype
GGA/GCA
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Wild-type sequence T A T G T A G G A T C T G A C
Patient Sample
Sample 4a R
Sample 7b R
Sample 9a G
Sample 10b T
Sample 11a Y
Sample 12a T
Sample 18 T
Sample 23 T
Sample 24 T
Sample 27 Y R
Sample 29 T
Sample 33 C Y
Sample 38 T
Sample 46 Y W Y
Sample 52 T
Sample 55 T
Sample 56 T
Sample 58 T
Sample 64 T
Sample 66 T
Sample 72 T
Sample 77 T
Sample 94 T
Sample 96 T
Sample 97 K T
Sample 99 T
Sample 103 T
Sample 8b A
Sample 12b R S T
Sample 4b R S
Sample 5a W
Sample 9b R G
Sample 10a T
Sample 11b R Y
Sample 20 Y R
Sample 21 Y W G
Sample 25 T
Sample 28 T
Sample 32 G T
Sample 36 C A
Sample 37 S T
Sample 44 G
Sample 47 C T T
Sample 50 K
Sample 53 R
Sample 59 T C
Sample 61 C
Sample 62 G
Sample 65 T
Sample 69 R
Sample 75 C T
Sample 78 G
Sample 81 G
Sample 84 T
Sample 85 A C Y
Sample 101 R S
Sample 102 Y T
Modification: None                                                                     
Result: Correct prediction
Modification: None                                       
Result: Discordant prediction
Modification: None                                                                     
Result: No prediction
Table 3.18. No result and discordant patient sequences with polymorphisms within the binding region of the 
G190A assay probes. Correctly genotyped samples without polymorphisms were excluded.
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Discordance arose with sample 8b which had the G190T (AGA) mutation and was identified as 
wild-type by HRMA. The other discordant prediction, with sample 12b, was identified as wild-
type (GGA) by HRMA but GGA/C by population sequencing. The 1.7% error rate does not 
reflect the insensitivity of population sequencing but rather the inaccuracy of the 190 HRMA 
assay. 
 
HRMA did not detect G190A minority population in any samples and so the limit of detection 
could not be studied by clonal analysis. However a patient sample (10b) which was wild-type by 
population sequencing and by HRMA was selected for clonal analysis. One of the 100 (1%) 
clones harboured G190A which were not detected by HRMA or population sequencing. 
 
In summary the G190A assay is not as useful as the preceding assays in genotyping the 
respective mutation codons as only 73 samples could be genotyped (Table 3.17 and Appendix D, 
Table D6). Despite this, the discordance was low as only two samples generated incorrect 
genotypes. Polymorphism severely affected the 190 assay and the altered primers did not allow 
for accurate masking in 41 samples. No particular sequence appeared to generate the aberrant 
melting peaks for assay G190A and so additional polymorphism masking techniques were not 
attempted.  
 
3.5.6 K65R Assay 
K65R (AAG → AGG) is a multi NRTI resistance mutation selected for by TDF, ABC, ddI, and 
d4T (Xu et al., 2009). The probes designed for the K65R assay included complementary probes 
and probes incorporating mismatches and deletions (Table 3.19). 
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Table 3.19. Probe sequences for K65R assay. 
Codon (sequence) Name Sequence (5' -3') Modification Length (bp) G+C (%) 
K65 (AAG) wt65G  TGTCCTTCTTTTTTA - 15 27 
K65R (AGG) mt65      GTCCTTCCTTTTTAT - 15 33 
K65 (AAG) wt65G.MM TGTCATTCTTTTTTA Mismatch 15 20 
K65R (AGG) mt65.MM     GTCATTCCTTTTTAT Mismatch 15 27 
K65 (AAG) wt65.del    AC___CCTTCCTTTTTAT Deletion 15 20 
K65R (AGG) mt65.del    AC___CCTTCCTTTTTAT Deletion 15 27 
Mismatched base is in blue, the extra nucleotides are in purple and the deleted bases are represented by the 
orange underscores. 
  
 
The wild-type (AAG) and mutant (AGG) plasmids were accurately genotyped with the 
complementary probes.  When applied to the patient samples, multiple indistinct melting peaks 
were generated (examples are shown in Figure 3.20). A C→A transversion was introduced into 
the probes to destabilize the probe-target interaction. The plasmids were accurately genotyped 
with these mismatched probes; however the majority of wild-type patient samples produced 
multiple, small or no melting peaks (illustrated in Figure 3.20). Three samples harboured K65R, 
and the complementary  and mismatched probes correctly identified these clinically relevant 
mutations. The Tm of the amplicon-amplicon duplexes was 74.5 ± 2 °C and the Tm of the probe-
amplicon duplexes was 70 ± 2 °C. Representative melting plots are shown in Figures 3.20 and 
3.21. Selected genotype and HRMA results for the K65R assay are summarized in Appendix D, 
Table D7. 
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Figure 3.20. Application of 65 HRMA assay to plasmids and patient samples. Negative first derivative (-dF/dT) 
plots of common SNP genotypes at position 65, obtained by using either engineered plasmids (1) or patient 
samples (2) and complementary  probes (left panels) or mismatched probes (right panels). The smaller probe peak 
at a lower Tm indicates successful probe binding, allowing for the allocation of a 65 genotype to the sample. Wild-
type (AAG) plasmid with (1A) complementary  and (1B) mismatched probes. Mutant (AGG) plasmid with (1C) 
complementary  and (1D) mismatched probes. Wild-type (AAG) patient sample with (2A) complementary  and (2B) 
mismatched probes. Mutant (AGG) patient sample with (2C) complementary  and (2D) mismatched probes. 
 
K65R Plasmids
AAG (K65)                                          AGG (K65R)
K65R Patient Samples
A B
C
AAG AAG
AGG
Mismatched probe
Mismatched probe
Wild-type 65 AAG plasmid
D
AGG
Wild-type 65 AAG plasmid
Mutant 65 AGG plasmid
Mutant 65 AGG plasmid
A B
C D
AAG
AGG
AAG
AGG
Mismatched probe
Mismatched probe
Sample 91 (AAG)
Sample 83 (AGG) Sample 83 (AGG)
Sample 91 (AAG)
AAG (K65)                                          AGG (K65R)
1 
2 
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As the complementary  probes were 15 bp long, the region of binding intersected with both 
codon 65 and the highly polymorphic codon 67 (Kuiken et al., 2009). Probes were then designed 
lacking the bases complementary to position 67. Three additional bases were included to 
maintain the optimal 15 bp probe length (Table 3.19). The deletion probes produced melting 
peaks when applied to the plasmids, but not when applied to the patient samples (examples are 
shown in Figure 3.21).  
 
 
 
Figure 3.21. Application of 65 HRMA assay with polymorphism masking to plasmids and patient samples. 
Negative first derivative (-dF/dT) plots of the common SNP genotypes at position 65, obtained by using either 
engineered plasmids (left panels) or patient samples (right panels) and deletion probes. (A) Wild-type (AAG) 
plasmid and (B) wild-type patient sample. (C) Mutant (AGG) plasmid and (D) mutant patient sample. 
 
 
 
In summary the complementary, mismatched and deletion probes were unsuitable to genotype 
the wild-type codon 65. However, the complementary  and mismatched probes were able to 
genotype K65R in the patient samples (n=3) that harboured this mutation (Appendix D, Table 
D7). 
K65R Plasmids
AAG (K65)                                          AGG (K65R)
K65R Patient Samples
Wild-type 65 AAG plasmid
A
Mutant 65 AGG plasmid
Deletion probe
AGG
C
Deletion probe
AAG
B
Deletion probe
Sample 91 (AAG)
Deletion probe
D
No genotype
No genotype
Sample 83 (AGG)
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3.5.7 V106M Assay 
V106M (GTA/G → ATG) is selected for by EFV but is associated with broad NNRTI resistance 
(Brenner et al., 2003). The probes designed for the V106M assay included complementary 
probes and probes incorporating mismatches at selected sites (Table 3.20). 
 
Table 3.20. Probe sequences for V106M assay. 
Codon (sequence) Name Sequence (5' -3') Modification Length (bp) G+C (%) 
V106 (GTA) wt106A GTACTGTTACTGATT - 15 33 
V106 (GTG) wt106G GTACTGTCACTGATT - 15 40 
V106M (ATG) mt106           ACTGTCATTGATTTT - 15 27 
V106 (GTA) wt106A.mm GTACTATTACTGATT  Mismatch 15 27 
V106 (GTG) wt106G.mm GTACTATCACTGATT Mismatch 15 33 
V106M (ATG) mt106.mm           ACTGTCATTAATTTT Mismatch 15 20 
Mismatched base is in blue. 
 
 
When applied to the wild-type (GTG) plasmid each of the three complementary  probes 
generated a peak, indicating non-specific binding (examples are shown in Figure 3.22). However 
the Tm of the mt106 probe melting peak differed when the probe was applied to wild-type (GTG) 
and mutant (ATG) plasmids or patient samples. Specifically, the Tm of the melting peak was ~2 
°C lower than the Tm when applied to wild-type as compared to mutant samples (illustrated in 
Figure 3.23C and E).  
 
By noting the differences in the Tm, the V106M samples could be identified. Of the 15 samples 
harbouring V106M, 13 (87%) were correctly genotyped, while two could not be genotyped 
probably due the presence of  an G→A transition five bases upstream from the probe center. The 
wt106A probe, in some cases, generated an accurate small peak when applied to wild-type GTA 
patient samples (Figure 3.23A). The Tm of the amplicon-amplicon duplexes was 77 ± 1 °C and 
the Tm of the probe-amplicon duplexes was 72.5 ± 1 °C. Representative melting plots are shown 
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in Figures 3.22 and 3.23. Selected genotype and HRMA results for the V106M assay are 
summarized in Appendix D, Table D8. 
 
 
 
Figure 3.22. Application of 106 HRMA assay to plasmids. Negative first derivative (-dF/dT) plots of common SNP 
genotypes at position 106. The presence of a probe peak alongside the amplicon peak indicates successful probe 
binding, allowing for the allocation of a 106 genotype to the sample. The curves were obtained by using wild-type 
(GTG, top panels) and mutant (ATG, bottom panels) engineered plasmids and complementary  probes (left panels) 
or mismatched probes (right panels). No wild-type GTA plasmid was constructed. 
 
 
As the complementary probes were stable in the presence of a central mismatch, an A→G 
transition was introduced in order to destabilize non-specific probe-target interactions (Table 
3.20). This mismatch was one base pair upstream from the central nucleotide of the probe. The 
mismatch (A→G) in the mt106.mm probe was in a different location to the wild-type probes in 
order to ensure that the type and position of the mismatch was the same in each of the probes. 
The wt106G.mm mismatched probe rarely generated a peak when applied to wild-type GTG 
patient samples. The remaining mismatched probes did not generate melting peaks when applied 
to the plasmids or patient samples (examples are shown in Figure 3.23). 
V106M Plasmids
GTA (V106) GTG (V106) ATG (V106M)
A B
C
GTA/GTG/ATG
No genotype
ATG
Mismatched probe
Mismatched probe
D
Wild-type GTG 106 plasmid Wild-type GTG 106 plasmid
Mutant ATG 106 plasmid Mutant ATG 106 plasmid
No genotype
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Figure 3.23. Application of 106 HRMA assay to patient samples. Negative first derivative (-dF/dT) plots of 
common SNP genotypes at position 106, obtained by using patient samples and complementary  probes (top 
panels) and mismatched probes (bottom panels). Wild-type (GTA) patient sample with the (A) complementary  and 
(B) mismatched probes. Wild-type (GTG) patient sample with the (C) complementary  and (D) mismatched probes. 
Mutant (ATG) patient sample with the (C) complementary  and (D) mismatched probes. 
 
 
In summary the wild-type complementary and mismatched probes did not produce accurate 
melting peaks. While the complementary mutant probe produced a melting peak in the absence 
of a mutant sequence, the Tm of the peak differed from that generated with a mutant sample. In 
this way the clinically relevant mutant patient samples (n=15) were identified (Appendix D, 
Table D8). 
 
3.5.8 M41L Assay 
M41L (ATG → C/TTG) is a type I thymidine analogue mutation (TAM) that confers resistance 
to the thymidine analogues (ZDV and d4T) in the presence of K70R, M184V and T215Y/F 
V106M Patient Samples
GTA (V106) GTG (V106) ATG (V106M)
A E
B FD
C
Mismatched probe
GTA
Mismatched probeMismatched probe
No genotype
GTG
Sample 52 (GTA) Sample 62 (ATG)
Sample 52 (GTA) Sample 62 (ATG)
No genotype
Sample 7a (GTG)
Sample 7a (GTG)
ATG
GTA/GTG/ATG
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(Garcia-Lerma, 2005). The probes designed for the M41L assay included complementary probes 
and probes incorporating mismatches (Table 3.21). 
 
Table 3.21. Probe sequences for M41L assay. 
Codon (sequence) Name Sequence (5' -3') Modification Length (bp) G+C (%) 
M41 (ATG) wt41A  TTCTCCATTTCTTCA - 15 33 
M41L (TTG) mt41T  TTCTCCAATTCTTCA - 15 33 
M41L (CTG) mt41C  TTCTCCAGTTCTTCA - 15 40 
M41 (ATG) wt41A.mm  TTTTCCATTTCTTCA Mismatch 15 27 
M41L (TTG) mt41T.mm  TTTTCCAATTCTTCA Mismatch 15 27 
M41L (CTG) mt41C.mm  TTTTCCAGTTCTTCA Mismatch 15 33 
Mismatched base is in blue. 
 
 
When the probes were applied to plasmids or patient samples, multiple melting peaks where 
generated (examples are shown in Figure 3.24). Consequently, a C→T transition was introduced 
in order to destabilize non-specific probe binding. This modification allowed for accurate 
genotyping of the wild-type (ATG) and mutant (C/TTG) plasmids. However, the masking did 
not allow genotyping of the patient samples as multiple peaks were still generated. However, in 
some cases the wt41A.mm probe did generate accurate melting peaks (Figure 3.24 2B). The Tm 
of the amplicon-amplicon duplexes was 73.5 ± 2 °C and the Tm of the probe-amplicon duplexes 
was 69 ± 2 °C. Representative melting plots are shown in Figure 3.24. 
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Figure 3.24. Application of 41 HRMA assay to plasmids and patient samples. Negative first derivative (-dF/dT) 
plots of the common SNP genotypes at position 41, obtained by using either engineered plasmids (1) or patient 
samples (2) and complementary  probes (top panels of each box) or mismatches probes (bottom panels of each 
box). The presence of a probe peak alongside the amplicon peak indicates successful probe binding, allowing for 
the allocation of a 41 genotype to the sample. Wild-type (ATG) plasmid with the (1A) complementary  and (1B) 
mismatched probes. Mutant (TTG) plasmid with the (1C) complementary  and (1D) mismatched probes. Mutant 
(CTG) plasmid with the (1E) complementary  and (1F) mismatched probes. The same combination of probes in (1) 
are contained in (2) but applied to patient samples. 
 
 
In summary the complementary probes were unable to genotype codon 41 in plasmids or patient 
samples. The introduction of a mismatch allowed genotyping of the plasmids but not the patient 
samples. 
M41L Patient Samples2
M41L Plasmids1
ATG (M41) TTG (M41L) CTG (M41L)
ATG (M41) TTG (M41L) CTG (M41L)
A EC
FDB Mismatched probe Mismatched probeMismatched probe
ATG/TTG/CTG CTG TTG/CTG
ATG TTG CTG
Wild-type ATG 41 plasmid
Wild-type ATG 41 plasmid
Mutant CTG 41 plasmidMutant TTG 41 plasmid
Mutant CTG 41 plasmidMutant TTG 41 plasmid
Sample 85 (CTG)
Sample 85 (CTG)
A E
B FD
C
Mismatched probe Mismatched probeMismatched probe
ATG/TTG/CTG ATG/TTG
ATG ATG/TTG/CTG ATG/TTG/CTG
Sample 89 (ATG)
Sample 89 (ATG)
Sample 68 (TTG)
Sample 68 (TTG)
ATG/TTG/CTG
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3.5.9 D67N Assay 
D67N (GAC/T → AAC) is a type II TAM and is associated with ZDV and d4T resistance when 
present with particular combinations of type I and II TAMs (Garcia-Lerma, 2005; Menendez-
Arias, 2008). Complementary probes were designed to identify the common wild-type and 
mutant genotypes. Additionally, a mismatch was introduced into the mutant probe (Table 3.22). 
 
Table 3.22. Probe sequences for D67N assay. 
Codon (sequence) Name Sequence (5' -3') Modification Length (bp) G+C (%) 
D67 (GAC) wt67C TAGTACTGTCCTTCT - 15 40 
D67 (GAT) wt67T TAGTACTATCCTTCT - 15 33 
D67N (AAC) mt67C.mm         GTACTTTTCTTCTTT Mismatch 15 27 
Mismatched base is in blue. 
 
 
Due to the high G+C content, a G→T transversion was introduced into the mutant mt67.mm 
probe to reduce the binding affinity of the probe to its target. When the two wild-type 
complementary probes and the mismatched mutant probe were applied to the wild-type (GAC/T) 
and mutant (AAC) plasmids, small and indistinct melting peaks were formed when the G/AAC 
sequences were present. No probe melting peak was formed when the complementary probes 
were applied to the wild-type GAT sequence. Upon application of the probes to patient samples, 
inconsistent and indistinct peaks were generated with the GAC sequence, while no peaks formed 
with GAT and AAC. The Tm of the amplicon-amplicon duplexes was 74.3 ± 1 °C and the Tm of 
the probe-amplicon duplexes was 72 ± 1 °C. Representative melting plots are shown in Figure 
3.25. 
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Figure 3.25. Application of 67 HRMA assay to plasmids and patient samples. Negative first derivative (-dF/dT) 
plots of the common SNP genotypes at position 67, obtained by using either engineered plasmids (top panels) or 
patient samples (bottom panels) and probes. The presence of a smaller probe peak at a lower Tm indicates 
successful probe binding, allowing for the allocation of a 67 genotype to the sample. (A) Wild-type (GAC) plasmid 
and (B) wild-type (GAC) patient sample. (C) Wild-type (GAT) plasmid and (D) wild-type (GAT) patient sample. (E) 
Mutant (AAC) plasmid and (F) mutant (AAC) patient sample. Each probe was complementary  besides for the 
mt67C.mm mismatched probe 
 
 
In summary the complementary and mismatch probes had very limited success in genotyping 
position 67 in the plasmids. The probes performed poorly when applied to patient samples. 
 
3.5.10 K70R Assay 
K70R (AAA/G → AGG) is a type II TAM and is associated with strong thymidine analogue 
resistance when present with particular combinations of type I and type II TAMs (Garcia-Lerma, 
2005; Menendez-Arias, 2008). Complementary probes were designed to genotype 70 codon 
(Table 3.23). 
 
D67N Plasmids
D67N Patient Samples
B D F
GAC GAT
No genotype
Mismatched probe
Sample 64 (GAC) Sample 63 (AAC)Sample 11a (GAY)
GAC
No genotype AAC
Wild-type GAC 67 plasmid Wild-type GAT 67 plasmid Mutant 67 AAC plasmid
A C E
Mismatched probe
GAC (D67) GAT (D67) AAC (D67N)
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Table 3.23. Probe sequences for K70R assay. 
Codon (sequence) Name Sequence (5' -3') Modification Length (bp) G+C (%) 
K70 (AAA) wt70A TTCTCCATTTAGTAC - 15 33 
K70 (AAG) wt70G  TTCTCCACTTAGTAC - 15 40 
K70R (AGG) mt70      TCTCCACCTAGTACT - 15 47 
 
 
Representative melting plots are shown in Figure 3.26 and 3.27. Non-distinct and small peaks 
were produced upon melting of the probes with the respective wild-type (AAA/G) and mutant 
(AGG) plasmids (examples are shown in Figure 3.26). The Tm of the amplicon-amplicon 
duplexes was 74 ± 2 °C and the Tm of the probe-amplicon duplexes was 72 ± 1 °C. No melting 
peaks were produced when the probes were applied to patient samples (illustrated in Figure 
3.27).  
 
 
 
Figure 3.26. Application of 70 HRMA assay to plasmids. Negative first derivative (-dF/dT) plots of the common 
SNP genotypes at position 70, obtained by using (A) wild-type (AAG) and (B) mutant (AGG) engineered plasmids 
and complementary  probes. The presence of a smaller probe peak at a lower Tm indicates successful probe 
binding, allowing for the allocation of a 70 genotype to the sample. No wild-type AAA plasmid was constructed. 
 
 
 
K70R Plasmids
AAG (K70)    AGG (K70R) AAA (K70)
AAG AGG
Wild-type 70 AAG plasmid Mutant AGG 70 plasmid
A B
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Figure 3.27. Application of 70 HRMA assay to patient samples. Negative first derivative (-dF/dT) plots of the 
common SNP genotypes at position 70, obtained by using a (A) wild-type (AAA) patient sample, (B) wild-type (AAG) 
patient sample and (C) mutant (AGG) patient sample with complementary  probes. 
 
In summary the complementary probes produced small melting peaks when applied to plasmids 
and no melting peaks upon application to patient samples.  
 
3.5.11 T215F and T215Y Assay 
T215Y and T215F are type I and II TAMs, respectively. Similar to D67N and K70R, T215F and 
T215Y when associated with other TAMs confer ZDV and d4T resistance (Garcia-Lerma, 2005; 
Menendez-Arias, 2008). ACC is the wild-type sequence at position 215 and so multiple 
nucleotide changes are required for the mutant T215F (TTC) and T215Y (TAC) to develop. 
Complementary probes were designed to genotype the 215 codon (Table 3.24). 
 
Table 3.24. Probe sequences for T215F/Y assay. 
Codon (sequence) Name Sequence (5' -3') Modification Length (bp) G+C (%) 
T215 (ACC) wt215 TGGTGTGGTAAATCCC - 16 47 
T215F (TTC) mt215F TGGTGTGAAAAATCCC - 16 44 
T215Y (TAC) mt215Y TGGTGTGTAAAATCCC - 16 44 
 
 
The probes were designed with the two polymorphic bases in the center. To achieve this, an extra 
base was added to the probe, bringing the total length to 16 bp (Table 3.24). A single probe 
melting peak was formed when the probes were applied to wild-type (T215, ACC) plasmids. 
K70R Patient Samples
AAG (K70)    AGG (K70R) AAA (K70) 
No genotype
Patient sample 86 (AAA)
C
No genotype No genotype
Patient sample 22 (AAG) Patient sample 71 (AGG)
BA
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However multiple probe melting peaks were generated when the probes were applied to the wild-
type (AAC) patient samples (examples are shown in Figure 3.28). The mt215F probe did 
produce accurate melting peaks with a patient sample and not the plasmids. However only one 
patient sample in the cohort had TTC at the 215 locus and so the accuracy of this probe cannot 
be verified. Multiple peaks were generated when the mt215Y probe was applied to plasmids and 
patient samples. The Tm of the amplicon-amplicon duplexes was 78.5 ± 1 °C and the Tm of the 
probe-amplicon duplexes was 69.5 ± 1.5 °C. Representative melting plots are shown in Figure 
3.28. 
 
 
Figure 3.28. Application of 215 HRMA assay to plasmids and patient samples. Negative first derivative (-dF/dT) 
plots of the common SNP genotypes at position 215, obtained by using either engineered plasmids (top panels) or 
patient samples (bottom panels) and complementary  probes. A probe peak alongside the amplicon peak indicates 
successful probe binding, allowing for the allocation of a 215 genotype to the sample. (A) Wild-type (ACC) plasmid 
and (B) wild-type (ACC) patient sample. (C) Mutant (TTC) plasmid and (D) mutant (TTC) patient sample. (E) Mutant 
(TAC) plasmid and (F) mutant (TAC) patient sample. 
 
 
T215F/Y Plasmids
T215F/Y Patient Samples
AAC (T215) TTC (T215F) TAC (T215Y)
B
D
F
ACC/TAC
TTC
TAC/TTC
Sample 68 (TAC)Sample 28 (TTC)Sample 81 (ACC)
TAC/TTCTAC/TTCACC
A C E
Wild-type ACC 215 plasmid Mutant TAC 215 plasmidMutant TTC 215 plasmid
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In summary the complementary probes failed to genotype codon 215 in plasmids or patient 
samples. The probe complementary  to TTC (T215F) was able to genotype this position, 
however more samples need to be tested. 
 
3.5.12 P225H Assay 
P225H (CCC/T → CAC) is a secondary NNRTI mutation that is usually associated with a 
primary NNRTI mutation to confer NVP and EFV resistance (Shafer and Schapiro, 2008). 
Complementary probes were designed to genotype the two wild-type and single mutant sequence 
at this codon (Table 3.25). 
 
Table 3.25. Probe sequences for P225H assay. 
Codon (sequence) Name Sequence (5' -3') Modification Length (bp) G+C (%) 
P225 (CCC) wt225C GAAATGGGGGTTCTT - 15 47 
P225 (CCT) wt225T GAAATGGAGGTTCTT - 15 40 
P225H (CAC) mt225H AAATGGGTGTTCTTT - 15 40 
 
 
Representative melting plots are shown in Figures 3.29 and 3.30. No probe melting peaks were 
generated when the probes were applied to plasmids (examples are shown in Figure 3.29). The 
probes routinely produced multiple or no melting peaks with the patient samples (example in 
Figure 3.30). The wt225C probe (Figures 3.29 and 3.30 in red) consistently generated a flat line 
with each patient sample; the reason for this aberrant melting peak formation is unknown. The 
Tm of the amplicon-amplicon duplexes was 77.5 ± 1 °C and the Tm of the probe-amplicon 
duplexes was 75 ± 1 °C.  
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Figure 3.29. Application of 225 HRMA assay to plasmids. Negative first derivative (-dF/dT) plots of the common 
genotypes at position 225, obtained by using (A) wild-type (CCC) and (B) mutant (CAC) engineered plasmids and 
complementary  probes. A probe peak at a lower Tm indicates successful probe binding, allowing for the allocation 
of a 225 genotype to the sample. No wild-type CCT plasmid was constructed. 
 
 
 
Figure 3.30. Application of 225 HRMA assay to patient samples. Negative first derivative (-dF/dT) plots of the 
common genotypes at position 225, obtained by using patient samples and complementary  probes. (A) Wild-type 
(CCC) patient sample, (B) mutant (CAC) patient sample and (C) mutant (CCT) patient sample. 
 
In summary the complementary probes failed to genotype codon 225 in plasmids and the 
majority of patient samples. 
 
3.6 HRMA Validation 
Validation procedures typically include sensitivity, specificity, repeatability, reproducibility and 
limit of detection. Sensitivity and specificity are statistical measures of the true positive and true 
negative test results, respectively (Figure 3.31). Repeatability and reproducibility compares the 
P225H Plasmids
CCC (P225)                        CAC (P225H) CCT (P225)
No genotype No genotype
Wild-type CCC 225 plasmid Mutant CAC 225 plasmid
A B
P225H Patient Samples
CCC (P225) CAC (P225H) CCT (P225)
A CB
No genotype CCTCAC
Sample 63 (CCC) Sample 102 (CAC) Sample 75 (CCT)
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intra-run and inter-run precision, respectively. A guideline for HRMA validation, by 
Norambuena and colleagues was used as a model for the validation of the K103N, Y181C, 
M184V, Q151M and G190A assays reported here (Norambuena et al., 2009).  
 
3.6.1 Specificity and Sensitivity 
 
 
FPof  numberTNof  number
TNof  number
ySpecificit

              
FNof  numberTPof  number
TPof  number
ySensitivit

  
 
 
 
 
 
 
3.6.1.1 K103N 
Twenty-one samples with no result were removed for the calculations. The specificity was 100% 
(n=62) and the sensitivity was 94% (n=31) due to two false negatives, samples 20 and 54 
(Appendix D, Table D2). 
 
3.6.1.2 Y181C 
Eleven samples with no result were removed for the calculations. The specificity (n=95) was 
97% due to three false positives (samples 6b, 69 and 73; Appendix D, Table D3). However as the 
assay has a higher limit of detection than population sequencing the samples may indeed be 
mutant and so the specificity is probably 100%. The sensitivity was 100% (n=7). 
Figure 3.31. Formulae for the calculation of specificity and sensitivity*. 
True negative (TN) = Wild-type correctly identified as wild-type. 
False positive (FP) = Wild-type incorrectly identified as mutant. 
True positive (TP) = Mutant correctly identified as mutant. 
False negative (FN) = Mutant incorrectly identified as wild-type. 
*The genotypes as determined by the complementary probes were used to calculate the 
specificity and sensitivity for each assay. 
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3.6.1.3 M184V 
Twenty samples with no result were removed for the calculations. The specificity (n=55) was 
95% due to three false positives (samples 10b, 55 and 92; Appendix D, Table D4). However as 
the assay has a higher limit of detection than population sequencing the specificity is probably 
100%. Sample 35 was a false negative and so the sensitivity was 97% (n=37). 
 
3.6.1.4 Q151M 
Thirty-one samples with no result were removed for the calculations. Samples 10b, 14, 67 and 70 
were identified as wild-type CAA, CAG, CAG and CAG by sequencing, while HRMA identified 
the codons as CAG, CAA, CAA and CAA, respectively (Appendix D, Table D5). This did not 
affect the specificity, which was 100% (n=76) and the sensitivity was 100% (n=5). 
 
3.6.1.5 G190A 
Fourty-one samples with no result were removed for the calculations. The specificity (n=68) was 
100% while the sensitivity (n=5) was 71% due to two false negatives (samples 8b and 12b; 
Appendix D, Table D6). 
 
3.6.2 Repeatability and Reproducibility 
Samples representing each genotype (both wild-type and mutant) of the above mentioned codons 
were selected. Each reaction was repeated five times during a single PCR run for repeatability 
and then run five times on different days for reproducibility. The repeatability and 
reproducibility was 100% 
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3.7 Summary of HRMA Results 
The HRMA assays successfully genotyped most of the wild-type and mutant 103, 181, 184, 151 
and 190 codons with a high sensitivity and specificity. The limit of detection for the K103N and 
Y181C assays were 5% and for the M184V assay, 20%. The probes for assay 151 could not 
detect Q151M and the G190A plasmids could not be amplified for use in serial dilutions and so 
the limit of detection for these assays could not be determined. The assays for codons 65 and 106 
were not able to genotype the wild-type sequences at the respective sites; however the clinically 
relevant mutant sequences were genotyped. Table 3.26 (page 95) summarizes these results. The 
assays for codons 41, 67, 70, 215 and 225 generally were unable to genotype plasmids or patient 
samples and so were excluded from the Table.  
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Chapter 4:  Discussion and Conclusion 
 
 
During HIV infection, quasi-species harbouring drug resistance mutations can expand and 
become dominant if anti-retroviral (ARV) drug therapy is non-suppressive (Clavel and Hance, 
2004). The presence of one or a number of specific mutations in p66/p51 of pol generally has 
major consequences on the efficacy of the RT inhibitors for the treatment of HIV infection 
(Shafer and Schapiro, 2008). While Sanger population sequencing is the gold standard for HIV 
genotyping, it is time-consuming, laborious and costly (Hanna and D’Aquila, 2001). Newly 
introduced high resolution melting analysis (HRMA) allows for rapid and cost effective closed-
tube genotyping and mutation scanning. Accurate genotyping of specific loci by HRMA relies on 
melting curves generated upon the dissociation of unlabelled probes from a DNA target. The 
process is monitored in real-time by the fluorescence emitted from a saturating dsDNA binding 
dye (Zhou et al., 2005). In this study, I showed that HRMA can be used to genotype key HIV-1 
drug resistance mutations. 
 
The assays designed to genotype codons 103, 181, 184, 151 and 190 accurately genotyped these 
loci in 80%, 88%, 79% 69% and 63% of 116 HIV-1 samples from 103 patients. The genotype 
predictions were discordant in 1.7%, 2.6%, 3.4%, 3.4% and 1.7% of the samples. The K65R and 
V106M assays genotyped only mutant samples and failed to genotype the wild-type sequences 
that these positions. The assays for codons 41, 67, 70, 215 and 225 had limited success in 
genotyping the engineered plasmids and could not genotype the patient samples. 
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The 1.7% (n=2) discordance for the 103 assay may be bypassed by the design of probes that 
include a distal mismatch. This may prevent probe melting peak formation in the presence of the 
rare AGA/T/C 103 genotypes but allow accurate genotyping with AAA/G/C/T at 103. Evidence 
for this lies in the inaccurate melting patterns generated with the AGA/T/C mutations in the 
absence of additional polymorphisms (underlined base differs between the common and unusual 
103 genotypes). In the presence of additional polymorphisms no melting peaks were formed 
 
The 2.6% (n=3) and 3.4% (n=4) discordance for assays 181 and 184 is probably a function of the 
limited analytical sensitivity of population sequencing, rather than HRMA inaccuracy. The three 
Y181C assay discordances and three of the four M184V assay discordances occurred as a result 
of the detection of minor mutant populations, which were not detected by population sequencing. 
The HRMA assays have a higher analytical sensitivity and the presence of mutant populations 
was confirmed by clonal analysis on three discordant samples (Vossen et al., 2009a); 
consequently the discordance for assays 181 and 184 is likely to be 0% and 0.9%, respectively.  
 
The 3.4% (n=4) discordance between results for the 151 assay involved the wild-type genotypes 
and not the clinically relevant Q151M mutant. As wild-type samples of one genotype were 
inaccurately identified as the other wild-type 151 genotype, it would not affect treatment options 
or drug resistance surveillance. 
 
The G190T (AGA) genotype (n=1) is rare and probes were not designed to genotype this codon. 
For similar reasons as for the unusual 103 genotypes, a deliberate mismatch may prevent 
erroneous probe melting peak formation and prevent discordant predictions with G190T samples. 
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The highly polymorphic nature of HIV probably prevented the genotyping of every patient 
sample (Preston et al., 1988; Roberts et al., 1988). Despite this, many samples that had 
polymorphisms within the probe binding region were genotyped. Polymorphisms closer to the 
extremities of the probes usually did not disrupt HRMA, as did the more destabilizing 
centralized variation (Naiser et al., 2008; Wu et al., 2009). In contrast, in some instances, no 
probe melting patterns were generated when the assays were applied to samples with the 
corresponding genotype. This variation may be a consequence of preferential amplification, of a 
particular quasi-species, harbouring a different genotype than the predominate species. 
Alternatively, during melting analysis, as the samples are cooled, secondary structures within the 
HIV-1 derived amplicons may form which may alter melting results. 
 
Validation of the 103, 181, 184, 151 and 190 HRMA assays was carried out. The specificity of 
the 103, 151 and 190 assays was 100%. The 181 and 184 assays had a specificity of 97% and 
95%, respectively; however due to the increased limit of detection the specificity is probably 
100%. The sensitivity was 94%, 100%, 97%, 100% and 71% for the 103, 181, 184, 151 and 190 
assays. The repeatability and reproducibility for each assay was 100%. However, the sensitivity 
for assays 151 and 190 were calculated with five mutant samples and so this may not represent 
the true sensitivities of the assays, therefore a larger number of mutant samples is required. As 
the assays were validated on the patient sample cohort on which optimization was performed, the 
results may be biased and further validation should be performed on a different patient sample 
set. 
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There appears to be a loose association between the G+C content adjacent to the target mutant 
nucleotide and assay success. The assays for codons 103, 181 and 184 produced the most distinct 
probe melting peaks. Other than identical probe length, the other similarity was the A+T content 
flanking the mutation sites. The weak A+T interactions in the center of the probe may allow for 
early dissociation of the mismatched probes, allowing for optimum HRMA. In contrast, the 
probes for codon 215 and 225 failed to genotype either plasmids or patient samples. The centers 
of these probes were flanked with, or were rich in G or C. This extra stability appears to have 
prevented early dissociation of the mismatched probes, leading to extra melting peak formation. 
Additionally the probes for position 215 were 16 bp in length which would have increased the 
binding stability (Zhou et al., 2004).  
 
A central distribution of A+T was also found at codons 41, 65, 67 and 70. The use of ZDV and 
d4T has been widespread amongst South Africa patients receiving HAART, and so the 
thymidine analogue mutation (TAM) D67N is very common (Wallis et al., 2009). As the probes 
targeting codon 65 covered the highly polymorphic 67 codon, it probably disrupted successful 
genotyping of 65. Multiple melting peaks were formed when probes were applied to codon 41. 
Despite the introduction of a mismatch into the codon 41 probes, which decreased the G+C 
content to < 33%, multiple peak formation still occurred. In contrast, the probes for codon 70 had 
a G+C content of > 33%, yet no melting peaks were produced with the patient samples. 
Additionally, the wt67C probe, with 40% G+C, genotyped plasmids and some patient samples, 
while the other probes for position 67 (33% and 27% G+C) were unsuccessful. The reasons for 
this highly unpredictable stability are unknown.  
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The probes for codon 151 and 190 contained both pyrimidines and purines directly flanking the 
target mutation at the probe center. While these assays were successful, melting peak formation 
was not always distinct, which may be due to the extra probe stability. This extra stability may 
account for the increased atypical melting peak formation generated by the 151 and 190 rather 
than the 103, 181 and 184 assays. 
 
Various polymorphism masking techniques were applied to samples that could not be genotyped 
with the unmodified (complementary) probes. The masking techniques included altered primers, 
short probes, LNAs and ambiguous, mismatched, universal and deleted bases. Polymorphism 
masking techniques have been reported twice previously (Margraf et al., 2007; Margraf et al., 
2006). In both instances the assays were applied to human DNA, probe length varied from 27–33 
bp and deleted, mismatched and universal bases were utilized. In these studies, each masking 
method produced similar, accurate results, save for a deletion adjacent the target site. As with 
other HRMA assays, the probe length is a significant difference between these assays, and those 
reported here. The longer probes are steadier in the presence of mismatches or deletions and so 
generate a signal despite instability. However longer probes will increase the interaction of the 
probes with polymorphisms. The short probes utilized for HIV-1 HRMA usually did not tolerate 
mismatches or deletions due to the weaker probe-target interaction, and therefore did not 
generate a signal. The exceptions were the wt106G.mm, wt151A.mm, the codon 41 mismatched 
probes and the codon 181 deletion probes. The differences in the response of the mismatched 
probes may be due to the varying degree of thermal stability of mismatches. Of the mismatches, 
“A:A” is of the most unstable, and so may account for the success of the wt151A.mm probe (Wu 
et al., 2009). The mismatches incorporated into the other probes were not as unstable, due to the 
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presence of G/C and so this may have prevented accurate melting peak generation in patient 
samples. The codon 181 and 65 deletion probes had one and three deleted bases, respectively. 
The failure of the latter is probably as a result of the heightened instability of the binding 
interaction due to the codon deletion. It appears that the small size of the probes for HIV-1 
HRMA limits the potential for successful polymorphism masking. 
 
Others have successfully utilized the universal base 5-nitroindole for polymorphism masking 
(Margraf et al., 2006). Inosine was incorporated into the codon 181 probes but did not mask the 
polymorphisms efficiently. This is probably because inosine is not truly indiscriminate, with a 
decreasing binding stability of I·C > I·A > I·T ≈ I· G > I·I (Loakes, 2001; Watkins Jr and 
SantaLucia Jr, 2005). Moreover a deletion at this site, which is more cost effective than inosine, 
generated accurate melting peaks. Consequently, deletions, 5-nitroindole or universal bases, 
other than inosine, should be tested for further HRMA application. 
 
Altered primers, designed to bind directly adjacent to each mutation codon, have not been 
reported in the literature. These primers were applied to polymorphic samples for codons 103, 
184, 151 and 190. The melting peaks generated were difficult to identify and the discordance 
was high. The low signal, high noise and high discordance may be due to the small amplicons 
produced. Another drawback is the necessity to design a pair of primers for each mutation codon.  
Use of these primers is not recommended for future HRMA assays. 
 
The use of ambiguous bases for HRMA is also an unreported masking method. The majority of 
the polymorphic samples genotyped with these probes did not produce a probe melting signal. 
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As only a sixteenth of the probe mix participates during HRMA, the fluorescence signal is lower 
than usual, which probably prevented melting peak formation. Ambiguous bases, comprising of 
two different bases at the polymorphic site, rather than the tested four, might produce a stronger 
signal for HRMA. 
 
Short probes of 11 bp and the probes incorporating LNAs did not generate melting peaks. Due to 
the low thermal stability of these short probes, the probes may have dissociated before the melt 
program began recording fluorescence changes at 40 °C, the lowest temperature at which the 
LightCycler 480 Real-Time PCR system (Roche Applied Science, GmbH, Germany) can be set. 
It has been reported that probes of 10 bases can be detected when the G+C content is 100% 
(Zhou et al., 2004). 
 
Genotyping by HRMA is limited to the identification of single bases or short stretches of 
conserved sequences (Vaughn and Elenitoba-Johnson, 2004). Additionally, HRMA assay design 
relies on sequence information of the target area, which cannot be elucidated by HRMA alone. In 
contrast, long stretches of a genome can be genotyped de novo by population sequencing or 
pyrosequencing (Ahmadian et al., 2006). Despite these advantages, HRMA can be used in place 
of de novo genotyping if the loci of interest have known genotypes. In this way, HRMA presents 
a far more rapid genotyping methodology than de novo techniques. It is also more cost effective 
than population sequencing as melting instruments and the required reagents are comparatively 
less expensive than those required for population and pyrosequencing. The cost of HRM master 
mix and population sequencing dye is approximately R5 and R33 per reaction, respectively. 
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An additional shortcoming is the inability of current HRMA software to perform automatic base 
calling as does the software for population sequencing. As such, traditional HRMA curve 
interpretation is subjective and lacks statistical interrogation. However a new generation of 
HRMA software has introduced statistical analysis which allows automated sample genotyping. 
Currently this software is applicable to normalized melting curve interpretation rather than the 
negative derivative plots utilized in this study (Reja et al., 2010). 
 
Another marked difference between population sequencing and HRMA, is that the latter is often 
disrupted by unexpected sequence variation. Consequently, genotyping by HRMA is suited for 
use with conserved, non-polymorphic genetic material; and so most HRMA studies are 
conducted on human genetic material. In this setting, genotyping by mutation scanning is 
possible and most assays designed for human genetic material do not utilize probes (Grievink 
and Stowell, 2008; Hill et al., 2006; Krenková et al., 2009; Krypuy et al., 2006; Liew et al., 
2004; Poláková et al., 2008; Reed and Wittwer, 2004; Simi et al., 2008; Willmore-Payne et al., 
2005). Despite the convenience of mutation scanning, assays utilizing unlabeled probes 
investigating mutations associated with cystic fibrosis, cancer, metabolic diseases and vascular 
malformations have been designed (Nguyen-Dumont et al., 2009; Poulson and Wittwer, 2007; 
van der Stoep et al., 2009; Vandersteen et al., 2007; Zhou et al., 2004; Zhou et al., 2005). HRMA 
assays, with or without probes, show a high concordance with sequence data. In most instances 
the sensitivity and specificity of the assays ranges from > 95%-100% (Montgomery et al., 2010). 
As the location, type and prevalence of polymorphisms in human DNA are well established, 
these sites can be avoided or masked accordingly. In contrast, the number of polymorphism is far 
higher in HIV and many changes are uncommon, so masking of each polymorphism under the 
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probe binding region is not feasible. Nevertheless, I show here that selected polymorphisms can 
be masked to allow successful genotyping. 
 
The limit of detection for the HRMA assays reported here is higher than that of population 
sequencing and appears to be assay dependent, ranging from ~ 5%-20%. No data on the limit of 
detection for probe based HRMA assays was found in the literature. However mutation scanning 
assays have analytical sensitivities of 0.1%-10%. The 0.1% limit of detection is applicable to 
methylation analysis rather than SNP detection assays. The lower limit of detection of HRMA 
for SNP detection in mixed species is ~ 3% (Krypuy et al., 2006; Simi et al., 2008; Wojdacz and 
Dobrovic, 2007). Thus as HRMA is more sensitive than population sequencing, it allows for the 
detection of clinically relevant drug resistant minority species (Gardner et al., 2009). 
 
When applied to bacteria or viruses, HRMA is usually utilized for subtyping, rather than specific 
loci genotyping. Mutation scanning assays have been designed to differentiate clinically relevant 
Mycobacteria, Campylobacteri, Mycoplasma and Legionella bacterial species or strains (Cheng 
et al., 2006; Giglio et al., 2005; Jeffery et al., 2007; Odell et al., 2005; Price et al., 2007). 
Similarly assays have been designed to type DNA viruses (adenoviruses, varicella-zoster and 
human papillomavirus type 16) and RNA viruses (noroviruses, influenza A/B and infectious 
bronchitis virus) (Hewson et al., 2009; Lin et al., 2008; Nakagawa et al., 2009; Sabol et al., 2009; 
Steer et al., 2009; Tajiri-Utagawa et al., 2009; Toi and Dwyer, 2008). Except for the RNA 
viruses, the mutation rates of these organisms are far lower than that of HIV. Nevertheless, 
polymorphisms do not exert a strong influence on the outcome of mutation scanning assays for 
subtyping purposes. Large amplicons, usually > 100 bp are generated and so the distribution and 
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extent of G+C influences subtyping. To the author’s knowledge, only one published paper 
explores the application of unlabelled probes and HRMA to viral genetic material. Dames and 
coworkers designed an assay to type herpes simplex virus 1 and 2 (HSV) (Dames et al., 2007). 
The majority of the samples were correctly classified by mutation scanning, and the use of 
unlabelled probes increased the success rate to 99%. The higher success rate may be due to the 
lower mutation rate of HSV and the use of longer probes (> 30 bp), with five mismatches along 
the probe length. The stronger probe signal decreases the interference that noise introduces into 
melting peak interpretation and stabilizes the probe in the presence of polymorphisms. Despite 
the drawbacks the short probes and highly polymorphic genetic material introduce, the success 
rates of the assays reported here are comparable to that of Dames and colleagues.  
 
While longer probes may tolerate mismatches and deletions for use in polymorphism masking, 
shorter probes offer certain advantages. The 103, 181, 184, 151 and 190 assays utilize very short 
probes which do not generate melting peaks when the target sequence is absent. Melting peak 
identification is simple, as the presence or absence of a peak, at a specific Tm, signals the 
genotype of the locus. In contrast, long probes generate ≥ 1 melting peak/s, which makes melting 
curve interpretation difficult, as the number and position of each peak is critical to genotype 
elucidation (Zhou et al., 2004). A balance between probe length and polymorphism masking 
robusticity may be a probe of < 21 bp, as probes of this length do not generate a peak when a 
non-corresponding genotype is present (Zhou et al., 2004). Thus a comparatively longer (< 21 
bp) probe than those utilized here may allow for more effective polymorphism masking, while 
permitting simple curve interpretation. 
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In addition to short probes, another feature of the assays reported here, which does not usually 
appear in other probe based HRMA assays is probe redundancy. For the assays reported here, at 
least one probe was designed to identify the wild-type and at least one other probe, the mutant 
base at the site of interest. This reduced erroneous base classification as the absence of a peak 
was not sufficient for genotype prediction. Rather, information from both probes was sufficient 
to genotype the loci in question. This is important for HIV-1 HRMA, as 10%-30% of the patient 
samples did not generate melting peaks. If one probe was used to genotype a wild-type location, 
then the absence of that peak would signal the presence of the mutant genotype. However this 
result may be a consequence of a polymorphism rather than a mismatch, due the mutant 
genotype. Thus a peak generated from a wild-type or mutant probe should be used to formulate 
an accurate base prediction when HRMA is applied to highly polymorphic genetic material. 
 
If the interrogation of a limited number of sites is required then HRMA is an attractive option.  
While these assays cannot genotype each drug resistance mutation codon in HIV-1 the three 
most prevalent drug resistance mutations (M184V, K103N and V106M) in South Africa were 
indentified accurately and with high sensitivity and specificity (Marconi et al., 2008; Orrell et al., 
2009; Wallis et al., 2009). Additionally, other major mutations, K65R, Y181C, Q151M and 
G190A were detected. These assays could not genotype TAMs, which include M41L, D67N, 
K70R and T215Y/F. TAMs are widespread in resource limited populations as ZDV and d4T are 
commonly used. Additionally, TAMs are the most commonly transmitted NRTI mutations 
(Shafer and Schapiro, 2008). While the secondary mutations (M41L, D67N, K70R, T215F/Y and 
P225H) could not be identified, these mutations are almost exclusively found in the presence of 
the detectable major NNRTI (K103N, V106M, Y181C and G190A) and NRTI (K65R, Q151M 
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and M184V) mutations (http://hivdb.stanford.edu/) (Bacheler et al., 2000). The assays can 
therefore be used to screen HIV-1 patient samples for major reverse transcriptase related drug 
resistance mutations. If major mutations are detected then samples would be subjected to 
population sequencing to identify secondary mutations. 
 
HRMA assays are cost effective, require less technical expertise than other population 
sequencing and a single specialized melting machine. Therefore, the assays can be implemented 
to genotype specific major HIV-1 reverse transcriptase drug resistance mutations in resource 
limited settings. In this way, the sequencing burden can be decreased by > 60%-90%, as only 
samples generating no result require sequencing.  
 
The detection of major drug resistance mutations is integral to the treatment success of patients 
receiving ARV drug therapy. Due to the expansion of ARVs drug resistance is an increasing 
problem in resource limited areas. As a result of increased resistance, transmission of drug 
resistant viruses may increase which will compromise the treatment of drug naïve patients 
(WHO/UNAIDS, 2008). Consequently drug resistance testing for surveillance of the prevalence 
of resistance and transmitted resistance is essential (Bennett et al., 2008).  Additionally, 
resistance testing is helpful for the formulation of appropriate drug regimens in cases of 
treatment failure (Torre and Tambini, 2002). Due to the cost, expertise and equipment 
requirements, population sequencing for resistance testing has not been widely implemented in 
resource limited areas. The advantages HRMA has over population sequencing may allow for, 
after further development, rapid and cost effective resistance testing for surveillance and clinical 
purposes. 
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Appendix A: Primer Sequences 
 
The primers for the nested RT-PCR, cDNA synthesis and Sanger population sequencing (Table 
A1) were manufactured by the University of Cape Town. The primers for site-directed 
mutagenesis (Table A2) were manufactured by Invitrogen (USA). 
 
Table A1. Primer sequences for cDNA synthesis, nested RT-PCR and population sequencing. 
Name Sequence (5'-3') Tm (°C) Product Length     
IN3 TCTCAGCCATCTAAAAATAGTACTTTCCTGATTCC 71 n/a 
pFor-out AAAATGATAGGAGGAATTGG 52 
1129bp 
pRev-out CATGGAGTATATTATGACCCAT 56 
pFor-in CACCTGTCAACATAATTGG 53 
986bp 
pRev-in GCAGAGAACAGGGAAATT 51 
LC-outFor TTCAGGGAACTCAATAAAAG 52 n/a 
M8 CTGTATATCATTGACAGTCCAG 58 n/a 
n/a = Not applicable, as the primers were used for cDNA synthesis or population sequencing. 
 
 
 
Table A2. Primer sequences for site-directed mutagenesis. 
Name Sequence (5'-3') Modification G+C (%) Tm (°C) 
M41La GCATTAACAGCAATTTGTGAAGAATTGGAAAAGGAAGG 
ATG→TTG 
36 57 
M41La-as CCTTCCTTTTCCAATTCTTCACAAATTGCTGTTAATGC 36 57 
M41Lb GCATTAACAGCAATTTGTGAAGAACTGGAAAAGGAAGG 
ATG→CTG 
39 58 
M41Lb-as CCTTCCTTTTCCAGTTCTTCACAAATTGCTGTTAATCG 39 58 
D67Na CCAGTATTTGCCATAAAAAAGAAGAACAGTACCAAGTGGAG 
GAC→AAC 
39 59 
D67Na-as CTCCACTTGGTACTGTTCTTCTTTTTTATGGCAAATACTGG 39 59 
D67Nb CCAGTATTTGCCATAAAAAAGAAGAATAGTACCAAGTGGAG 
GAC→AAT 
36 58 
D67Nb-as CTCCACTTGGTACTATTCTTCTTTTTTATGGCAAATACTGG 36 58 
K70Ra GAAGGACAGTACCAGGTGGAGAAAATTAGTAGATTTCAGGG 
AAG→AGG 
43 61 
K70Ra-as CCCTGAAATCTACTAATTTTCTCCACCTGGTACTGTCCTTC 43 61 
Q151Ma CAATATAATGTGCTTCCAATGGGATGGAAAGGATCACC 
CAG→ATG 
42 59 
Q151Ma-as GGTGATCCTTTCCATCCCATTGGAAGCAGATTATATTG 42 59 
G190a GGATGACTTGTATGTAGCATCTGATTTAGAAATAAAGCAACATAGAGC 
GGA→GCA 
35 60 
G190a-as GCTCTATGTTGCTTTATTTCTAAATCAGATGCTACATACAAGTCATCC 35 60 
T215a CTATTAAAGTGGGGATTTTTCACACCAGACAAGAAACATCAG 
ACC→TTC 
38 59 
T215a-as CTGATGTTTCTTGTCTGGTGTGAAAAATCCCCACTTTAATAG 38 59 
T215b CTATTAAAGTGGGGATTTTTTACACCAGACAAGAAACATCAG 
ACC→TTT 
35 58 
T215b-as CTGATGTTTCTTGTCTGGTGTAAAAAATCCCCACTTTAATAG 35 58 
T215c CTATTAAAGTGGGGATTTTACACACCAGACAAGAAACATCAG 
ACC→ACT 
38 59 
T215c-as CTGATGTTTCTTGTCTGGTGTGTAGTAAAATCCCCACTTTAATAG 38 59 
T215d CTATTAAAGTGGGGATTTTACACACCAGACAAGAAACATCAG 
ACC→TAC 
38 59 
T215d-as CTGATGTTTCTTGTCTGGTGTGTAAAATCCCCACTTTAATAG 38 59 
P225Ha GAAACATCAGAAAGAACACCCATTTCTTTGGATGGGG 
CCC→CAC 
43 59 
P225Ha-as CCCCATCCAAAGAAATGGGTGTTCTTTCTGATGTTTC 43 59 
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 Appendix B: Vector Map 
 
The following diagram depicts the vector map of the pCR 2.1-TOPO vector (Invitrogen, USA). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B1. Diagram of pCR 2.1 TOPO vector. 
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Appendix C: Media and Reagents 
 
Bacterial Culture Reagents 
 Ampicillin (100 mg/mL) 
Mixed 1 g of ampicillin with 10 mL of dH2O, stored at -20 °C, used within 6 months. 
 
 Lysogeny broth (LB)  
LB Ultra pure (USB, USA): 10 g/L casein peptone, 5 g/L Yeast extract and 5 g/L NaCl. Added 
25 g of LB to 1 L of dH2O. Mixed thoroughly and autoclaved for 20 minutes at 121 °C. Cooled 
and added 100 mg of ampicillin. 
 
 LB agar  
LB agar (Lennox L agar, Invitrogen, USA): 10g/L select peptone 140, 5 g/L select yeast extract, 
5 g/L NaCl and 12 g/L select agar. Added 32 g of LB agar to 1 L of dH2O. Mixed and autoclaved 
for 20 minutes at 121 °C. Cooled and added 100 mg of ampicillin. After mixing aliquoted 25 mL 
into agar plates. 
 
 X-Galactosidase (40 mg/mL) 
Added 0.4 g of X-Gal to 10 mL of dimethylformamide. Protected from light and stored at -20 
°C. 
 
Agarose Gel Electrophoresis Solutions 
 TAE Buffer (1x) 
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50 x TAE (per 1 x solution): 40 mM Tris, 20 mM acetic acid and 1 mM EDTA. Added 20 mL of 
50 x TAE to 1800 mL of dH2O. 
 
 Agarose Gels 
For 1% agarose gel, added 0.5 g of agarose (Bioline, London, UK) to 50 mL of 1 x TAE buffer. 
Mixed and then boiled in a microwave. Cooled to ~ 60 °C and added 5 µL of 10 mg/mL 
ethidium bromide (Biorad, California, USA). Mixed and poured into agarose gel mould with 
well comb in place, allowed to set for 20 minutes. For 2% agarose gel, followed same method, 
but added 1 g of agarose to 50 mL of 1 x TAE buffer. 
 
 Tracking Dye 
Added 0.025% bromophenol blue to 30% glycerol in TE. 
 
DNA Buffer 
 Tris-HCl (pH 8) 
Added 12.11 g of Tris to 90 mL of dH2O. Adjusted to pH 8 with HCl, made up to 100 mL with 
dH2O. 
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Appendix D: HRMA Results 
 
The following Tables contain the Sanger population sequencing results and HRMA predictions 
for the K103N (D2), Y181C (D3), M184V (D4), Q151M (D5), G190A (D6), K65R (D7) and 
V106M (D8) HIV-1 RT mutation codons. Samples with discordant HRMA results are in red and 
samples with no result (NR) are in blue. A guide to the nomenclature used in the following 
Tables is in Table D1. 
 
Table D1. DNA bases and incompletely specified bases. 
A Adenine 
C Cytosine 
T Thymine 
G Guanine 
R G or A 
Y T or C 
M A or C 
S G or C 
W A or T 
H A or C or T 
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Table D2. Population sequences and HRMA predictions for the 103 assay. 
Patient 
sample 
103 
Sequence 
103 
HRM 
Altered 
primer 
Ambiguous 
probe  
Patient 
sample 
103 
Sequence 
103 
HRM 
Altered 
primer 
Ambiguous 
probe 
Sample 1a AAA AAA Sample 47 AAG AAG     
Sample 1b AAM AAM     Sample 48 AAC AAC 
Sample 2a AAA AAA Sample 49 AAR AAR     
Sample 2b AAM AAM     Sample 50 AAA NR AAA NR 
Sample 3a AAA AAA Sample 51 AAA AAA     
Sample 3b AAA AAA     Sample 52 AAC AAC 
Sample 4a AAA AAR Sample 53 AAA AAA     
Sample 4b AAM AAM     Sample 54 AGT AAG 
Sample 5a AAA NR AAA AAA Sample 55 AAA AAA     
Sample 5b AAA NR AAA AAM Sample 56 AAC AAC 
Sample 6a AAA AAA Sample 57 AAC AAC     
Sample 6b AAC AAC     Sample 58 AAA AAA 
Sample 7a AAA AAA Sample 59 AAA AAA     
Sample 7b AAM AAM     Sample 60 AAM NR AAC NR 
Sample 8a AAA AAA Sample 61 AAA AAA     
Sample 8b AAA NR NR AAA Sample 62 AAC AAC 
Sample 9a AAA AAA Sample 63 AAT AAT     
Sample 9b AAA AAA     Sample 64 AAA AAA 
Sample 10a AAA AAA Sample 65 AAA AAA     
Sample 10b AAM NR NR AAT Sample 66 AAA AAA 
Sample 11a AAA AAA Sample 67 AGA NR AAA NR 
Sample 11b AAW NR NR AAA Sample 68 AAA NR AAA AAA 
Sample 12a AAA AAA Sample 69 AAA AAA     
Sample 12b AAM NR AAA NR Sample 70 AAA AAA 
Sample 13a AAA AAA Sample 71 AGC NR NR NR 
Sample 13b AAM AAM     Sample 72 AAC AAC 
Sample 14 AAA AAA Sample 73 AAT AAY     
Sample 15 AAA AAA     Sample 74 AAG AAG 
Sample 16 AAA AAA Sample 75 AAA AAA     
Sample 17 AAA AAA     Sample 76 AAT AAT 
Sample 18 AAA AAA Sample 77 AAA NR NR NR 
Sample 19 AAM AAM     Sample 78 AAC AAC 
Sample 20 AGA AAA Sample 79 AAA NR AAA NR 
Sample 21 AAA AAA     Sample 80 AAA AAA 
Sample 22 AAC NR AAC NR Sample 81 AAA AAA     
Sample 23 AAA AAA     Sample 82 AAA AAA 
Sample 24 AAC AAC Sample 83 AAA AAA     
Sample 25 AAA AAA     Sample 84 AAC AAC 
Sample 26 AAA AAA Sample 85 AAA AAA     
Sample 27 AAA AAA     Sample 86 AAG AAG 
Sample 28 AAA NR AAA AAA Sample 87 AAC AAC     
Sample 29 AAC AAC     Sample 88 AAA AAA 
Sample 30 AAT AAY Sample 89 AAG AAG     
Sample 31 AAA AAA     Sample 90 AAA AAA 
Sample 32 AGA NR NR AAA Sample 91 AAG AAG     
Sample 33 AGA NR NR NR Sample 92 AAC AAC 
Sample 34 AAC AAC Sample 93 AAA AAA     
Sample 35 AAA AAA     Sample 94 AAC NR AAC AAC 
Sample 36 AAC AAC Sample 95 AAA AAA     
Sample 37 AAA AAA     Sample 96 AAA AAA 
Sample 38 AAC AAY Sample 97 AAA NR NR NR 
Sample 39 AAG AAR     Sample 98 AAA AAA 
Sample 40 AAC NR AAC NR Sample 99 AAA AAA     
Sample 41 AAC AAC     Sample 100 AAA AAA 
Sample 42 AAA AAA Sample 101 AAA AAA     
Sample 43 AAC AAC     Sample 102 AAC AAC 
Sample 44 AAT AAT Sample 103 AAC AAC     
Sample 45 AAA AAA     The AAC, AAT, AGA, AGT or AGC genotypes at codon 103 result 
in drug resistance. Sample 46 AAA NR NR AAC 
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Table D3. Population sequences and HRMA predictions for the 181 assay. 
Patient 
sample 
181 
Sequence 
181 
HRM 
Deletion 
probe 
Universal 
probe  
Patient 
sample 
181 
Sequence 
181 
HRM 
Deletion 
probe 
Universal 
probe 
Sample 1a TAT TAT Sample 47 TAT TAT     
Sample 1b TRT TRT     Sample 48 TAT TAT 
Sample 2a TAT TAT Sample 49 TAT NR TAT NR 
Sample 2b TAT TAT     Sample 50 TAT TAT 
Sample 3a TAT TAT Sample 51 TAT TAT     
Sample 3b TRT TRT     Sample 52 TAT TAT 
Sample 4a TAT TAT Sample 53 TAT TAT     
Sample 4b TAT TAT     Sample 54 TAT TAT 
Sample 5a TAT TAT Sample 55 TAT NR TAT TAT 
Sample 5b TAT TAT     Sample 56 TAT TAT 
Sample 6a TAT TAT Sample 57 TAT TAT     
Sample 6b TAT TRT     Sample 58 TAT NR TAT NR 
Sample 7a TAT TAT Sample 59 TAT TAT     
Sample 7b TAT TAT     Sample 60 TAT TAT 
Sample 8a TAT TAT Sample 61 TAT TAT     
Sample 8b TAT TAT     Sample 62 TAT NR NR NR 
Sample 9a TAT TAT Sample 63 TAT TAT     
Sample 9b TAT TAT     Sample 64 TAT TAT 
Sample 10a TAT TAT Sample 65 TAT TAT     
Sample 10b TRT TRT     Sample 66 TAT TAT 
Sample 11a TAT NR TAT TAT Sample 67 TAT TAT     
Sample 11b TAT NR TAT TAT Sample 68 TAT TAT 
Sample 12a TAT TAT Sample 69 TAT TRT     
Sample 12b TAT TAT     Sample 70 TAT TAT 
Sample 13a TAT TAT Sample 71 TAT TAT     
Sample 13b TAT TAT     Sample 72 TAT TAT 
Sample 14 TAT TAT Sample 73 TAT TRT     
Sample 15 TAT NR TAT NR Sample 74 TAT TAT 
Sample 16 TAT TAT Sample 75 TAT TAT     
Sample 17 TAT TAT     Sample 76 TAT TAT 
Sample 18 TAT TAT Sample 77 TAC NR NR NR 
Sample 19 TRT TRT     Sample 78 TAT TAT 
Sample 20 TAT TAT Sample 79 TAT TAT     
Sample 21 TAT TAT     Sample 80 TAT TAT 
Sample 22 TAT TAT Sample 81 TAT TAT     
Sample 23 TAT TAT     Sample 82 TAT TAT 
Sample 24 TAT TAT Sample 83 TAT TAT     
Sample 25 TAT TAT     Sample 84 TAT TAT 
Sample 26 TAT NR NR NR Sample 85 TRT TRT     
Sample 27 TAY TAT     Sample 86 TGT TRT 
Sample 28 TAT TAT Sample 87 TAT TAT     
Sample 29 TAT TAT     Sample 88 TAT TAT 
Sample 30 TAT TAT Sample 89 TAT TAT     
Sample 31 TAT TAT     Sample 90 TAC NR NR NR 
Sample 32 TAT TAT Sample 91 TAT TAT     
Sample 33 TAT TAT     Sample 92 TAT TAT 
Sample 34 TAT NR TAT NR Sample 93 TRT TRT     
Sample 35 TAT TAT     Sample 94 TAT TAT 
Sample 36 TAT TAT Sample 95 TAT TAT     
Sample 37 TAT TAT     Sample 96 TAT TAT 
Sample 38 TAT TAT Sample 97 TAT TAT     
Sample 39 TAT TAT     Sample 98 TAT TAT 
Sample 40 TAT TAT Sample 99 TAT TAT     
Sample 41 TAT TAT     Sample 100 TAT TAT 
Sample 42 TAT TAT Sample 101 TAT TAT     
Sample 43 TAT TAT     Sample 102 TAT TAT 
Sample 44 TAT TAT Sample 103 TAT TAT     
Sample 45 TAT TAT     The TGT genotype at codon 181 results in drug resistance. 
Sample 46 TAT TAT 
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Table D4. Population sequences and HRMA predictions for the 184 assay. 
Patient sample 
184 
Sequence 
184 HRM 
Altered 
primer  
Patient sample 
184 
Sequence 
184 HRM 
Altered 
primer 
Sample 1a ATG ATG Sample 47 GTG GTG   
Sample 1b ATG ATG   Sample 48 GTG GTG 
Sample 2a ATG ATG Sample 49 GTG NR GTG 
Sample 2b ATG ATG   Sample 50 ATG ATG 
Sample 3a ATG ATG Sample 51 RTG RTG   
Sample 3b ATG ATG   Sample 52 GTA NR NR 
Sample 4a ATG ATG Sample 53 GTG RTG   
Sample 4b ATG ATG   Sample 54 GTG GTG 
Sample 5a ATG ATG Sample 55 ATG RTG   
Sample 5b ATG ATG   Sample 56 ATG ATG 
Sample 6a ATG ATG Sample 57 GTG GTG   
Sample 6b ATG ATG   Sample 58 ATG NR ATG 
Sample 7a ATG ATG Sample 59 ATG ATG   
Sample 7b ATG ATG   Sample 60 ATG ATG 
Sample 8a ATG NR n/a Sample 61 GTG GTG   
Sample 8b GGA NR n/a Sample 62 GTG NR GTG 
Sample 9a ATG ATG Sample 63 ATG NR ATG 
Sample 9b ATG ATG   Sample 64 ATG NR NR 
Sample 10a ATG ATG Sample 65 GTR GTG   
Sample 10b ATG RTG   Sample 66 ATG NR NR 
Sample 11a ATG ATG Sample 67 ATG ATG   
Sample 11b ATG ATG   Sample 68 ATG ATG 
Sample 12a ATG ATG Sample 69 GTR GTG   
Sample 12b ATG ATG   Sample 70 GTG GTG 
Sample 13a ATG ATG Sample 71 GTA NR NR 
Sample 13b ATG ATG   Sample 72 GTG GTG 
Sample 14 ATG ATG Sample 73 ATG ATG   
Sample 15 ATG NR NR Sample 74 ATG ATG 
Sample 16 ATG ATG Sample 75 GTG GTG   
Sample 17 ATG ATG   Sample 76 ATG ATG 
Sample 18 ATG ATG Sample 77 ATG ATG   
Sample 19 ATG ATG   Sample 78 GTG GTG 
Sample 20 ATG ATG Sample 79 GTG RTG   
Sample 21 GTG GTG   Sample 80 GTG RTG 
Sample 22 GTG GTG Sample 81 ATG ATG   
Sample 23 GTG GTG   Sample 82 ATG ATG 
Sample 24 GTG RTG Sample 83 ATG ATG   
Sample 25 RTG RTG   Sample 84 ATG NR ATG 
Sample 26 GTG GTG Sample 85 ATG NR n/a 
Sample 27 ATG ATG   Sample 86 GTG RTG 
Sample 28 GTR GTG Sample 87 GTG GTG   
Sample 29 GTG GTG   Sample 88 GTG GTG 
Sample 30 GTG GTG Sample 89 ATG NR ATG 
Sample 31 ATG ATG   Sample 90 GTG GTG 
Sample 32 ATG NR NR Sample 91 GTG NR GTG 
Sample 33 GTG GTG   Sample 92 ATG RTG 
Sample 34 ATG NR ATG Sample 93 GTG GTG   
Sample 35 RTR ATG   Sample 94 GTG RTG 
Sample 36 GTG GTG Sample 95 ATG ATG   
Sample 37 ATG ATG   Sample 96 ATG ATG 
Sample 38 ATG ATG Sample 97 ATG ATG   
Sample 39 ATG ATG   Sample 98 ATG ATG 
Sample 40 GTG GTG Sample 99 ATG NR ATG 
Sample 41 GTG GTG   Sample 100 ATG NR ATG 
Sample 42 ATG ATG Sample 101 ATG ATG   
Sample 43 ATG ATG   Sample 102 GTG RTG 
Sample 44 GTG GTG Sample 103 ATG ATG   
Sample 45 ATG NR NR n/a = no amplification. The GTG or GTA genotypes at 
codon 184 result in drug resistance. Sample 46 RTG RTG 
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Table D5. Population sequences and HRMA predictions for the 151 assay. 
Patient 
sample 
151 
Sequence 
151 HRM 
MM 
151 
HRM  
Altered 
primer 
Patient 
sample 
151 
Sequence 
151 HRM 
MM 
151 
HRM  
Altered 
primer 
Sample 1a CAG CAG CAR Sample 47 CAG CAG CAR   
Sample 1b CAG CAG CAR   Sample 48 CAA NR NR CAA 
Sample 2a CAG CAG CAR Sample 49 CAG CAG CAG   
Sample 2b CAG CAG CAR   Sample 50 CAG CAG CAR 
Sample 3a CAG CAG CAR Sample 51 CAG CAG CAG   
Sample 3b CAG CAG CAG   Sample 52 CAA NR NR NR 
Sample 4a CAG CAG CAR Sample 53 CAG CAG CAR   
Sample 4b CAG CAG CAR   Sample 54 CAG CAG CAG 
Sample 5a CAG CAG CAR Sample 55 CAG CAG CAR   
Sample 5b CAG CAG CAR   Sample 56 CAG NR NR NR 
Sample 6a CAG CAG CAR Sample 57 CAG NR NR CAG 
Sample 6b CAG CAG CAR   Sample 58 CAG NR NR CAG 
Sample 7a CAA NR NR n/a Sample 59 CAG NR NR CAG 
Sample 7b CAA NR NR n/a Sample 60 CAG CAG CAG 
Sample 8a CAA CAA CAA Sample 61 CAG CAG CAR   
Sample 8b CAA CAA CAA   Sample 62 CAG CAG CAR 
Sample 9a CAG CAG CAR Sample 63 CAA NR CAA CAA 
Sample 9b CAG CAG CAR   Sample 64 CAG NR NR CAG 
Sample 10a CAA CAA NR Sample 65 CAG NR NR CAG 
Sample 10b CAA CAG CAG n/a Sample 66 CAG CAG CAG 
Sample 11a CAG CAG CAR Sample 67 CAG CAA NR   
Sample 11b CAG CAG CAR   Sample 68 CAG CAG CAR 
Sample 12a CAG CAG CAR Sample 69 CAG CAG CAG   
Sample 12b CAG CAG CAR   Sample 70 CAG CAA CAG 
Sample 13a CAA NR NR NR Sample 71 CAG CAG CAG   
Sample 13b CAA NR NR NR Sample 72 CAA CAA CAA 
Sample 14 CAG CAA NR n/a Sample 73 CAA CAA CAA   
Sample 15 CAG CAG CAG   Sample 74 CAG NR NR CAG 
Sample 16 CAG CAG CAR Sample 75 CAG NR NR CAG 
Sample 17 CAG CAG CAR   Sample 76 CAG NR NR CAG 
Sample 18 CAG NR NR NR Sample 77 CAA CAA CAA   
Sample 19 CAG CAG CAG   Sample 78 CAG CAG CAR 
Sample 20 CAG NR NR NR Sample 79 CAG CAG CAR   
Sample 21 CAG NR NR NR Sample 80 CAG CAG CAR 
Sample 22 CAG CAG CAR Sample 81 CAG CAG CAG   
Sample 23 CAG CAG CAG   Sample 82 ATG ATG ATG 
Sample 24 CAG CAG CAR Sample 83 CAG CAG CAR   
Sample 25 CAG CAG CAR   Sample 84 ATG ATG ATG 
Sample 26 CAG CAG CAR Sample 85 ATG ATG ATG   
Sample 27 CAG CAG CAR   Sample 86 CAG CAG CAR 
Sample 28 CAG CAG CAR Sample 87 CAG CAG CAG   
Sample 29 CAA NR CAA CAA Sample 88 CAA CAA CAA 
Sample 30 CAA CAA CAA 
 
Sample 89 CAG CAG CAR   
Sample 31 CAG CAG CAR   Sample 90 CAG NR NR NR 
Sample 32 CAA CAA CAA Sample 91 CAG CAG CAR   
Sample 33 CAG CAG CAR   Sample 92 CAG CAG CAR 
Sample 34 CAG NR NR CAG Sample 93 CAG CAG CAR   
Sample 35 CAG CAG CAR   Sample 94 CAG CAG CAR 
Sample 36 CAG CAG CAG Sample 95 CAG NR NR CAG 
Sample 37 CAG CAG CAR   Sample 96 CAG CAG CAR 
Sample 38 CAG NR NR NR Sample 97 MTG ATG ATG   
Sample 39 CAG CAG CAR   Sample 98 CAG CAG CAR 
Sample 40 CAG NR NR CAG Sample 99 CAG NR NR CAG 
Sample 41 CAA CAA NR   Sample 100 ATG ATG ATG 
Sample 42 CAG NR NR CAG Sample 101 CAG CAG CAR   
Sample 43 CAA NR NR NR Sample 102 CAG CAG CAG 
Sample 44 CAA NR NR NR Sample 103 CAG NR NR CAG 
Sample 45 CAG NR NR CAG n/a = no amplification. The ATG genotype at codon 151 results 
in drug resistance. Sample 46 CAG CAG CAG 
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Table D6. Population sequences and HRMA predictions for the 190 assay. 
Patient sample 190 Sequence 190 HRM 
 
Patient sample 190 Sequence 190 HRM 
Sample 1a GGA GGA Sample 47 GGA NR 
Sample 1b GGA GGA Sample 48 GGA GGA 
Sample 2a GGA GGA Sample 49 GGA NR 
Sample 2b GGA GGA Sample 50 GGA NR 
Sample 3a GGA GGA Sample 51 GGA GGA 
Sample 3b GGA NR Sample 52 GGA GGA 
Sample 4a GGA GGA Sample 53 GGA NR 
Sample 4b GSA NR Sample 54 GCA GCA 
Sample 5a GGA NR Sample 55 GGA GGA 
Sample 5b GGA NR Sample 56 GGA GGA 
Sample 6a GGA GGA Sample 57 GGA GGA 
Sample 6b GGA NR Sample 58 GGA GGA 
Sample 7a GGA GGA Sample 59 GGC NR 
Sample 7b GGA GGA Sample 60 GGA GGA 
Sample 8a GGA GGA Sample 61 GGA NR 
Sample 8b ACA GGA Sample 62 GGA NR 
Sample 9a GGA GGA Sample 63 GGA GGA 
Sample 9b GGA NR Sample 64 GGA GGA 
Sample 10a GGA NR Sample 65 GGA NR 
Sample 10b GGA GGA Sample 66 GGA GGA 
Sample 11a GGA GGA Sample 67 GGA GGA 
Sample 11b GGA NR Sample 68 GCA GCA 
Sample 12a GGA GGA Sample 69 GGR NR 
Sample 12b GSA GGA Sample 70 GGA GGA 
Sample 13a GGA GGA Sample 71 GGA NR 
Sample 13b GGA GGA Sample 72 GGA GGA 
Sample 14 GGA GGA Sample 73 GCA NR 
Sample 15 GGA GGA Sample 74 GGA GGA 
Sample 16 GGA GGA Sample 75 GCA NR 
Sample 17 GGA GGA Sample 76 GCA GCA 
Sample 18 GGA GGA Sample 77 GGA GGA 
Sample 19 GGA NR Sample 78 GGA NR 
Sample 20 GGR NR Sample 79 GCA GCA 
Sample 21 GGA NR Sample 80 GGA GGA 
Sample 22 GGA GGA Sample 81 GGA NR 
Sample 23 GGA GGA Sample 82 GGA GGA 
Sample 24 GGA GGA Sample 83 GGA GGA 
Sample 25 GGA NR Sample 84 GGA NR 
Sample 26 GGA GGA Sample 85 AGC NR 
Sample 27 GGR GGA Sample 86 GGA NR 
Sample 28 GGA NR Sample 87 GGA NR 
Sample 29 GGA GGA Sample 88 GGA GGA 
Sample 30 GGA GGA Sample 89 GGA GGA 
Sample 31 GGA GGA Sample 90 GGA GGA 
Sample 32 GGA NR Sample 91 GGA GGA 
Sample 33 GCA GCA Sample 92 GGA NR 
Sample 34 GGA GGA Sample 93 GSA NR 
Sample 35 GSA NR Sample 94 GGA GGA 
Sample 36 GGC NR Sample 95 GGA NR 
Sample 37 GSA NR Sample 96 GGA GGA 
Sample 38 GGA GGA Sample 97 GGA GGA 
Sample 39 GGA GGA Sample 98 GGA GGA 
Sample 40 GGA GGA Sample 99 GGA GGA 
Sample 41 GGA GGA Sample 100 GGA GGA 
Sample 42 GGA GGA Sample 101 GSA NR 
Sample 43 GGA GGA Sample 102 GGA NR 
Sample 44 GGA NR Sample 103 GGA GGA 
Sample 45 GGA GGA The GCA, ACA or AGC genotypes at codon 190 result 
in drug resistance. Sample 46 GGA GGA 
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Table D7. Selected population sequences and HRMA predictions for the 65 assay. 
Patient sample 65 sequence 65 HRM 
Sample 83 ARG AGG 
Sample 84 ARG AGG 
Sample 97 ARG AGG 
The AGG genotype at codon 65 results in drug resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table D8. Selected population sequences and HRMA predictions for the 106 assay. 
Patient sample 106 sequence 106 HRM 
Sample 2b RTG ATG 
Sample 5b RTG NR 
Sample 12b RTG NR 
Sample 21 ATG ATG 
Sample 23 ATG ATG 
Sample 28 ATG ATG 
Sample 32 ATG ATG 
Sample 33 ATG ATG 
Sample 35 ATG ATG 
Sample 40 ATG ATG 
Sample 51 ATG ATG 
Sample 53 ATG ATG 
Sample 62 ATG ATG 
Sample 67 ATG ATG 
Sample 68 ATG ATG 
The ATG genotype at codon 106 results in drug resistance. 
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